---
title: "Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Product information and disease description"
description: "Formulary evidence on Lirafugratinib (Lyrfigtu, RLY-4008) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Product information and disease description. Covers Product description and Place of product in therapy. 355 evidence topics quoted from 108 sources."
canonical: "https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/product-information-and-disease-description"
published: "2026-09-27T09:44:05-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Summary: development and regulatory status as of November 2026

Lirafugratinib (RLY-4008), discovered by Relay Therapeutics and licensed worldwide to Elevar Therapeutics in December 2024, was approved by the FDA on 23 September 2026 as Lyrfigtu capsules for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement. The new drug application (NDA 220425) was received on 27 January 2026, was granted priority review, and used the Real-Time Oncology Review pilot program and the Assessment Aid. Lirafugratinib had received orphan drug designation for cholangiocarcinoma in January 2022 and breakthrough therapy designation in 2023. The application was not referred to an advisory committee. The approval letter states the application is approved for use as recommended in the agreed-upon labeling, and neither the letter nor the prescribing information contains the accelerated approval statement that appears in the labeling of pemigatinib, futibatinib, and infigratinib; the ReFocus cohort had been described in 2024 as designed to support accelerated approval. Approval rests on 116 FGFR inhibitor-naive participants in the single-arm phase 1/2 REFOCUS trial (NCT04526106), with an objective response rate of 46% (95% CI 36 to 55) and a median duration of response of 11.8 months. The FDA required a randomized trial comparing 70 mg once daily with a lower dosage and a P-gp and BCRP drug interaction trial, and accepted a commitment to validate a companion diagnostic. Elevar expected product availability in the fourth quarter of 2026, and its patient support site gave December 2026 as the expected availability in November 2026. A marketing authorization application was submitted to the European Medicines Agency in September 2026, and a phase 2 tumor-agnostic study (ReFocus202, NCT07359820) began dosing in June 2026.

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf); [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic); [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf); [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/); [Elevar Therapeutics EMA submission announcement (2026)](https://elevartx.com/2026/09/15/elevar-ema-authorization-application-1/); [Elevar Therapeutics ReFocus202 first patient announcement (2026)](https://elevartx.com/2026/06/22/elevar-first-patient-dosed-lira/); [Elevar Therapeutics and Relay Therapeutics licensing announcement (2024)](https://elevartx.com/2024/12/03/elevar-therapeutics-relay-therapeutics-licensing-agreement/); [Relay Therapeutics Form 10-K (2024)](https://www.sec.gov/Archives/edgar/data/1812364/000095017024018797/rlay-20231231.htm); [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf); [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf); [FDA TRUSELTIQ prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf); [Elevar Care Connect (2026)](https://elevarcareconnect.com/)

<a id="topic-2.1.1-2"></a>

##### Regulatory status: Approved; NDA submitted January 2026 and approved September 2026

> “On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.”

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

> “Please refer to your new drug application (NDA) received January 27, 2026, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

> “today announced it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational drug lirafugratinib as a second-line treatment option for cholangiocarcinoma (CCA) patients with FGFR2 fusion or rearrangement.”

Source: [Elevar Therapeutics NDA submission announcement (2026)](https://elevartx.com/2026/01/28/elevar-therapeutics-new-drug-application-lirafugratinib/)

<a id="topic-2.1.1-3"></a>

##### Launch: Anticipated in December 2026

> “Expected Availability December 2026”

Source: [Elevar Care Connect (2026)](https://elevarcareconnect.com/)

> “Lyrfigtu is expected to be available to patients in the U.S. by Q4 2026.”

Source: [Elevar Therapeutics NCCN Guidelines announcement (2026)](https://elevartx.com/2026/11/03/elevar-lyrfigtu-nccn-guidelines/)

> “Lyrfigtu is expected to be available to patients in the U.S. by Q4 2026.”
> “Our team is thrilled to bring this therapy to market and focused on getting Lyrfigtu to doctors and patients as quickly as possible”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.1.1-4"></a>

##### FDA approval on 23 September 2026

> “On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.”
> “Efficacy was evaluated in REFOCUS (NCT04526106), a multicenter, open-label, single-arm trial in 116 patients with unresectable or metastatic cholangiocarcinoma who were naïve to FGFR inhibitor treatment and had received prior chemotherapy or chemoimmunotherapy.”
> “ORR was 46% (95% CI: 36, 55) and median DOR was 11.8 months (95% CI: 7.5, 13.0).”

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

> “We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.1.1-5"></a>

##### Approval pathway: pivotal cohort designed for accelerated approval, approved without an accelerated approval statement in labeling

> “The study includes a pivotal cohort in patients with FGFR2-fusion CCA that was designed to support accelerated approval and is fully enrolled.”
> “Earlier in 2024, Relay Therapeutics met with the U.S. Food and Drug Administration (FDA) to discuss data from the ReFocus trial and potential regulatory pathways. The FDA recommended that the company first file an NDA for FGFR2-driven CCA, followed by a supplemental NDA for FGFR2-altered other solid tumors with data from an expanded cohort of patients.”

Source: [Elevar Therapeutics and Relay Therapeutics licensing announcement (2024)](https://elevartx.com/2024/12/03/elevar-therapeutics-relay-therapeutics-licensing-agreement/)

> “LYRFIGTU is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement [see Dosage and Administration (2.1)].”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.1-6"></a>

##### Expedited programs: priority review, breakthrough therapy, orphan drug designation, and Real-Time Oncology Review

> “This review used the Real-Time Oncology Review (RTOR) pilot program, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.”
> “This application was granted priority review. Lirafugratinib received breakthrough therapy and orphan drug designations.”

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

> “Lirafugratinib received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in 2022 and Breakthrough Therapy Designation in 2023. Elevar submitted a New Drug Application for lirafugratinib to the FDA in January 2026, and the application was granted Priority Review.”

Source: [Elevar Therapeutics EMA submission announcement (2026)](https://elevartx.com/2026/09/15/elevar-ema-authorization-application-1/)

> “In January 2022, the FDA granted orphan drug designation to lirafugratinib for the treatment of cholangiocarcinoma.”

Source: [Relay Therapeutics Form 10-K (2024)](https://www.sec.gov/Archives/edgar/data/1812364/000095017024018797/rlay-20231231.htm)

> “The FDA determined that the NDA is sufficiently complete to permit a substantive review and granted Priority Review”

Source: [Elevar Therapeutics priority review announcement (2026)](https://elevartx.com/2026/03/30/elevar-fda-acceptance-lira/)

<a id="topic-2.1.1-7"></a>

##### Advisory committee

> “Your application for Lyrfigtu was not referred to an FDA advisory committee because outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.1.1-8"></a>

##### Clinical development: ReFocus dose escalation and recommended phase 2 dose

> “The first part of the trial, or the dose escalation, is complete, and the second part of the trial, or the dose expansion, is ongoing at the 70mg once daily recommended Phase 2 dose.”

Source: [Relay Therapeutics Form 8-K (2023)](https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/rlay-20231012.htm)

<a id="topic-2.1.1-9"></a>

##### Development beyond cholangiocarcinoma: ReFocus202 tumor-agnostic phase 2 study

> “The trial, known as ReFocus202 (Protocol ID ELE-4008-202; NCT07359820), is an open-label, single-arm study evaluating the efficacy and safety among a broad scope of tumors containing an FGFR2 fusion or rearrangement. The primary endpoint is objective response rate.”
> “In the Phase 1/2 ReFocus study, data from 42 non-CCA solid tumor patients with FGFR2 fusion/rearrangement (13 tumor types) showed meaningful antitumor activity of lirafugratinib.”

Source: [Elevar Therapeutics ReFocus202 first patient announcement (2026)](https://elevartx.com/2026/06/22/elevar-first-patient-dosed-lira/)

<a id="topic-2.1.1-10"></a>

##### Regulatory submission outside the United States: European Medicines Agency

> “today announced the submission of a marketing authorization application to the European Medicines Agency (EMA) for lirafugratinib as a second-line treatment for patients with advanced/metastatic cholangiocarcinoma (CCA) harboring FGFR2 fusions or rearrangements.”

Source: [Elevar Therapeutics EMA submission announcement (2026)](https://elevartx.com/2026/09/15/elevar-ema-authorization-application-1/)

<a id="topic-2.1.1-11"></a>

##### Patent term

> “As of the date of this Annual Report on Form 10-K, we own granted patents in Eurasia, Europe, Taiwan, Japan, Hong Kong, and the United States covering the composition of matter of lirafugratinib.”

Source: [Relay Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/rlay-20251231.htm)

Additional sources: [ClinicalTrials.gov NCT04526106](https://clinicaltrials.gov/study/NCT04526106); [ClinicalTrials.gov NCT07359820](https://clinicaltrials.gov/study/NCT07359820)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Elevar Therapeutics

> “On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor”

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

> “Elevar has an exclusive license to lirafugratinib from Relay Therapeutics, Inc. for commercialization worldwide.”
> “Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for cancer patients”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.1.2.1-2"></a>

###### Nonproprietary name, brand name, and development code

> “Lyrfigtu (lirafugratinib, aka RLY-4008) is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

> “The proposed name Lyrfigtu (pronounced leer fig tu) was developed in accordance with the FDA’s guidance on proprietary names.”

Source: [Elevar Therapeutics brand name announcement (2026)](https://elevartx.com/2026/09/22/elevar-conditional-acceptance-lyrfigtu/)

<a id="topic-2.1.2.1-3"></a>

###### Therapeutic class

> “LYRFIGTU is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a FGFR2 fusion or other rearrangement.”
> “Lirafugratinib is a small molecule kinase inhibitor that inhibits FGFR2. Lirafugratinib covalently binds FGFR2.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “Lirafugratinib is an irreversible inhibitor that selectively targets FGFR2, differentiating it from existing pan-FGFR inhibitors that broadly inhibit FGFR1, FGFR3, and/or FGFR4 in addition to FGFR2.”

Source: [Elevar Therapeutics EMA submission announcement (2026)](https://elevartx.com/2026/09/15/elevar-ema-authorization-application-1/)

<a id="topic-2.1.2.1-4"></a>

###### Chemical description and salt form

> “Lirafugratinib hydrochloride is the salt form of lirafugratinib, a kinase inhibitor.”
> “Lirafugratinib hydrochloride is practically insoluble in water.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.1-5"></a>

###### Originator and license: Relay Therapeutics

> “In December 2024, the Company and Elevar Therapeutics, Inc. ("Elevar") entered into the Exclusive License Agreement (as amended from time to time, the "Elevar Agreement"), pursuant to which Elevar was granted exclusive global development and commercialization rights for lirafugratinib (RLY-4008), the Company's selective oral small molecule inhibitor of fibroblast growth factor receptor 2 ("FGFR2").”
> “Under the terms of the Elevar Agreement, we received $5.0 million upon execution, $3.7 million upon transfer of active pharmaceutical ingredient and other materials, and $10.0 million in milestone payments as of June 30, 2026. We are eligible to receive up to $485.0 million in regulatory and commercial milestone payments, as well as tiered royalties.”

Source: [Relay Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1812364/000119312526338056/rlay-20260630.htm)

> “Relay Therapeutics is eligible to receive up to $75 million in upfront and regulatory milestones, plus up to $425 million in potential commercial milestone payments, as well as tiered royalties up to the low-teens percentage.”

Source: [Elevar Therapeutics and Relay Therapeutics licensing announcement (2024)](https://elevartx.com/2024/12/03/elevar-therapeutics-relay-therapeutics-licensing-agreement/)

<a id="topic-2.1.2.1-6"></a>

###### Manufacturing, packaging, and distribution

> “Manufactured by Quotient Sciences - Philadelphia, LLC”
> “Distributed by: Elevar Therapeutics, Inc. Fort Lee, NJ 07024, USA”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Capsule strengths and appearance

> “Capsules: 20 mg and 30 mg.”
> “20 mg: Opaque, white, size 3 capsules with “LIR” printed in black ink on the cap and “20 mg” printed in black ink on the body.”
> “30 mg: Opaque, size 2 capsules with olive green cap and white body, with “LIR” printed in black ink on the cap and “30 mg” printed in black ink on the body.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.2-2"></a>

###### Salt content and inactive ingredients

> “Each 20 mg LYRFIGTU capsule contains 21.43 mg of lirafugratinib hydrochloride (approximately 20 mg of lirafugratinib base), and each 30 mg LYRFIGTU capsule contains 32.15 mg of lirafugratinib hydrochloride (approximately 30 mg of lirafugratinib base).”
> “Both capsule strengths contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.”
> “The capsule shell for both the 20 mg and 30 mg capsules includes gelatin, and titanium dioxide.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Daily dose packs and national drug codes

> “LYRFIGTU capsules are packaged in blister cards and supplied in child-resistant DosePaks”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

| Daily dose package | Carton contents | NDC |
| --- | --- | --- |
| 70 mg daily dose | “2 blister packs containing twenty-eight 20 mg capsules and fourteen 30 mg capsules each” | “82827-070-01” |
| 50 mg daily dose | “2 blister packs containing fourteen 20 mg capsules and fourteen 30 mg capsules each” | “82827-050-01” |
| 40 mg daily dose | “2 blister packs containing twenty-eight 20 mg capsules each” | “82827-040-01” |
| 30 mg daily dose | “1 blister pack containing twenty-eight 30 mg capsules” | “82827-030-01” |
| 20 mg daily dose | “1 blister pack containing twenty-eight 20 mg capsules” | “82827-020-01” |

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.2-4"></a>

###### Storage and expiry dating

> “Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “Based on the stability data submitted to date, the expiry dating period for Lyrfigtu (lirafugratinib) capsule shall be 36 months from the date of manufacture when stored at 20°C to 25°C (68°F to 77°F)”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Summary: estimated monthly and annual cost

- Price basis: no wholesale acquisition cost or average sales price had been published as of 17 November 2026, and the product was not yet available. The estimate rests on a company projection reported in October 2026: the chief executive of HLB, the parent company of Elevar Therapeutics, expected a price 15% to 20% above a monthly treatment cost of about $30,000 for competing FGFR2 inhibitors. The figures are a projection and will change when a list price is published.
- Dosing basis: 70 mg orally once daily until disease progression or unacceptable toxicity, dispensed in daily-dose cartons of 70, 50, 40, 30, or 20 mg; each carton holds a 28-day supply (the 70 mg carton holds 2 blister packs of twenty-eight 20 mg and fourteen 30 mg capsules, 1,960 mg ÷ 70 mg = 28 days).
- Base case: midpoint premium of 17.5%, read as a price per month: $30,000 × 1.175 = $35,250 per month; × 12 = $423,000 per year.
- Range: $34,500 to $36,000 per month ($30,000 × 1.15 and × 1.20), or $414,000 to $432,000 per year. If the projected amount is instead the price of one 28-day carton: $34,500 ÷ 28 days × 365 days = $449,732 per year ($37,478 per month) to $36,000 ÷ 28 days × 365 days = $469,286 per year ($39,107 per month).
- Rationale for the range: the projection states the premium as 15% to 20%; the cartons supply 28 days, so a price set per carton yields about 13 fills per year; dose reductions for adverse reactions (to 50, 40, 30, or 20 mg once daily, reported in 81% of patients) and reductions to 50 or 40 mg with moderate or strong CYP3A inhibitors change the carton dispensed and lower the cost only if lower-dose cartons are priced lower, which no published price yet shows; no dosage modification is recommended for mild or moderate hepatic impairment.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.

Source: [Korea Biomedical Review HLB pricing report (2026)](https://www.koreabiomed.com/news/articleView.html?idxno=33516); [Elevar Care Connect (2026)](https://elevarcareconnect.com/); [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.3-2"></a>

###### Wholesale acquisition cost and average sales price of lirafugratinib

No evidence found.

<a id="topic-2.1.2.3-3"></a>

###### Company projection of the United States price, October 2026: 15% to 20% above competing FGFR2 inhibitors

> “HLB said Thursday that it expects its cholangiocarcinoma (CCA) drug Lyrfigtu (lirafugratinib) to be priced 15 to 20 percent above other fibroblast growth factor receptor 2 (FGFR2) inhibitors in the U.S.”
> “The monthly treatment cost per patient of competitors’ drugs in the current U.S. market is about $30,000. However, we expect Lyrfigtu can receive a premium price about 15 to 20 percent higher than this,”
> “So it appears the price set with insurers going forward will be higher than existing competing drugs,”

Source: [Korea Biomedical Review HLB pricing report (2026)](https://www.koreabiomed.com/news/articleView.html?idxno=33516)

<a id="topic-2.1.2.3-4"></a>

###### Commercial status bearing on the absence of a published price

> “Lyrfigtu is expected to be available to patients in the U.S. by Q4 2026.”

Source: [Elevar Therapeutics NCCN Guidelines announcement (2026)](https://elevartx.com/2026/11/03/elevar-lyrfigtu-nccn-guidelines/)

> “NOW APPROVED!”
> “Expected Availability December 2026”

Source: [Elevar Care Connect (2026)](https://elevarcareconnect.com/)

<a id="topic-2.1.2.3-5"></a>

###### Average monthly United States price of futibatinib, an approved comparator

> “The cost of drugs was obtained from www.pharmacychecker.com using the FDA label to determine the dosage and number of tablets required per day. This methodology excludes any private or governmental insurance coverage, which would cover the entire cost or more likely a fraction of the stated price.”
> “The average monthly cost for the treatment of neoplastic diseases was $17,900 with a price of $44,000 for futibatinib (used to treat cholangiocarcinomas with FGFR2 fusions) and minimum of $5100 for binimetinib (melanoma).”
> “We retrieved drug prices in November 2023 from www.pharmacychecker.com for the average patient living in the state of North Carolina (ZIP code 28791). These values represent the retail price of a drug at the pharmacy as determined by negotiations between pharmacies and insurers and reflect both wholesale and retail markups.”

Source: [Roskoski (2024)](https://pubmed.ncbi.nlm.nih.gov/38096958/)

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Pharmacologic classification in the prescribing information

> “LYRFIGTU is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a FGFR2 fusion or other rearrangement.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.4-2"></a>

###### Mechanistic classification: FGFR2-selective irreversible inhibitor

> “RLY-4008 is a highly selective, irreversible FGFR2 inhibitor designed to overcome these limitations.”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

<a id="topic-2.1.2.4-3"></a>

###### AHFS classification or ATC code

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Approved indication

> “LYRFIGTU is indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement [see Dosage and Administration (2.1)].”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “This NDA provides for the use of Lyrfigtu (lirafugratinib) capsule for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.1.2.5-2"></a>

###### Patient selection and the absence of an FDA-authorized test

> “Select patients for the treatment of locally advanced or metastatic cholangiocarcinoma with LYRFIGTU based on the presence of an FGFR2 gene fusion or rearrangement [see Clinical Studies (14)].”
> “An FDA-authorized test for detection of FGFR2 gene fusions or other rearrangements in patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma for selecting patients for treatment with LYRFIGTU is not available.”
> “Qualifying in-frame fusions and other FGFR2 rearrangements were predicted to have a breakpoint within intron 17/exon 18 of the FGFR2 gene leaving the FGFR2 kinase domain intact.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.5-3"></a>

###### Population in which efficacy was established

> “The efficacy of LYRFIGTU was evaluated in REFOCUS (RLY-4008-101; NCT04526106), a multicenter, open-label, single-arm trial in 116 patients with unresectable or metastatic cholangiocarcinoma who were naïve to FGFR inhibitor treatment and had received prior chemotherapy or chemoimmunotherapy.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.5-4"></a>

###### Indications under development

> “Elevar continues to evaluate Lyrfigtu for other indications in ongoing clinical development programs, including studies in other FGFR2-altered solid tumors. Any future indications will be subject to regulatory review and approval.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Mechanism of action in the prescribing information

> “Lirafugratinib is a small molecule kinase inhibitor that inhibits FGFR2. Lirafugratinib covalently binds FGFR2. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Lirafugratinib inhibited FGFR2 phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR2 alterations, including FGFR fusions/rearrangements, amplifications, and mutations.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.6.1-2"></a>

###### Covalent binding to FGFR2 Cys491 and the basis of isoform selectivity

> “We leveraged differences in conformational dynamics between FGFR2 and other FGFRs observed through long timescale molecular dynamics simulations to enable the design of RLY-4008, an FGFR2-selective inhibitor that covalently binds to Cys491 (Fig. 1B).”
> “Although FGFR2 was labeled rapidly (t1/2 = 8 s), labeling of FGFR1 occurred much more slowly (t1/2 = 351 s; Fig. 1D), consistent with the observation from molecular dynamics simulations that RLY-4008 induces a conformation in FGFR1 that is not favorable for covalent bond formation.”
> “In contrast, the irreversible pan-FGFRi, futibatinib, covalently labeled both FGFR1 and FGFR2 at a similar rate (FGFR1 t1/2 = 8 s; FGFR2 t1/2 = 13 s) under identical experimental conditions (Fig. 1E), consistent with its reported covalent inhibition of all FGFRs”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

> “Simulations of FGFR1 binding one of our early selective compounds suggested that its selectivity arose because the compound stabilized the FGFR1 P-loop in an extended conformation with such a low degree of flexibility that covalent engagement of Cys488 (homologous to FGFR2 Cys491) was discouraged.”

Source: [Schönherr et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10861881/)

<a id="topic-2.1.2.6.1-3"></a>

###### Selectivity over FGFR1, FGFR3, and FGFR4

> “RLY-4008 demonstrates potent inhibition of FGFR2 enzyme activity in biochemical assays (IC50 = 3 nmol/L) but markedly weaker inhibition of other FGFRs (Supplementary Table S2). RLY-4008 has >250-fold selectivity over FGFR1, and >80- and >5,000-fold selectivity over FGFR3 and FGFR4, respectively (Fig. 1G).”
> “Therefore, FGFR2 is the only kinase expected to be irreversibly inhibited by RLY-4008, resulting in previously unachieved selectivity.”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

> “Lirafugratinib demonstrated the highest selectivity to inhibit FGFR2 without substantial inhibition of FGFR1, 3, 4 compared to the other FGFR inhibitors tested.”

Source: [Schram et al. (2026)](https://elevartx.com/wp-content/uploads/2026/06/Schram-et-al_AACR-Lira-poster-31Mar2026.pdf)

<a id="topic-2.1.2.6.1-4"></a>

###### Rationale for sparing FGFR1 and FGFR4: hyperphosphatemia and diarrhea

> “Hyperphosphatemia is attributed to the inhibition of FGFR1, which then increases phosphate reabsorption in the kidney”
> “In addition, diarrhea is reported in 15% to 36% of patients (all CTCAE grades), owing to inhibition of FGFR4”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

> “Our drug discovery efforts culminated in the development of lirafugratinib (RLY-4008), a covalent inhibitor of FGFR2 that shows substantial selectivity over FGFR1 (~250-fold) and FGFR4 (~5,000-fold) in vitro, causes tumor regression in multiple FGFR2-altered human xenograft models, and was recently demonstrated to be efficacious in the clinic at doses that do not induce clinically significant hyperphosphatemia or diarrhea.”

Source: [Schönherr et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10861881/)

<a id="topic-2.1.2.6.1-5"></a>

###### Activity against FGFR2 resistance mutations, including the V564F gatekeeper mutation

> “Our data align with these clinical findings, showing that current pan-FGFRi do not retain potency on FGFR2V564F, resulting in a >55-fold shift in IC50 between FGFR2WT and this mutation. In contrast, RLY-4008 is more potent on FGFR2V564F than FGFR2WT.”
> “For the FGFR2N549K mutation, RLY-4008 and futibatinib demonstrate an ∼10-fold shift in potency relative to FGFR2WT, whereas other pan-FGFRi demonstrate shifts of ∼30 to >100-fold.”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Pharmacodynamics in the prescribing information: exposure-response and QTc

> “Lirafugratinib exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized.”
> “The largest mean increase in QTcF from baseline was 7 ms (upper confidence interval = 12 ms) after administration of LYRFIGTU 70 mg in patients with unresectable or metastatic cholangiocarcinoma or other advanced tumors.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.6.2-2"></a>

###### Preclinical: cellular potency and kinome selectivity

> “The cellular potency (expressed as IC50) of RLY-4008 is 6 nmol/L (pFGFR) and 3 nmol/L (pERK), consistent with the observed biochemical potency on FGFR2.”
> “At the test concentration of 500 nmol/L (which resulted in 94.1% inhibition of FGFR2), only two additional kinases showed greater than 75% inhibition: MEK5 (92.4%) and MKNK2 (89%).”
> “In contrast to pan-FGFRi, RLY-4008 did not have strong inhibitory activity in FGFR1-, FGFR3-, or FGFR4-dependent cell lines.”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

<a id="topic-2.1.2.6.2-3"></a>

###### Preclinical: tumor regression and target inhibition in FGFR2-altered xenograft models

> “RLY-4008, administered orally, twice daily from 1 to 30 mg/kg, exhibited dose-dependent antitumor activity and induced tumor regression in all models (Fig. 3A, C, and E).”
> “In each model, at a dose of 30 mg/kg twice daily, RLY-4008 led to ≥90% pFGFR2 inhibition that was sustained throughout the 12-hour dosing interval and resulted in tumor regression.”
> “Pemigatinib and futibatinib, dosed to achieve exposures similar to those achieved at their recommended human doses of 13.5 mg and 20 mg, respectively (Supplementary Table S4), were less efficacious than 30 mg/kg of RLY-4008.”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

<a id="topic-2.1.2.6.2-4"></a>

###### Preclinical: serum phosphate at efficacious exposures compared with pan-FGFR inhibitors

> “All compounds caused tumor regression (Fig. 3G), whereas only pan-FGFRi demonstrated a statistically significant increase in serum phosphate, consistent with clinical observations (32%–47% over vehicle; P < 0.0001, one-way ANOVA; Fig. 3H).”
> “RLY-4008 led to tumor regression at doses of 10 and 30 mg/kg once daily without significantly altering serum phosphate levels (P > 0.2, one-way ANOVA), demonstrating that RLY-4008 is the only molecule tested that spares FGFR1 at efficacious exposures in vivo (Fig. 3H).”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

<a id="topic-2.1.2.6.2-5"></a>

###### Preclinical: activity in a gatekeeper-mutant cholangiocarcinoma model after pan-FGFR inhibitor progression

> “Strikingly, RLY-4008 caused rapid regression of ICC13-7–FGFR2V564F tumors at a dose of 2 mg/kg once daily (Fig. 4C), lower than that required to drive regression of ICC13-7 tumors (Fig. 3G).”
> “In contrast, pan-FGFRi were ineffective (Fig. 4C), consistent with the finding that they do not retain potency on FGFR2V564F (Fig. 4B).”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

<a id="topic-2.1.2.6.2-6"></a>

###### Clinical mechanisms of resistance to lirafugratinib

> “Circulating tumor DNA (ctDNA) samples from 28 patients treated with lirafugratinib (16 FGFR inhibitor-naive, 12 FGFR inhibitor-refractory) were analyzed using targeted next-generation sequencing.”
> “Polyclonal FGFR2 kinase domain mutations and receptor tyrosine kinase-mitogen activated protein kinase (RTK-MAPK) bypass alterations emerged as common lirafugratinib resistance mechanisms in the FGFR inhibitor-naive context (8/16 and 9/16 patients, respectively).”
> “Resistance profiles differed markedly from pan-FGFR inhibitors, with decreased FGFR2 V565F/L and N550H/K mutations, increased M538I and L618F mutations, and more frequent RTK-MAPK bypass alterations.”
> “Lirafugratinib retains activity against multiple mutations that confer clinical resistance to pan-FGFR inhibitors.”

Source: [Ellis et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41571046/)

<a id="topic-2.1.2.6.2-7"></a>

###### Nonclinical: phototoxicity and tissue distribution

> “Lirafugratinib absorbs UV radiation and demonstrated phototoxic potential in an in vitro phototoxicity study in BALB/c-3T3 mouse fibroblast cells. In rat tissue distribution studies, lirafugratinib was present in skin and pigmented eyes.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.6.2-8"></a>

###### Nonclinical: carcinogenicity, genotoxicity, and fertility

> “Carcinogenicity studies have not been conducted with lirafugratinib.”
> “Lirafugratinib was not mutagenic in the bacterial reverse mutation (Ames) assay. Lirafugratinib was clastogenic in the in vitro chromosomal aberration assay in human peripheral blood lymphocytes but not clastogenic in the in vivo peripheral blood reticulocyte micronucleus assay in rats.”
> “Dedicated fertility studies with lirafugratinib have not been conducted.”
> “Partial reversibility of these findings was observed following a recovery period.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Dose proportionality, accumulation, and steady state

> “Lirafugratinib maximum concentration (Cmax) is 4.7 mcg/mL (30%) and systemic exposure (AUC) is 77 mcg·h/mL (29%).”
> “increases in a dose proportional manner over the dose range from 20 mg to 100 mg orally once daily (0.3 to 1.4 times the recommended dosage). Lirafugratinib accumulation is approximately 2-fold at the approved recommended dosage. Lirafugratinib steady state is reached in approximately 4 days.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.6.3-2"></a>

###### Absorption and food effect

> “Lirafugratinib median (min, max) time to maximum plasma concentration (Tmax) is 3.9 (1.9 to 8) hours.”
> “No clinically significant difference in lirafugratinib pharmacokinetics were observed following administration of a high-fat, high-calorie meal (approximately 800 to 1000 total calories with 500 to 600 calories from fat).”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### Distribution, metabolism, and elimination

> “Lirafugratinib apparent (oral) volume of distribution is 22 (22%) L. Lirafugratinib plasma protein binding is >99% and is not concentration-dependent in vitro.”
> “Lirafugratinib blood-to-plasma ratio is approximately 0.4.”
> “Lirafugratinib elimination half-life is 23 (34%) hours with an apparent (oral) clearance of 1 (32%) L/h.”
> “Lirafugratinib is primarily metabolized by CYP3A4 and CYP2J2 and to a lesser extent by non-CYP enzymes in vitro.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.6.3-4"></a>

###### Mass balance and excretion in healthy volunteers

> “Lirafugratinib and its metabolites were mainly excreted in feces. Unchanged lirafugratinib represented the predominant circulating component in plasma.”

Source: [Wei et al. (2026)](https://elevartx.com/wp-content/uploads/2026/09/Wei-et-al-ASCPT-Lira-poster-20FEB2026.pdf)

<a id="topic-2.1.2.6.3-5"></a>

###### Recovery of a radiolabeled dose in the prescribing information

> “Following a single oral dose of radiolabeled lirafugratinib 70 mg to healthy subjects, approximately 80% of the dose was recovered in feces (23% unchanged), and 8% was recovered in urine (unchanged lirafugratinib not quantified).”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.6.3-6"></a>

###### Specific populations

> “No clinically significant differences in the pharmacokinetics of lirafugratinib were observed based on age (20-87 years), sex, race (White 59%, Asian 16%, or Black 2.7%), body weight (34-147 kg), CLcr 30-89 mL/min (estimated by Cockcroft-Gault), or mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) hepatic impairment.”
> “The effect of severe renal impairment (CLcr < 30 mL/min) and severe (Child-Pugh Class C) hepatic impairment on lirafugratinib pharmacokinetics is unknown.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Summary: labeled contraindications, warnings, and adverse reactions

The prescribing information lists no contraindications and three warnings and precautions: ocular toxicity, hyperphosphatemia and soft tissue mineralization, and embryo-fetal toxicity. Among 385 participants in the REFOCUS safety population (232 with cholangiocarcinoma and 153 with other solid tumors), retinal pigment epithelial detachment occurred in 31% (grade 3 in 1.8%), with a median time to onset of 57 days, blurred vision in 18%, dry eye in 38%, corneal toxicity or keratitis in 11%, and hyperphosphatemia in 21%, with a median time to onset of 15 days and one dose interruption (0.3%). Ophthalmological examination including optical coherence tomography of the macula is required before treatment, every 2 months for the first 13 months, and every 4 months thereafter. Among the 116 participants with cholangiocarcinoma, serious adverse reactions occurred in 32% and one participant died of hemorrhage; the most frequent adverse reactions were nail toxicity (89%, grade 3 or 4 in 12%), palmar-plantar erythrodysesthesia syndrome (82%, grade 3 or 4 in 33%), stomatitis (80%, grade 3 or 4 in 12%), and alopecia (66%). Treatment-related adverse events led to dose reduction in 75.9%, dose interruption in 82.8%, and discontinuation in 4.3% of participants in the ASCO Gastrointestinal Cancers Symposium 2026 report, and the prescribing information reports permanent discontinuation for an adverse reaction in 5%, dosage interruption in 88%, and dose reduction in 81%. The FDA required a postmarketing randomized trial to characterize severe stomatitis, palmar-plantar erythrodysesthesia syndrome, retinal pigment epithelial detachment, and nail toxicities at 70 mg once daily compared with a lower dosage.

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf); [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/); [Elevar Therapeutics NDA submission announcement (2026)](https://elevartx.com/2026/01/28/elevar-therapeutics-new-drug-application-lirafugratinib/); [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.1.2.7.1-2"></a>

###### Contraindications and boxed warning

> “Contraindications: None.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

> “The prescribing information includes warnings and precautions for ocular toxicity, hyperphosphatemia and soft tissue mineralization, and embryo-fetal toxicity.”

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

<a id="topic-2.1.2.7.1-3"></a>

###### Ocular toxicity: retinal pigment epithelial detachment

> “LYRFIGTU can cause RPED, which may cause symptoms such as blurred vision.”
> “The median time to onset of RPED was 57 days (range 4 to 221).”
> “Perform a comprehensive ophthalmological examination, including OCT of the macula, prior to initiation of therapy, every 2 months for the first 13 months, and every 4 months thereafter. For onset of visual symptoms, obtain ophthalmologic evaluation urgently, with follow-up every 3 weeks until resolution or discontinuation of LYRFIGTU.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “Among 385 patients who received LYRFIGTU, RPED occurred in 31% of patients, including Grade 3 events in 1.8%. The median time to first onset was 57 days. RPED led to dose interruption in 15% of patients and dose reduction in 10%.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.1.2.7.1-4"></a>

###### Ocular toxicity: blurred vision, dry eye, and corneal toxicity

> “Among 385 patients who received LYRFIGTU, blurred vision occurred in 18% of patients with Grade 3 events in 1.3% of patients.”
> “Dry eye occurred in 38% of patients. Treat patients with ocular demulcents as needed.”
> “Among 385 patients who received LYRFIGTU, corneal toxicity/keratitis occurred in 11% of patients. Treat patients with ocular demulcents as needed.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.1.2.7.1-5"></a>

###### Hyperphosphatemia and soft tissue mineralization

> “LYRFIGTU can cause hyperphosphatemia leading to soft tissue mineralization, calcinosis, nonuremic calciphylaxis, and vascular calcification.”
> “The median time to onset of hyperphosphatemia was 15 days (range 6-194).”
> “Monitor patients for hyperphosphatemia throughout treatment.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “Hyperphosphatemia occurred in 21% of patients. The median time to onset was 15 days. Hyperphosphatemia led to dose interruption in one (0.3%) patient and no permanent discontinuation.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.1.2.7.1-6"></a>

###### Embryo-fetal toxicity

> “Based on findings from animal studies and its mechanism of action, LYRFIGTU can cause fetal harm or loss of pregnancy when administered to a pregnant woman.”
> “Advise females of reproductive potential to use effective contraception during treatment with LYRFIGTU and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with LYRFIGTU and for 3 months after the last dose”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.7.1-7"></a>

###### Safety population in the prescribing information

> “The safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to LYRFIGTU 70 mg orally once daily in 385 patients with multiple advanced solid tumors evaluated in REFOCUS including 232 patients with cholangiocarcinoma and 153 patients with other advanced solid tumors.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.7.1-8"></a>

###### Serious adverse reactions, fatal events, and discontinuations in cholangiocarcinoma

> “Serious adverse reactions occurred in 32% of patients. Serious adverse reactions reported in ≥2% of patients were infection (6%), pneumonia (3.4%), fatigue (2.6%), and hemorrhage (2.6%). A fatal adverse reaction of hemorrhage occurred in one patient.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

> “Adverse reactions requiring permanent discontinuation of LYRFIGTU included palmar-plantar erythrodysesthesia syndrome (3 patients), stomatitis, anaphylactic reaction, and infection (1 patient each).”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “Most common Grade ≥3 treatment-related adverse events (TRAEs) were palmar-plantar erythrodysesthesia (32.8%) and stomatitis (12.1%). TRAEs led to dose reduction, dose interruption, and treatment discontinuation were observed in 75.9%, 82.8%, and 4.3%, respectively.”

Source: [Elevar Therapeutics NDA submission announcement (2026)](https://elevartx.com/2026/01/28/elevar-therapeutics-new-drug-application-lirafugratinib/)

<a id="topic-2.1.2.7.1-9"></a>

###### Permanent discontinuation, dosage interruption, and dose reduction for adverse reactions in cholangiocarcinoma

> “Permanent discontinuation due to an adverse reaction occurred in 5% of patients who received LYRFIGTU.”
> “Dosage interruptions due to an adverse reaction occurred in 88% of patients who received LYRFIGTU 70 mg once daily. Adverse reactions requiring dose interruption in ≥5% of patients included palmar-plantar erythrodysesthesia syndrome, nail toxicity, stomatitis, retinal pigment epithelial detachment, rash, infection, fatigue, blurred vision, corneal toxicity, blood bilirubin increased, alanine transferase increased, and pyrexia.”
> “Dose reductions due to an adverse reaction occurred in 81% of patients who received LYRFIGTU. Adverse reactions requiring dose reductions in ≥2% of patients included palmar-plantar erythrodysesthesia syndrome, nail toxicity, stomatitis, retinal pigment epithelial detachment, rash, blurred vision, alanine aminotransferase increased, fatigue, aspartate aminotransferase increased, corneal toxicity and hyponatremia.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.7.1-10"></a>

###### Adverse reactions in 15% or more of participants with cholangiocarcinoma (N=116)

| Adverse reaction | All grades (%) | Grade 3 or 4 (%) |
| --- | --- | --- |
| Nail toxicity | “89” | “12” |
| Palmar-plantar erythrodysaesthesia syndrome | “82” | “33” |
| Stomatitis | “80” | “12” |
| Alopecia | “66” | “0” |
| Dry eye | “53” | “0” |
| Dry mouth | “50” | “0” |
| Fatigue | “43” | “3.4” |
| Dysgeusia | “39” | “0.9” |
| Retinal pigment epithelial detachment | “38” | “1.7” |
| Constipation | “37” | “0.9” |
| Dry skin | “37” | “0” |
| Infection | “34” | “8” |
| Rash | “34” | “5” |
| Abdominal pain | “28” | “3.4” |
| Blurred vision | “22” | “0.9” |
| Diarrhea | “22” | “0.9” |
| Hemorrhage | “22” | “2.6” |
| Nausea | “21” | “1.7” |
| Decreased appetite | “20” | “0” |

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.7.1-11"></a>

###### Laboratory abnormalities worsening from baseline in participants with cholangiocarcinoma

| Laboratory abnormality | All grades (%) | Grade 3 or 4 (%) |
| --- | --- | --- |
| Phosphate increased | “75” | “0” |
| Alanine aminotransferase increased | “53” | “7” |
| Creatinine increased | “52” | “0.9” |
| Sodium decreased | “49” | “20” |
| Hemoglobin decreased | “49” | “8” |
| Lymphocytes decreased | “47” | “7” |
| Blood bilirubin increased | “45” | “5” |
| Aspartate aminotransferase increased | “42” | “5” |
| Platelets decreased | “39” | “3.4” |
| Glucose increased | “37” | “5” |

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.7.1-12"></a>

###### Postmarketing required trial on severe dermatologic, mucosal, ocular, and nail toxicities

> “known serious risks of severe stomatitis, palmar-plantar erythrodysesthesia syndrome, retinal pigment epithelial detachment, and nail toxicities; and to assess a signal of a serious risk of increased drug toxicity when lirafugratinib is used concomitantly with sensitive P-gp and BCRP substrates.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pregnancy and pregnancy testing

> “There are no available data on the use of LYRFIGTU in pregnant women.”
> “Verify pregnancy status of females of reproductive potential prior to initiating LYRFIGTU”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Lactation

> “Because of the potential for serious adverse reactions from LYRFIGTU in breastfed children, advise women not to breastfeed during treatment with LYRFIGTU and for 1 week after the last dose.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.8-3"></a>

###### Contraception and male fertility

> “Advise females of reproductive potential to use effective contraception during treatment with LYRFIGTU and for 6 months after the last dose.”
> “Based on findings from animal studies, LYRFIGTU may impair male reproductive function and fertility.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.8-4"></a>

###### Pediatric use and waiver of pediatric studies

> “The safety and efficacy of LYRFIGTU have not been established in pediatric patients.”
> “In a repeat-dose toxicology study, administration of lirafugratinib to rats for 3 months resulted in marked odontoblast degeneration and fracture of the incisors”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “We are waiving the pediatric studies requirement for this application, in pediatric patients less than 17 years of age because necessary studies are impossible or highly impracticable, due to the exceedingly low incidence of FGFR2 altered tumors.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Geriatric use

> “Of the 385 patients treated with LYRFIGTU 70 mg once daily in REFOCUS, 32% were 65 years or older, and 7% of patients were 75 years or older. No clinically meaningful differences in safety or effectiveness of LYRFIGTU have been observed between patients 65 years or older and younger adult patients.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.8-6"></a>

###### Hepatic impairment

> “No dosage modifications are recommended for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. LYRFIGTU has not been studied in patients with severe (Child-Pugh Class C) hepatic impairment.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.8-7"></a>

###### Renal impairment

> “No clinically significant differences in the pharmacokinetics of lirafugratinib were observed based on age (20-87 years), sex, race (White 59%, Asian 16%, or Black 2.7%), body weight (34-147 kg), CLcr 30-89 mL/min (estimated by Cockcroft-Gault)”
> “The effect of severe renal impairment (CLcr < 30 mL/min) and severe (Child-Pugh Class C) hepatic impairment on lirafugratinib pharmacokinetics is unknown.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Lirafugratinib

<a id="topic-2.1.2.9.1-1"></a>

###### Strong and moderate CYP3A inhibitors

> “Avoid concomitant use of LYRFIGTU with strong or moderate CYP3A inhibitors. Reduce LYRFIGTU dosage if concomitant use cannot be avoided [see Dosage and Administration (2.4)].”
> “increased 1.3-fold and AUC 2-fold following coadministration with itraconazole 200 mg once daily for 8 days.”
> “is predicted to increase 1.1-fold and AUC 1.7-fold following coadministration with erythromycin (moderate CYP3A inhibitor) 500 mg four times a day for 15 days.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.9.1-2"></a>

###### Strong and moderate CYP3A inducers

> “Avoid concomitant use of strong or moderate CYP3A inducers.”
> “Concomitant use of LYRFIGTU with a strong or moderate CYP3A inducer may decrease lirafugratinib exposure [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of LYRFIGTU.”
> “is predicted to decrease to 65% and AUC to 25% following coadministration of rifampicin (strong CYP3A inducer) 600 mg once daily for 19 days.”
> “is predicted to decrease to 85% and AUC to 43% following coadministration of efavirenz (moderate CYP3A inducer) 600 mg once daily for 19 days.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.9.1-3"></a>

###### Acid-reducing agents, P-gp inhibitors, and transporter substrate status

> “No clinically significant differences in lirafugratinib pharmacokinetics are predicted when used concomitantly with quinidine (P-gp inhibitor). No clinically significant differences in lirafugratinib pharmacokinetics were observed when administered concomitantly with esomeprazole (proton pump inhibitor).”
> “Lirafugratinib is a P-gp and BCRP substrate, but not of OCT1, OATP1B1, OATP1B3, or BSEP.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Lirafugratinib on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### P-gp, BCRP, OATP1B1, and OATP1B3 substrates

> “Monitor for increased adverse reactions for P-gp, BCRP, OATP1B1, and/or OATP1B3 substrates in which minimal concentration changes may lead to serious adverse reactions. Follow the recommended dosage modifications in the approved prescribing information for these substrates.”
> “Lirafugratinib inhibits P-gp, BCRP, OATP1B1, and OATP1B3 in-vitro. Lirafugratinib may increase exposure of drugs that are substrates of P-gp, BCRP, OATP1B1, or OATP1B3, which may increase the risk of adverse reactions of these substrates [see Clinical Pharmacology (12.3)].”
> “Lirafugratinib inhibits P-gp,MATE1, MATE2-K, OCT1, OCT2, OATP1B1, OATP1B3, BCRP, and BSEP, but does not inhibit OAT1 or OAT3.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.9.2-2"></a>

###### Cytochrome P450 substrates

> “No clinically significant differences in the pharmacokinetics of the following drugs are predicted when used concomitantly with lirafugratinib: repaglinide (CYP2C8 substrate), tolbutamide (CYP2C9 substrate), omeprazole (CYP2C19 substrate), desipramine (CYP2D6 substrate), midazolam (CYP3A substrate), and caffeine (CYP1A2 substrate).”
> “Lirafugratinib both induces and inhibits CYP2B6.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.9.2-3"></a>

###### Required clinical drug interaction trial with a P-gp and BCRP substrate

> “Conduct a clinical pharmacokinetic trial to assess a serious potential risk of increased drug toxicity by evaluating the effect of repeat doses of lirafugratinib on the single dose pharmacokinetics of a sensitive P-gp and BCRP substrate and inform appropriate management strategies for clinically relevant drug interactions.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.1.2.9.2-4"></a>

###### Preclinical inhibition of ABCG2 (BCRP)-mediated efflux

> “Our findings reveal that lirafugratinib, at concentrations that do not impair cell viability, restores sensitivity to ABCG2-substrate chemotherapeutic drugs and enhances apoptosis in ABCG2-overexpressing nonsmall cell lung cancer cells.”
> “Mechanistically, lirafugratinib impedes the efflux capability of ABCG2 without altering its protein expression.”
> “Submicromolar concentrations of lirafugratinib (100–500 nM) markedly reduced the IC50 values of the ABCG2 substrate drugs mitoxantrone, SN-38, and topotecan”
> “In contrast, lirafugratinib had no effect on the cytotoxicity of the non-ABCG2 substrate cisplatin, used as a negative control (Fig. 2D, H, L). Notably, lirafugratinib did not enhance the efficacy of chemotherapeutic agents in ABCB1-overexpressing models (data not shown), further supporting its selectivity toward ABCG2.”
> “At 1 μM, lirafugratinib significantly increased intracellular PhA fluorescence in H460-MX20 (Fig. 4A), A549-Bec150 (Fig. 4B), and ABCG2-transfected HEK293 cells (Fig. 4C), to an extent comparable”
> “These findings indicate that ABCG2 overexpression does not measurably influence lirafugratinib cytotoxicity and support the conclusion that lirafugratinib is not efficiently transported by ABCG2 at cytotoxic concentrations.”

Source: [Wu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41831281/)

| ABCG2 substrate, resistant cell line | IC50 without lirafugratinib, nM (FR) | IC50 with lirafugratinib 0.5 μM, nM (FR) | IC50 with Ko143 1.0 μM, nM (FR) |
| --- | --- | --- | --- |
| Mitoxantrone, H460-MX20 | “127.47 ± 19.02 (1.0)” | “5.26 ± 0.54*** (24.2)” | “5.10 ± 0.55*** (25.0)” |
| SN-38, H460-MX20 | “287.93 ± 57.81 (1.0)” | “10.49 ± 2.03** (27.4)” | “5.74 ± 1.26** (50.2)” |
| Topotecan, H460-MX20 | “476.00 ± 135.61 (1.0)” | “30.23 ± 6.11** (15.7)” | “26.77 ± 7.41** (17.8)” |
| Mitoxantrone, A549-Bec150 | “177.86 ± 29.58 (1.0)” | “8.07 ± 0.99*** (22.0)” | “16.10 ± 2.49*** (11.0)” |
| SN-38, A549-Bec150 | “550.15 ± 62.74 (1.0)” | “16.04 ± 2.44*** (34.3)” | “12.54 ± 1.26*** (43.9)” |
| Topotecan, A549-Bec150 | “386.80 ± 105.85 (1.0)” | “38.02 ± 6.68** (10.2)” | “39.51 ± 8.09** (9.8)” |

Source: [Wu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41831281/)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Recommended dosage

> “The recommended dosage of LYRFIGTU is 70 mg orally once daily until disease progression or unacceptable toxicity.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “The first part of the trial, or the dose escalation, is complete, and the second part of the trial, or the dose expansion, is ongoing at the 70mg once daily recommended Phase 2 dose.”

Source: [Relay Therapeutics Form 8-K (2023)](https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/rlay-20231012.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Dose reductions for adverse reactions

| Dose reduction | Dosage |
| --- | --- |
| First | “50 mg once daily” |
| Second | “40 mg once daily” |
| Third | “30 mg once daily” |
| Fourth | “20 mg once daily” |

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “Permanently discontinue LYRFIGTU if the patient is unable to tolerate 20 mg once daily.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.10.1-3"></a>

###### Dose modification for retinal pigment epithelial detachment

> “Continue LYRFIGTU at the current dose and continue periodic ophthalmic evaluation”
> “Withhold LYRFIGTU until resolution, then resume at 1 dose level lower”
> “Withhold LYRFIGTU until resolution, then resume at 2 dose levels lower”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.10.1-4"></a>

###### Dose modification for other adverse reactions

| Severity | Dosage modification |
| --- | --- |
| “Grade 3” | “Withhold LYRFIGTU until toxicity resolves to Grade ≤1 or baseline, then resume LYRFIGTU at 1 dose level lower.” |
| “Grade 3” | “If Grade 3 toxicity recurs, withhold LYRFIGTU until toxicity resolves to Grade ≤1 or baseline, then resume at 1 dose level lower or permanently discontinue LYRFIGTU.” |
| “Grade 4” | “Withhold LYRFIGTU until toxicity resolves to Grade ≤2 or baseline, then resume LYRFIGTU at 1 dose level lower or permanently discontinue LYRFIGTU” |

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.10.1-5"></a>

###### Dose modification with strong or moderate CYP3A inhibitors

> “Avoid concomitant use. If concomitant use cannot be avoided, reduce LYRFIGTU dosage to 40 mg once daily.”
> “Avoid concomitant use. If concomitant use cannot be avoided, reduce LYRFIGTU dosage to 50 mg once daily.”
> “After a CYP3A inhibitor has been discontinued for 3 elimination half-lives, resume LYRFIGTU at the dosage that was used before starting the inhibitor [see Clinical Pharmacology (12.3)].”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.10.1-6"></a>

###### Dosage in organ impairment

> “No dosage modifications are recommended for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Route, food, and swallowing

> “Take LYRFIGTU with or without food [see Clinical Pharmacology (12.3)].”
> “Swallow capsules whole. Do not open, break or chew the capsules.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.10.2-2"></a>

###### Missed doses and vomiting

> “If a dose of LYRFIGTU is missed, take the missed dose as soon as possible within 4 hours. If a dose is missed by 4 hours or more, skip the missed dose and take the dose at the next scheduled time.”
> “If vomiting occurs after taking LYRFIGTU, do not take another dose. Take LYRFIGTU at the next scheduled time.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.10.2-3"></a>

###### Patient counseling on phototoxicity

> “Inform patients that LYRFIGTU may cause phototoxicity and advise the use of sunscreen, protective clothing, and sunglasses, as well as minimizing sun exposure [see Nonclinical Toxicology (13.2)].”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Commercial availability

> “Lyrfigtu is expected to be available to patients in the U.S. by Q4 2026.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.1.2.11-2"></a>

###### Patient support program: Elevar Care Connect, with expected availability in December 2026

> “Elevar Is Committed to Supporting Patients Throughout Their Treatment Journey With Elevar Care Connect”
> “NOW APPROVED!”
> “Expected Availability December 2026”

Source: [Elevar Care Connect (2026)](https://elevarcareconnect.com/)

> “Learn about financial support programs, including co-pay assistance and prescription assistance.”

Source: [Elevar Therapeutics LYRFIGTU website](https://lyrfigtu.com/)

<a id="topic-2.1.2.11-3"></a>

###### Companion diagnostic availability

> “An FDA-authorized test for detection of FGFR2 gene fusions or other rearrangements in patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma for selecting patients for treatment with LYRFIGTU is not available.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “For example, we have engaged Foundation Medicine, Inc. to develop its FoundationOne®CDx as a companion diagnostic for lirafugratinib.”

Source: [Relay Therapeutics Form 10-K (2024)](https://www.sec.gov/Archives/edgar/data/1812364/000095017024018797/rlay-20231231.htm)

> “Conduct adequate analytical and clinical validation studies to support revisions to the labeling of lirafugratinib to specify the use of an FDA-authorized in vitro companion diagnostic device to accurately and reliably identify patients using blood and/or tissue samples who have FGFR2 fusions and other rearrangements and for whom lirafugratinib therapy is indicated.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.1.2.11-4"></a>

###### Specialty pharmacy and distribution network

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Prior systemic therapy required before lirafugratinib

> “All patients had received at least one prior line of platinum-based systemic therapy”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.12-2"></a>

###### Ocular demulcents and lubricating eye products

> “to use artificial tears or hydrating or lubricating eye gels to prevent or treat dry eyes [see Warnings and Precautions (5.1)].”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

> “Dry eye occurred in 38% of patients. Treat patients with ocular demulcents as needed.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.1.2.12-3"></a>

###### Serum phosphate monitoring and phosphate management

> “Monitor serum phosphate throughout treatment and manage as clinically appropriate.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

> “Phosphate binders were required in 7 (1.8%) patients who received LYRFIGTU.”
> “Inform patients that LYRFIGTU may cause hyperphosphatemia and soft tissue mineralization and to immediately inform their healthcare provider of any symptoms related to acute change in phosphate levels such as muscle cramps, numbness, or tingling around the mouth”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.12-4"></a>

###### Scheduled ophthalmologic examinations with optical coherence tomography

> “Perform a comprehensive ophthalmological examination, including OCT of the macula, prior to initiation of therapy, every 2 months for the first 13 months, and every 4 months thereafter.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.12-5"></a>

###### Contraception and sun protection

> “Advise males with female partners of reproductive potential to use effective contraception during treatment with LYRFIGTU and for 3 months after the last dose.”
> “Inform patients that LYRFIGTU may cause phototoxicity and advise the use of sunscreen, protective clothing, and sunglasses, as well as minimizing sun exposure [see Nonclinical Toxicology (13.2)].”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.1.2.12-6"></a>

###### Concomitant medications to avoid

> “Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, and herbal products.”

Source: [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Lirafugratinib on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Summary: comparison with other FGFR inhibitors approved for FGFR2 fusion-positive cholangiocarcinoma

Three other FGFR inhibitors have been approved by the FDA for previously treated FGFR2 fusion- or rearrangement-positive cholangiocarcinoma, each under accelerated approval based on response rate and duration of response: pemigatinib (Pemazyre, 2020), infigratinib (Truseltiq, 2021; withdrawn 16 May 2024, with United States distribution discontinued), and futibatinib (Lytgobi, 2022). Their pivotal single-arm trials reported objective response rates of 36% (pemigatinib, N=107), 23% (infigratinib, N=108), and 42% (futibatinib, N=103), with median durations of response of 9.1, 5.0, and 9.7 months; the FIGHT-202 final analysis reported an objective response rate of 37.0% for pemigatinib. In REFOCUS, lirafugratinib produced an objective response rate of 46% (N=116) with a median duration of response of 11.8 months. The labels differ in dosing (lirafugratinib 70 mg and futibatinib 20 mg once daily continuously; pemigatinib 13.5 mg for 14 of 21 days; infigratinib 125 mg for 21 of 28 days on an empty stomach). Hyperphosphatemia was reported in 93%, 82%, and 88% of participants receiving pemigatinib, infigratinib, and futibatinib across clinical trials, with phosphate-lowering therapy or binders in 33%, 83%, and 77%, compared with 21% for lirafugratinib, consistent with its preclinical selectivity over FGFR1. Retinal pigment epithelial detachment was reported in 31% of participants receiving lirafugratinib, with monitoring that included optical coherence tomography, and in 9% to 11% of participants receiving the other agents, whose trials did not routinely include optical coherence tomography; lirafugratinib labeling requires examination every 2 months for 13 months, compared with every 2 months for 6 months for pemigatinib and futibatinib. Pemigatinib and infigratinib were approved with an FDA-approved test, whereas no FDA-authorized test is available for lirafugratinib. Preclinically, lirafugratinib retained potency against the FGFR2 V564F gatekeeper mutation, against which pan-FGFR inhibitors showed a more than 55-fold loss of potency. No head-to-head or indirect treatment comparison of lirafugratinib with another FGFR inhibitor has been published. In an institutional cohort in which the second FGFR inhibitor after progression was lirafugratinib in 12 participants and futibatinib in 10, all 3 partial responses (13.6%) occurred with lirafugratinib, and the authors state that differences in clinical activity across FGFR inhibitors may reflect confounding factors. For the comparators, a matching-adjusted indirect comparison reviewed by NICE gave hazard ratios for futibatinib compared with pemigatinib of 0.95 (95% CI 0.72 to 1.21) for overall survival and 1.07 (95% CI 0.86 to 1.30) for progression-free survival. A reported average monthly United States price of $44,000 for futibatinib was identified, and NICE reports list prices in England of £7,159.04 for a pack of 14 pemigatinib 13.5 mg tablets and £2,386.33 per pack of futibatinib; no lirafugratinib price has been published.

Source: [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf); [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf); [FDA TRUSELTIQ prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf); [FDA Withdrawn Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals); [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf); [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic); [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/); [Vogel et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190465/); [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/); [Roskoski (2024)](https://pubmed.ncbi.nlm.nih.gov/38096958/); [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/); [NICE TA1005 committee discussion (2024)](https://www.nice.org.uk/guidance/ta1005/chapter/3-Committee-discussion); [NICE TA722 information about pemigatinib (2021)](https://www.nice.org.uk/guidance/ta722/chapter/2-Information-about-pemigatinib); [NICE TA1005 information about futibatinib (2024)](https://www.nice.org.uk/guidance/ta1005/chapter/2-Information-about-futibatinib)

<a id="topic-2.1.2.14-2"></a>

###### Lirafugratinib: REFOCUS efficacy supporting approval

> “ORR was 46% (95% CI: 36, 55) and median DOR was 11.8 months (95% CI: 7.5, 13.0).”

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

> “Median progression-free survival was 11.3 months (95% CI, 9.2, 14.8), with a 12-month rate of 49.2%.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.1.2.14-3"></a>

###### Pemigatinib (Pemazyre): labeled indication, regimen, and approval pathway

> “This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).”
> “Recommended dosage is 13.5 mg orally once daily for 14 consecutive days followed by 7 days off therapy in 21-day cycles.”

Source: [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Pemigatinib (Pemazyre): FIGHT-202 efficacy in the label

| Efficacy parameter | FIGHT-202, N=107 |
| --- | --- |
| ORR (95% CI) | “36% (27, 45)” |
| Median DoR, months (95% CI) | “9.1 (6.0, 14.5)” |
| Patients with DoR ≥ 6 months, n (%) | “24 (63%)” |

Source: [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Pemigatinib: FIGHT-202 final analysis

> “The ORR in cohort A was 37.0% (95% confidence interval 27.9% to 46.9%); complete and partial responses were observed in 3 and 37 patients, respectively.”
> “Median DOR was 9.1 (6.0-14.5) months; median PFS and OS were 7.0 (6.1-10.5) months and 17.5 (14.4-22.9) months, respectively.”
> “The most common TEAEs of any grade were hyperphosphatemia (58.5%), alopecia (49.7%), and diarrhea (47.6%).”

Source: [Vogel et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190465/)

<a id="topic-2.1.2.14-6"></a>

###### Pemigatinib (Pemazyre): hyperphosphatemia and retinal pigment epithelial detachment

> “Among 635 patients who received a starting dose of PEMAZYRE 13.5 mg across clinical trials, hyperphosphatemia was reported in 93% of patients based on laboratory values above the upper limit of normal.”
> “Phosphate lowering therapy was required in 33% of patients receiving PEMAZYRE.”
> “Among 635 patients who received a starting dose of PEMAZYRE 13.5 mg across clinical trials, RPED occurred in 11% of patients, including Grade 3-4 RPED in 1.3%.”

Source: [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

###### Futibatinib (Lytgobi): labeled indication, regimen, and approval pathway

> “LYTGOBI is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.”
> “This indication is approved under accelerated approval based on overall response rate and duration of response.”

Source: [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

###### Futibatinib (Lytgobi): TAS-120-101 efficacy in the label

| Efficacy parameter | TAS-120-101, N=103 |
| --- | --- |
| ORR (95% CI) | “42% (32, 52)” |
| Median DoR, months (95% CI) | “9.7 (7.6, 17.1)” |
| DoR ≥6 months, n (%) | “31 (72%)” |

Source: [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

###### Futibatinib: FOENIX-CCA2 phase 2 trial

> “A total of 43 of 103 patients (42%; 95% confidence interval, 32 to 52) had a response, and the median duration of response was 9.7 months.”
> “At a median follow-up of 17.1 months, the median progression-free survival was 9.0 months and overall survival was 21.7 months.”
> “Common treatment-related grade 3 adverse events were hyperphosphatemia (in 30% of the patients), an increased aspartate aminotransferase level (in 7%), stomatitis (in 6%), and fatigue (in 6%).”

Source: [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)

<a id="topic-2.1.2.14-10"></a>

###### Futibatinib (Lytgobi): hyperphosphatemia and retinal pigment epithelial detachment

> “Among 318 patients who received LYTGOBI across clinical trials [see Adverse Reactions (6.1)], hyperphosphatemia was reported in 88% of patients based on laboratory values above the upper limit of normal.”
> “Phosphate binders were received by 77% of patients who received LYTGOBI.”
> “Among 318 patients who received LYTGOBI across clinical trials [see Adverse Reactions (6.1)] where ophthalmologic monitoring did not routinely include optical coherence tomography (OCT), RPED occurred in 9% of patients.”

Source: [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf)

<a id="topic-2.1.2.14-11"></a>

###### Futibatinib (Lytgobi): confirmatory requirement

> “Conduct a randomized clinical trial comparing dosages of futibatinib 16 mg and 20 mg once daily to verify and describe the clinical benefit of futibatinib in patients with advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.”

Source: [FDA Ongoing Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)

<a id="topic-2.1.2.14-12"></a>

###### Pemigatinib (Pemazyre): confirmatory requirement

> “Submit the results of a randomized trial demonstrating improvement of PFS or OS in patients with unresectable locally advanced or metastatic cholangiocarcinoma with a FGFR2 gene fusion or rearrangement, to confirm clinical benefit of pemigatinib.”

Source: [FDA Ongoing Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals)

<a id="topic-2.1.2.14-13"></a>

###### Infigratinib (Truseltiq): labeled regimen and efficacy

> “Recommended dosage: 125 mg orally once daily for 21 consecutive days followed by 7 days off therapy, in 28-day cycles.”
> “Take on an empty stomach at least 1 hour before or 2 hours after food, at approximately the same time each day.”

Source: [FDA TRUSELTIQ prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf)

| Efficacy parameter | CBGJ398X2204, N=108 |
| --- | --- |
| ORR (95% CI) | “23% (16, 32)” |
| Median DoR, months (95% CI) | “5.0 (3.7, 9.3)” |
| Patients with DoR ≥6 months, n (%) | “8 (32%)” |

Source: [FDA TRUSELTIQ prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf)

<a id="topic-2.1.2.14-14"></a>

###### Infigratinib (Truseltiq): hyperphosphatemia and retinal pigment epithelial detachment

> “Among 351 patients who received TRUSELTIQ across clinical trials [see Adverse Reactions (6.1)], hyperphosphatemia was reported in 82% of patients based on laboratory values above the upper limit of normal.”
> “Phosphate binders were received by 83% of patients who received TRUSELTIQ.”

Source: [FDA TRUSELTIQ prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214622s000lbl.pdf)

<a id="topic-2.1.2.14-15"></a>

###### Infigratinib (Truseltiq): withdrawal of the accelerated approval

| Field | Quoted record |
| --- | --- |
| Drug name | “Truseltiq (infigratinib)” |
| Accelerated approval date | “5/28/2021” |
| Withdrawal date | “5/16/2024” |

Source: [FDA Withdrawn Cancer Accelerated Approvals (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals)

> “Infigratinib had also been approved for the treatment of this uncommon disorder, but the distribution of this FGFR inhibitor has been discontinued in the United States [84].”

Source: [Roskoski (2024)](https://pubmed.ncbi.nlm.nih.gov/38096958/)

<a id="topic-2.1.2.14-16"></a>

###### Guideline position of FGFR inhibitors after progression

> “Futibatinib [ESMO-Magnitude of Clinical Benefit (MCBS) v1.1 score: 3] and pemigatinib (ESMO-MCBS v1.1 score: 2) are recommended in patients with FGFR2 fusions or rearrangements who have progressed after one or more prior lines of systemic therapy [III, A; ESCAT score: I-B].”
> “These findings led to both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approval of pemigatinib and futibatinib.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.1.2.14-17"></a>

###### Selectivity and resistance-mutation coverage compared with pan-FGFR inhibitors

> “Although the clinical efficacy of pan-FGFR inhibitors (pan-FGFRi) validates FGFR2 driver status in FGFR2 fusion–positive intrahepatic cholangiocarcinoma, their benefit is limited by incomplete target coverage due to FGFR1- and FGFR4-mediated toxicities (hyperphosphatemia and diarrhea, respectively) and the emergence of FGFR2 resistance mutations.”
> “Our data align with these clinical findings, showing that current pan-FGFRi do not retain potency on FGFR2V564F, resulting in a >55-fold shift in IC50 between FGFR2WT and this mutation. In contrast, RLY-4008 is more potent on FGFR2V564F than FGFR2WT.”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

> “Lirafugratinib is an irreversible inhibitor that selectively targets FGFR2, differentiating it from existing pan-FGFR inhibitors that broadly inhibit FGFR1, FGFR3, and/or FGFR4 in addition to FGFR2. Consistent with its high selectivity, the rates of hyperphosphatemia and diarrhea – adverse events commonly associated with non-selective FGFR inhibitors – were 20.7% and 21.6%, respectively.”

Source: [Elevar Therapeutics EMA submission announcement (2026)](https://elevartx.com/2026/09/15/elevar-ema-authorization-application-1/)

<a id="topic-2.1.2.14-18"></a>

###### Acquired resistance to FGFR inhibition and next-generation agents

> “Cholangiocarcinoma is a rare, aggressive cancer often driven by FGFR2 fusions, which are targetable with inhibitors such as pemigatinib and futibatinib. However, resistance frequently develops due to acquired FGFR2 mutations.”
> “Among 51 patients included in the efficacy evaluable set, the objective response rate was 6·3% (95% CI 0·2-30·2; one confirmed partial response) in cohort A1, 30·0% (6·7-65·3; three confirmed partial responses) in cohort A2, 23·1% (5·0-53·8; three confirmed partial responses) in cohort B, and 0% in cohort C.”

Source: [Javle et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41349554/)

<a id="topic-2.1.2.14-19"></a>

###### Lirafugratinib and futibatinib as a second FGFR inhibitor in an institutional cohort

> “The only two second FGFRi used were lirafugratinib 12 (54.5%) and futibatinib 10 (45.5%).”
> “second FGFRi was associated with diminished efficacy with 10 (47.6%) vs 3 (13.6%) PR, all of them with lirafugratinib and none with futibatinib (Table 5).”
> “Interestingly, stable disease was achieved in 13 (59.1%) of patients treated by a second FGFRi in 7 patients with lirafugratinib and 6 with futibatinib.”
> “However, differences in clinical activity across FGFRi, such as the superior tumor shrinkage observed with lirafugratinib compared to infigratinib, may also reflect confounding factors such as FGFR alteration types or tumor type distribution, rather than intrinsic drug potency alone.”

Source: [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/)

<a id="topic-2.1.2.14-20"></a>

###### Head-to-head or indirect treatment comparisons

No evidence found.

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Summary: definition of cholangiocarcinoma and of FGFR2 fusion or rearrangement-positive disease

Cholangiocarcinoma is a malignancy of the biliary epithelium, usually an adenocarcinoma, classified by anatomic site as intrahepatic, perihilar, or distal. In the United States, perihilar disease accounts for approximately 50% to 60% of cholangiocarcinomas, distal disease for 20% to 30%, and intrahepatic disease for 10% to 20%, and cholangiocarcinoma comprises approximately 15% of primary liver tumours. Together with gallbladder and ampullary cancer, it forms biliary tract cancer, which accounts for less than 1% of all cancers worldwide.

The indication is defined by a genomic alteration. FGFR2 fusions or rearrangements occur almost exclusively in intrahepatic cholangiocarcinoma. The fusions most commonly join FGFR2 exons 1 to 17, which carry the extracellular and kinase domains, to one of many partner genes, and loss of the C-terminal negative regulatory domain encoded by exon 18 leads to constitutive kinase activity. The previously treated population is the population in which lirafugratinib was approved: adults with unresectable, locally advanced or metastatic disease after prior systemic therapy, which in REFOCUS meant prior chemotherapy or chemoimmunotherapy without a prior FGFR inhibitor.

Most established risk factors for cholangiocarcinoma share chronic inflammation of the biliary epithelium and bile stasis, including choledochal cyst, Caroli disease, primary sclerosing cholangitis, choledocholithiasis, cirrhosis, chronic hepatitis B and C, and, in endemic regions, liver fluke infection; cirrhosis, non-alcoholic fatty liver disease, and hepatitis B are more strongly associated with intrahepatic disease. In most locations the majority of cases have no identifiable risk factor. No risk factor specific to FGFR2 fusion-positive disease was identified in the cited sources; in one institutional series FGFR alterations were more frequent in participants aged 40 years or younger (20%) than in older participants (6.7%).

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/); [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10767308/); [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/); [Jain et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/35135097/); [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

<a id="topic-2.2.1.1-2"></a>

###### Definition: biliary tract cancer comprises cholangiocarcinoma, gallbladder cancer, and ampullary cancer

> “Biliary tract cancer is a term that includes cholangiocarcinoma (either intrahepatic or extrahepatic in origin) and cancers of the gallbladder and ampulla of Vater. These uncommon cancers arising from the biliary tract account for less than 1% of all cancers worldwide.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “Biliary tract cancer (BTC), including cholangiocarcinoma, gallbladder cancer, and (to a lesser degree) ampullary tumours, are aggressive malignancies.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.1-3"></a>

###### Definition: anatomical classification of cholangiocarcinoma

> “Cholangiocarcinoma (CCA) constitutes a diverse group of malignancies emerging in the biliary tree. CCAs are divided into three subtypes depending on their anatomical site of origin: intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) CCA”
> “iCCAs arise above the second-order bile ducts, whereas the point of anatomical distinction between pCCA and dCCA is the insertion of the cystic duct.”
> “In the USA, pCCA is the single largest group, accounting for approximately 50–60% of all CCAs, followed by dCCA (20–30%) and iCCA (10–20%)”
> “CCA is the second most common primary hepatic malignancy after hepatocellular carcinoma (HCC), comprising approximately 15% of all primary liver tumours and 3% of gastrointestinal cancers”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “Cholangiocarcinoma (CCA) is a highly lethal, epithelial cell malignancy that occurs anywhere along the biliary tree and/or within the hepatic parenchyma.”
> “These cancers are heterogeneous and are best classified according to the primary, anatomic subtype as intrahepatic CCA (iCCA), perihilar CCA (pCCA) or distal CCA (dCCA)”
> “Most CCAs are adenocarcinomas and other histological subtypes, such as adenosquamous carcinoma or clear cell carcinoma, are encountered rarely”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.1-4"></a>

###### Definition: guideline classification of biliary tract cancer and its subtypes

> “BTCs refer to a spectrum of invasive tumours, usually adenocarcinomas, arising from the gallbladder or cystic duct [gallbladder carcinoma (GBC)] or the biliary tree (CCA).”
> “pCCA and dCCA collectively comprise extrahepatic CCA, although this latter classification is discouraged due to insufficient anatomical specificity.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="topic-2.2.1.1-5"></a>

###### Definition: the previously treated advanced population after first-line cisplatin and gemcitabine

> “Patients were eligible if they were aged 18 years or older and had histologically or cytologically verified locally advanced or metastatic biliary tract cancer (including cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma) with documented radiological disease progression to previous first-line cisplatin and gemcitabine chemotherapy.”
> “In all enrolled patients, the primary tumour sites were intrahepatic cholangiocarcinoma (in 72 [44%] of 162 patients), extrahepatic cholangiocarcinoma (45 [28%]), gallbladder (34 [21%]), and ampullary cancer (11 [7%]).”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “More recently, the addition of immune checkpoint inhibitors [specifically durvalumab (TOPAZ-1 trial3) and pembrolizumab (KEYNOTE-966 trial4)] to cisplatin–gemcitabine has demonstrated significant improvements in overall survival (OS).”
> “However, for ∼60% of patients diagnosed with ABC, there is currently no targetable alteration identified; thus second-line therapy options will be limited to further cytotoxic chemotherapy.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.1-6"></a>

###### Etiology: chronic inflammation of the biliary epithelium and bile stasis

> “Several risk factors, both common and rare, have been linked to CCA (Table 1). Although some risk factors are shared by all forms of CCA, others seem to be more specific for one subtype and seem to be more important in different regions. A common characteristic amongst many of these risk factors is that they are associated with chronic inflammation of the biliary epithelium and bile stasis”
> “However, in most locations, the majority of CCA cases remain sporadic, without any identifiable risk factor present.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “In endemic regions, liver fluke infection is associated with CCA, owing to the oncogenic effect of the associated chronic biliary tract inflammation. In other regions, CCA can be associated with chronic biliary tract inflammation owing to choledocholithiasis, cholelithiasis, or primary sclerosing cholangitis, but most CCAs have no identifiable cause.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.1-7"></a>

###### Etiology: reported effect sizes for risk factors for cholangiocarcinoma

| Risk factor | Study type | Reported effect size, intrahepatic disease | Reported effect size, extrahepatic disease |
| --- | --- | --- | --- |
| Caroli disease | “Population-based study” | “OR 38 for iCCA” | “OR 97 for eCCA” |
| Choledochal cyst | “Meta-analysis” | “OR 26.71 for iCCA” | “OR 34.94 for eCCA” |
| Primary sclerosing cholangitis | “Population-based study” | “OR 22 for iCCA” | “OR 41 for eCCA” |
| Cirrhosis | “Meta-analysis” | “OR 15.32 for iCCA” | “OR 3.82 for eCCA” |
| Choledocholithiasis | “Meta-analysis” | “OR 10.08 for iCCA” | “OR 18.58 for eCCA” |
| Chronic hepatitis B | “Meta-analysis” | “OR 4.57 for iCCA” | “OR 2.11 for eCCA” |
| Chronic hepatitis C | “Meta-analysis” | “OR 4.28 for iCCA” | “OR 1.98 for eCCA” |
| Cholelithiasis | “Meta-analysis” | “OR 3.38 for iCCA” | “OR 5.92 for eCCA” |
| Chronic pancreatitis | “Population-based study” | “OR 2.7 for iCCA” | “OR 6.6 for eCCA” |
| Inflammatory bowel disease | “Meta-analysis” | “OR 2.68 for iCCA” | “OR 2.37 for eCCA” |
| Nonalcoholic fatty liver disease | “Meta-analysis” | “OR 2.2 for iCCA” | “OR 1.5 for eCCA” |
| Type 2 diabetes mellitus | “Meta-analysis” | “OR 1.73 for iCCA” | “OR 1.5 for eCCA” |

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.1-8"></a>

###### Etiology: liver fluke infection in endemic regions

> “Infections with specific trematodes are a major cause of CCA in some regions, and these flatworm parasites are group 1 biological carcinogens, that is, definite causes of cancer, including several fish-borne liver flukes of the Opisthorchiidae family”
> “The incidence of CCA associated with liver fluke infection, calculated as an age-standardized rate, varies by geographical region and other risk factors but has exceeded 100 per 100,000 in men and 40 per 100,000 in women in hotspots in northeast Thailand”
> “At least 700 million people are at risk of infection with these liver flukes”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.1-9"></a>

###### Etiology: subtype-specific risk factors outside endemic regions

> “In Western countries, primary sclerosing cholangitis is the most well-known risk factor for CCA7. Several risk factors are associated with all three subtypes, whereas others are subtype-specific. For example, Caroli disease and choledochal cysts (congenital disorders of the bile ducts) have a strong association with all three CCA subtypes52,53. By contrast, cirrhosis, non-alcoholic fatty liver disease (NAFLD) and hepatitis B have a stronger association with iCCA, whereas choledocholithiasis (bile duct stones) has a stronger correlation with pCCA and/or dCCA52. The global rise in obesity and NAFLD may be contributing to the rising rates of iCCA. Although multiple risk factors for CCA exist, most CCAs do not have an identifiable risk factor.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.1-10"></a>

###### Etiology: regional variation in risk factors and reported odds ratios

> “Risk factors for CCA, which vary between regions, share chronic inflammation of the biliary epithelium as a key feature.”
> “Cirrhosis and hepatotropic viruses are risk factors for iCCA, with odds ratios of 22.92 [95% confidence interval (CI) 18.24-28.79] for cirrhosis, 5.10 (95% CI 2.91-8.95) for hepatitis B virus (HBV) and 4.84 (95% CI 2.41-9.71) for hepatitis C virus (HCV), according to a recent meta-analysis.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

<a id="topic-2.2.1.2.1-1"></a>

###### Summary: incidence of cholangiocarcinoma and of the FGFR2 fusion-positive previously treated population

No registry reports the incidence of previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma. It is estimated from the incidence of cholangiocarcinoma, the frequency of FGFR2 fusions or rearrangements, and the proportion of participants who reach later-line therapy. The American Cancer Society estimates that about 8,000 people in the United States are diagnosed with bile duct cancer each year, and notes that the true number is likely higher because some cases are misclassified. In the Surveillance, Epidemiology, and End Results program, the age-adjusted incidence of intrahepatic cholangiocarcinoma rose 148.8% between 2001 and 2017, from 0.80 to 1.99 per 100 000 person-years, while extrahepatic cholangiocarcinoma rose 7.5%.

FGFR2 fusions or rearrangements are reported in 10% to 16% of intrahepatic cholangiocarcinomas and in 9.2% of 6,802 cholangiocarcinoma samples profiled in one genomic dataset (see 2.2.1.2.2). Only part of the incident population reaches second-line treatment: ABC-06 reported that 15% to 25% receive second-line therapy, and 46% of 413 participants in a United States commercial-claims cohort with advanced biliary tract cancer initiated a second line. Relay Therapeutics estimated that FGFR2-mediated cancers of all tumour types affect approximately 11,000 late-line patients annually in the United States.

Source: [American Cancer Society Key Statistics for Bile Duct Cancer (2024)](https://www.cancer.org/cancer/types/bile-duct-cancer/about/key-statistics.html); [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/); [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/); [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/); [Relay Therapeutics Form 10-K (2024)](https://www.sec.gov/Archives/edgar/data/1812364/000095017024018797/rlay-20231231.htm)

<a id="topic-2.2.1.2.1-2"></a>

###### Incidence: estimated new United States cases and deaths in 2026

| Cancer site | Estimated new cases, both sexes | Estimated deaths, both sexes |
| --- | --- | --- |
| Liver and intrahepatic bile duct | “42,340” | “30,980” |
| Gallbladder and other biliary | “12,640” | “4590” |
| All sites | “2,114,850” | “626,140” |

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)

<a id="topic-2.2.1.2.1-3"></a>

###### Incidence: SEER rates for liver and intrahepatic bile duct cancer

> “The rate of new cases of liver and intrahepatic bile duct cancer was 9.5 per 100,000 men and women per year.”
> “Liver and intrahepatic bile duct cancer is most frequently diagnosed among people aged 65–74.”

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

<a id="topic-2.2.1.2.1-4"></a>

###### Incidence: cholangiocarcinoma incidence and trends in the United States, 2001 to 2017

> “From 2001-2017, CCA, iCCA, and eCCA incidence (per 100 000 person-years) increased 43.8% (3.08 to 4.43), 148.8% (0.80 to 1.99), and 7.5% (2.28 to 2.45), respectively.”
> “CCA incidence increased with age, with greatest increase among younger patients (18-44 years, 81.0%).”
> “The overall age-adjusted incidence of CCA from 2001 to 2017 was 3.65 per 100 000 p-y (iCCA, 1.19; eCCA, 2.46).”
> “The overall age-adjusted incidence of CCA from 2001 to 2017 increased with patient’s age (18-44 years, 0.27; 45-64 years, 3.10; 65-84 years, 14.19; ≥85 years, 22.05)”
> “The overall incidence of CCA from 2001 to 2017 was 4.40 in men vs 3.08 in women”

Source: [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/)

<a id="topic-2.2.1.2.1-5"></a>

###### Incidence: trends by anatomic site in the United States, 1999 to 2013

> “We characterized demographic differences in biliary tract cancer incidence rates and time trends by anatomic site. We used population-based North American Association of Central Cancer Registries data to calculate age-adjusted incidence rates, incidence rate ratios (IRRs), and estimated annual percent change per year (eAPC) for 1999–2013 by site and demographic group.”
> “During this period, ICC (eAPC=3.2%/year, P<0.0001) and ECC (1.8%/year, P=0.001) rates steadily increased across sex and racial/ethnic groups.”
> “While GBC rates increased among 18–44-year-olds (eAPC=1.8%/year, P=0.01), they decreased among people ≥45 years (−0.4 %/year, P=0.009).”

Source: [Van Dyke et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6467796/)

<a id="topic-2.2.1.2.1-6"></a>

###### Incidence: global estimates for 2024

| Cancer site | Estimated new cases worldwide, 2024 | Percentage of all cases | Estimated deaths worldwide, 2024 |
| --- | --- | --- | --- |
| Liver and intrahepatic bile duct | “843,045” | “4.1” | “732,489” |
| Gallbladder | “126,384” | “0.6” | “92,029” |

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.2.1-7"></a>

###### Incidence: annual United States diagnoses of bile duct cancer

> “Bile duct cancer (cholangiocarcinoma) is rare. About 8,000 people in the United States are diagnosed with it each year. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers. But the actual number of cases is likely to be higher, because these cancers can be hard to diagnose, and some might be misclassified as other types of cancer.”
> “The average age of people in the US diagnosed with bile duct cancer is in the 70s.”

Source: [American Cancer Society Key Statistics for Bile Duct Cancer (2024)](https://www.cancer.org/cancer/types/bile-duct-cancer/about/key-statistics.html)

<a id="topic-2.2.1.2.1-8"></a>

###### Incidence: proportion of participants who reach second-line therapy

> “Patients with advanced biliary tract cancer often experience a rapid decline in performance status following progression on first-line chemotherapy, and only 15–25% receive second-line therapy.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “Of 413 patients, 84.5% received gemcitabine-based first-line (1L) treatment, 46% received second-line treatment, and 16.5% received third-line (3L) treatment.”
> “In total, 46% (n = 190) of patients initiated second line of therapy (2LOT), which predominantly involved 5-fluorouracil (5FU)-based mono- or combination chemotherapy”

Source: [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

<a id="topic-2.2.1.2.2-1"></a>

###### Summary: prevalence of FGFR2 fusions or rearrangements in cholangiocarcinoma

Reported frequencies of FGFR2 fusions or rearrangements in intrahepatic cholangiocarcinoma are 13.6% (9 of 66) by reverse-transcriptase polymerase chain reaction, 13% (12 of 96) by fluorescence in situ hybridization, 14% in a sequenced institutional cohort, and 13.9% in a European routine-testing cohort. Central prescreening for FIGHT-202 confirmed FGFR2 fusions or rearrangements in 107 of 1,206 participants (9%), which the investigators describe as broadly consistent with the published range of 10% to 16%. In a comprehensive genomic profiling dataset of 6,802 cholangiocarcinoma samples, 9.2% had FGFR2 rearrangements, of which 76.1% were classified as fusions and 20.7% as other rearrangements, with BICC1 the most common partner (26.7%). In the FIGHT-202 prescreening cohort analysed for clinicogenomic correlates, 74 participants (6.1%) had FGFR2 rearrangements, 15.2% in the United States, 7.4% in Europe, and 2.2% in the rest of the world, which the investigators attribute partly to inclusion of extrahepatic cholangiocarcinoma. In a multicentre Italian cohort of 312 participants with advanced intrahepatic cholangiocarcinoma, FGFR2 fusions or rearrangements occurred in 10.6%. In a surgical FISH series, FGFR2 rearrangements were found in 12/96 intrahepatic, 0/25 perihilar, and 0/31 extrahepatic tumours. Frequency varied with the biopsy site sampled (9% of primary tumour biopsies, 6% and 4% of other sites) and was enriched 2.1-fold in participants with African ancestry. The FGFR2 cohort of FIGHT-202 contained greater proportions of women and of participants younger than 65 years than the other cohorts, and in a resected cohort FGFR2 fusion was more often present in younger (53 vs. 62 years) and female (83 vs. 49%) participants, whereas a European routine-testing cohort found no association between FGFR2 fusions and age or sex.

Overall prevalence of the underlying cancer is limited by short survival: SEER estimated 116,514 people living with liver and intrahepatic bile duct cancer in the United States in 2023, and the 16-year limited-duration prevalence of cholangiocarcinoma from 2001 to 2017 was reported as 5.92, higher for extrahepatic (4.23) than intrahepatic (1.69) disease. Nearly 40% of biliary tract cancers harbour a genetic alteration that is a potential target for precision medicine.

Source: [Arai et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24122810/); [Graham et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24837095/); [Lowery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6642361/); [Arnouts et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729926/); [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/); [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/); [Israel et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8417854/); [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html); [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/); [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/); [Silverman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33218975/); [Genovesi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456632/); [Buckarma et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35718679/)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence: people living with liver and intrahepatic bile duct cancer in the United States

> “In 2023, there were an estimated 116,514 people living with liver and intrahepatic bile duct cancer in the United States.”
> “Approximately 1.1 percent of men and women will be diagnosed with liver and intrahepatic bile duct cancer at some point during their lifetime, based on 2021–2023 data.”

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

<a id="topic-2.2.1.2.2-3"></a>

###### Prevalence: limited-duration prevalence of cholangiocarcinoma in SEER, 2001 to 2017

> “From 2001 to 2017, the LDP of CCA was 5.92% (Table 3) and was higher for eCCA vs iCCA (4.23% vs 1.69%). The LDP of iCCA increased from 2001-2006 (0.60%) to 2007-2012 (0.98%) to 2013-2017 (1.37%), whereas the LDP for eCCA remained relatively stable.”
> “LDP is defined as the number of people alive on a certain day who had a diagnosis of the disease within the past 16 years; as of January 1, 2017.”

Source: [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/)

<a id="topic-2.2.1.2.2-4"></a>

###### FGFR2 fusion frequency in intrahepatic cholangiocarcinoma: FIGHT-202 prescreening

> “FGFR2 fusions and rearrangements are found almost exclusively in intrahepatic cholangiocarcinoma, occurring in 10–16% of patients.”
> “107 (9%) of the 1206 prescreened patients had centrally confirmed FGFR2 fusions or rearrangements.”
> “Nevertheless, this prevalence is broadly consistent with that reported in the published scientific literature (10–16%),”

Source: [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/)

<a id="topic-2.2.1.2.2-5"></a>

###### FGFR2 rearrangement frequency by region in the FIGHT-202 prescreening cohort

> “In the prescreening cohort, we identified 74 patients (6.1%) with FGFR2 rearrangements (Supplementary Table S1).”
> “The frequency of FGFR2 rearrangements varied among regions. In the United States, 21 patients (15.2%) were positive, whereas 42 (7.4%) were positive in Europe and 11 (2.2%) were identified in the rest of the world.”
> “For example, the frequency of FGFR2 rearrangements (6.1%) is lower than previously reported for pure intrahepatic cholangiocarcinoma populations (10–16%), likely due to the inclusion of patients with extrahepatic cholangiocarcinoma (typically negative for FGFR2 rearrangements) in the prescreening population.”

Source: [Silverman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33218975/)

<a id="topic-2.2.1.2.2-6"></a>

###### FGFR2 fusion frequency in intrahepatic cholangiocarcinoma: RT-PCR discovery series

> “In reverse-transcriptase polymerase chain reaction (RT-PCR) screening, the FGFR2 fusion was detected in nine patients with cholangiocarcinoma (9/102), exclusively in the intrahepatic subtype (9/66, 13.6%), rarely in colorectal (1/149) and hepatocellular carcinoma (1/96), and none in gastric cancer (0/212).”
> “FGFR2 fusions occur in 13.6% of intrahepatic cholangiocarcinoma.”

Source: [Arai et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24122810/)

<a id="topic-2.2.1.2.2-7"></a>

###### FGFR2 fusion frequency by fusion type and tumour type in an RT-PCR screening series

> “RT-PCR and Sanger sequencing analysis of 102 cholangiocarcinoma specimens (66 ICCs and 36 ECCs) from Japanese individuals, including eight who had been subjected to whole transcriptome sequencing, identified seven FGFR2-AHCYL1-positive and two FGFR2-BICC1-positive cases (Table 1; Supporting Table 4).”
> “The nine FGFR2-fusion-positive cases were ICC type tumors (9/66, 13.6%).”
> “The FGFR2-BICC1 fusion gene was detected in one colorectal cancer (0.7%) and one hepatocellular carcinoma (1.0%). These fusion-positive non-ICC cases were also hepatitis virus-positive (Table 1).”
> “However, fusion positive cases had a propensity for hepatitis virus infection (Table 2).”

Source: [Arai et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24122810/)

<a id="topic-2.2.1.2.2-8"></a>

###### FGFR2 translocation frequency by fluorescence in situ hybridization

> “Thirteen (10 women, 3 men; 8%) of 156 biliary tumors harbored FGFR2 translocations, including 12 intrahepatic cholangiocarcinomas (12/96; 13%) and 1 intraductal papillary neoplasm of the bile duct.”

Source: [Graham et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24837095/)

<a id="topic-2.2.1.2.2-9"></a>

###### FGFR2 translocation frequency by anatomic location in a surgical FISH series

> “Using FISH, FGFR2 translocations were identified in 12 cholangiocarcinomas and 1 IPNB for an overall frequency of 8% (13/156; Figs. 1 and 2). All specimens with FGFR2 translocation were intrahepatic, with a frequency of 13% (12/96) for intrahepatic cholangiocarcinomas.”
> “None of the FGFR2-translocated tumors occurred in patients with primary sclerosing cholangitis.”
> “The patients with FGFR2-rearranged tumors had a median age of 52 years (range, 36-83 years), which was 11 years younger than the median age for the biliary tumors without FGFR2 rearrangement, but this difference was not statistically significant (P = .121).”

Source: [Graham et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24837095/)

| Anatomic location | FGFR2 rearrangements by FISH, n/N (%) |
| --- | --- |
| Intrahepatic | “12/96 (13)” |
| Perihilar | “0/25 (0)” |
| Extrahepatic | “0/31 (0)” |

Source: [Graham et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24837095/)

<a id="topic-2.2.1.2.2-10"></a>

###### FGFR2 fusion frequency by anatomic subtype in a sequenced cholangiocarcinoma cohort

> “The most commonly altered genes in intrahepatic cholangiocarcinoma (IHC) were IDH1 (30%), ARID1A (23%) BAP1 (20%), TP53 (20%) and FGFR2 gene fusions (14%).”
> “BAP1 mutations and FGFR2 gene fusions were identified exclusively in patients with intrahepatic cholangiocarcinoma.”

Source: [Lowery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6642361/)

<a id="topic-2.2.1.2.2-11"></a>

###### FGFR2 rearrangement frequency in a comprehensive genomic profiling dataset of cholangiocarcinoma

> “Of 6802 CCA samples interrogated, 9.2% had FGFR2 rearrangements.”

Source: [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/)

<a id="topic-2.2.1.2.2-12"></a>

###### FGFR2 rearrangement classes and fusion partners in a comprehensive genomic profiling dataset

> “Of the 6802 samples tested, 629 (9.2%) had a total of 632 FGFR2 rearrangement events. These events were further classified as fusions (n = 481; 76.1%), rearrangements (n = 131; 20.7%), truncations (n = 18; 2.8%), and duplications (n = 2; 0.3%) (Figure 1A).”
> “The most common fusion partner was BICC1 (n = 169; 26.7%), followed by AHCYL1 (n = 19; 3.0%), TACC2 (n = 17; 2.7%), and CCDC6 (n = 16; 2.5%); 126 (19.9%) rearrangement events had a partner gene that was unique to a single patient (N-of-One), and 35 (11.1%) for which the partner was observed in only two patients (N-of-Two) (Figure 1B and Supplemental Table S5).”
> “Most FGFR2 rearrangements (54.4%) involved intrachromosomal rearrangements on chromosome 10, with BICC1, CCDC6, and TACC2 being the most common rearrangement partners.”
> “The frequency of FGFR2 rearrangements observed in our real-world data set of 6802 patients with CCA was 9.2%, which is slightly lower than estimates for iCCA of 10% to 15%.”
> “Given the lack of detailed clinical information in this data set, the cohort is likely not strictly iCCA and may include eCCA, perihilar CCA, and cancers of unknown primary, as the genomic test may have been ordered before the physician received the results of a full diagnostic assessment.”

Source: [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/)

<a id="topic-2.2.1.2.2-13"></a>

###### FGFR2 rearrangement frequency by biopsy site and ancestry in intrahepatic cholangiocarcinoma

> “In Pbx, Mbx, and Lbx, FGFR2 rearrangements were found in 9%, 6%, and 4%, and IDH1 mutations were identified in 16%, 5%, and 9% patients, respectively.”
> “Moreover, alterations in FGFR2 and IDH1 were significantly associated with distinct ancestries, including 2.1‐fold enrichment for FGFR2 rearrangements in patients with African ancestry and 1.5‐fold enrichment for IDH1 mutations in patients with admixed American (Hispanic) ancestry.”
> “The Pbx cohort of 1,048 patients was 51% female and had a median age of 65 years.”

Source: [Israel et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8417854/)

<a id="topic-2.2.1.2.2-14"></a>

###### FGFR2 fusion frequency across biliary tract cancer subtypes in a European routine-testing cohort

> “IDH1 mutations (17.3%) and FGFR2 fusions (13.9%) were exclusively observed in intrahepatic cholangiocarcinoma, KRAS mutations were most prevalent in extrahepatic cholangiocarcinoma (42.9%), and ERBB2 amplification was enriched in gallbladder cancer (16.7%).”

Source: [Arnouts et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729926/)

<a id="topic-2.2.1.2.2-15"></a>

###### FGFR2 alteration frequency in the full cohort and in intrahepatic disease in a European routine-testing cohort

> “Of the 224 included BTC cases, molecular alterations were identified in 133 (59.4%).”
> “The five most frequently observed alterations in the general cohort included KRAS mutations (20.4%), IDH1 mutations (11.3%), FGFR2 fusions (9.3%), ERBB2 amplification (8.8%), and BRAF mutations (5.7%).”
> “Notably, FGFR2 fusions, IDH1 mutations and IDH2 mutations were found exclusively in iCCAs and never co-occurred.”
> “iCCA was molecularly defined by IDH1/2 mutations (17.3% IDH1, 5.8% IDH2) and FGFR2 alterations (13.9% fusions, 2.9% mutations, 0.9% amplifications), which were nearly exclusive to this subgroup (excepting one FGFR2-mutant CCA NOS case).”
> “While FGFR2 alterations were mainly represented by fusions, a number of point mutations were also detected, with Y375C being the most frequently observed variant (40.0%; Figure 2B).”

Source: [Arnouts et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729926/)

<a id="topic-2.2.1.2.2-16"></a>

###### FGFR2 fusion or rearrangement frequency in a multicentre Italian real-world cholangiocarcinoma cohort

> “Molecular profiling among the 312 patients with advanced iCCA revealed IDH1 mutation as the most common druggable alteration, with a prevalence of 15.1% (47), followed by FGFR2 fusions/rearrangements (33, 10.6%), IDH2 mutation (10, 3.2%), MSI-high/deficient MMR status (6, 1.9%), and BRAF V600E mutations (4, 1.3%).”
> “The ANITA dataset comprised 42 patients with FGFR2-fused/rearranged disease and 59 patients with IDH1-mutated CCA, accounting for 11.4% and 15.2% of the profiled population, respectively. In both cases, iCCA was the most common site of origin (FGFR2: 95.2%; IDH1: 94.9%).”
> “Of the EMP-profiled tumors, 139 (28.6%) presented an ESCAT I-III alteration; this was significantly more frequent in iCCA (115, 36.9%) compared to pCCA (13, 15.3%) and dCCA (11, 12.4%), p < 0.001).”

Source: [Genovesi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456632/)

<a id="topic-2.2.1.2.2-17"></a>

###### Demographic features of participants with FGFR2 fusions or rearrangements

> “This cohort included greater proportions of women, patients aged younger than 65 years, and patients with disease confined to the liver, and included a smaller proportion of patients with an ECOG performance status of 2 than patients in the other cohorts (table 1).”

Source: [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/)

> “In patients with CCA, FGFR GAs occurred more frequently in younger patients (≤ 40 years; 20%) compared with older patients (> 40 years; 6.7%; P < .001)”

Source: [Jain et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/35135097/)

<a id="topic-2.2.1.2.2-18"></a>

###### Age and sex associations of FGFR2 fusions in resected and routine-testing cohorts

> “Twelve (13%) patients with iCCA were found to have an FGFR2 fusion based on FISH break-apart probe testing (Fig. 1). FGFR2 fusion was not found in any patients with pCCA or dCCA consistent with previously published reports.”
> “FGFR2 fusion was more often present in younger (53 vs. 62 years, p = 0.012) female (83 vs. 49%, p = 0.033) patients. Additionally, those diagnosed with CCA before the age of 40 years were more likely to be characterized by FGFR2 fusion (p = 0.01).”

Source: [Buckarma et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35718679/)

> “No association between FGFR2 fusions and age or sex was observed in our cohort, despite reports of enrichment in younger female iCCA patients”

Source: [Arnouts et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729926/)

<a id="topic-2.2.1.2.2-19"></a>

###### Prevalence: share of biliary tract cancers with a potentially targetable genetic alteration

> “Nearly 40% of patients with BTC harbour genetic alterations which are potential targets for precision medicine.”
> “There remains, therefore, an urgent need to develop new therapies, particularly for patients who lack a targetable genomic alteration.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Summary: survival across the disease course and in FGFR2 fusion-positive disease

Cholangiocarcinoma is usually diagnosed at an advanced stage. SEER reports 5-year relative survival for liver and intrahepatic bile duct cancer of 37.4% for localized, 13.4% for regional, and 3.6% for distant disease, and across 40,030 SEER cholangiocarcinoma cases diagnosed from 2001 to 2017 median overall survival from diagnosis was 8 months overall and 6 months for intrahepatic disease. In the first-line advanced setting, median overall survival was 12.9 months with durvalumab plus gemcitabine and cisplatin in the TOPAZ-1 three-year update and 12.7 months with pembrolizumab plus gemcitabine and cisplatin in KEYNOTE-966. After progression, median overall survival in ABC-06 was 6.2 months with FOLFOX plus active symptom control and 5.3 months with active symptom control alone.

FGFR2 fusion-positive disease has a comparatively favourable natural history. In an institutional series of 377 participants, FGFR genetic aberrations were associated with longer overall survival (37 versus 20 months, P < .001), which remained significant after excluding participants treated with FGFR inhibitors, and co-occurring TP53 and CDKN2A/B alterations were associated with shorter survival. Median cancer-specific survival was 123 versus 37 months with and without FGFR2 translocations in a FISH series, 5-year overall survival after resection of intrahepatic cholangiocarcinoma was 83% versus 32% by FGFR2 fusion status, and in a multicentre real-world cohort FGFR2 fusions or rearrangements retained a prognostic association with overall survival after exclusion of participants treated with targeted therapy. In the multicentre cohort, median overall survival was 26.5 months with and 17.0 months without FGFR2 fusions or rearrangements, with a hazard ratio of 0.54 (95% CI 0.30-0.95) at multivariate analysis, and after resection of intrahepatic cholangiocarcinoma 10-year overall survival was 46 vs. 22% by FGFR2 fusion status. Not every series found a difference: outcome did not differ significantly by FGFR2 fusion status in a Japanese RT-PCR series, and in a European routine-testing cohort median overall survival was 32.2 versus 13.6 months (HR = 0.81, p = 0.52). Participants with FGFR2 rearrangements may be less likely to benefit from first-line platinum chemotherapy, although time to progression did not differ by FGFR2 status in one sequenced cohort.

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html); [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/); [Oh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381735/); [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Jain et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/35135097/); [Graham et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24837095/); [Buckarma et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35718679/); [Genovesi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456632/); [Israel et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8417854/); [Lowery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6642361/); [Arai et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24122810/); [Arnouts et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729926/)

<a id="topic-2.2.1.3-2"></a>

###### Natural history: asymptomatic early disease and late presentation

> “CCAs are usually asymptomatic in early stages and, therefore, often diagnosed when the disease is already in advanced stages, which highly compromises therapeutic options, resulting in a dismal prognosis”
> “Despite advances in CCA awareness, knowledge, diagnosis and therapies, patient prognosis has not improved substantially in the past decade, with 5-year survival (7–20%) and tumour recurrence rates after resection still disappointing”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “The prognosis is poor, with an all-stage 5-year overall survival of less than 20%.”
> “Patients are rarely diagnosed with early-stage disease and therefore curative surgery and adjuvant therapy is only feasible for a small proportion of patients.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.1.3-3"></a>

###### Survival: SEER stage distribution and five-year relative survival, liver and intrahepatic bile duct cancer

| Stage at diagnosis | Percent of cases | 5-year relative survival |
| --- | --- | --- |
| Localized | “45%” | “37.4%” |
| Regional | “23%” | “13.4%” |
| Distant | “21%” | “3.6%” |
| Unknown | “10%” | “11.6%” |

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

> “For liver and intrahepatic bile duct cancer, 44.7% are diagnosed at the local stage. The 5-year relative survival for localized liver and intrahepatic bile duct cancer is 37.4%.”

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

<a id="topic-2.2.1.3-4"></a>

###### Survival: median overall survival by cholangiocarcinoma subtype in SEER

> “Median overall survival from diagnosis was 8, 6, 9, and 2 months for CCA, iCCA, eCCA, and CUP.”
> “The annual mortality rate declined from 45.2% in 2001 to 38.7% in 2016 for CCA, and from 57.1% in 2001 to 41.2% in 2016 for iCCA, but the rates for iCCA remained consistently higher than for eCCA, which generally remained stable (40.9% in 2001 vs 37.0% in 2016; Fig. 2F).”

Source: [Javle et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9526482/)

<a id="topic-2.2.1.3-5"></a>

###### Overall survival in cholangiocarcinoma with FGFR genetic aberrations compared with FGFR wild-type disease

> “Three hundred seventy-seven patients with CCA were identified, and 95 had FGFR GAs. FGFR2 GA was most common (n = 74, with 63 fusions) and seen in intrahepatic CCA. In patients with CCA, FGFR GAs occurred more frequently in younger patients (≤ 40 years; 20%) compared with older patients (> 40 years; 6.7%; P < .001), presented at an earlier stage (TNM stage I/II v III/IV: 35.8% v 22%, respectively; P = .001), and were associated with a longer OS compared with patients without FGFR GAs (37 v 20 months, respectively; P < .001). This difference remained significant after excluding 36 patients treated with FGFR inhibitors. There was no OS difference (P = .60) between CCA with FGFR2 fusions (n = 63) versus other FGFR GAs (n = 29). Patients with FGFR GAs had a better OS with FGFR-targeted therapy compared with standard treatment (P = .01). BAP1 mutation was the most common coexisting mutation without prognostic impact, whereas TP53 (P = .04) and CDKN2A/B (P = .04) were correlated with a shorter OS.”
> “CCA with FGFR GAs represents a unique subtype occurring in younger patients with an indolent disease course.”

Source: [Jain et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/35135097/)

<a id="topic-2.2.1.3-6"></a>

###### Cancer-specific survival with FGFR2 translocations

> “The median cancer-specific survival for patients whose tumors harbored FGFR2 translocations was 123 months compared to 37 months for cases without FGFR2 translocations (P = .039).”

Source: [Graham et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24837095/)

<a id="topic-2.2.1.3-7"></a>

###### Recurrence and death after resection by FGFR2 translocation status in a FISH series

> “For the 139 cases without FGFR2 translocations, 77 patients (55%) developed metastases or local recurrence, and 99 patients (71%) died during clinical follow-up.”
> “Six of the 12 (50%) patients whose tumors harbored FGFR2 translocations died during clinical follow-up, and 6 patients were alive without evidence of disease. Only 3 patients (25%) developed metastases or local recurrence.”
> “The median cancer-specific survival interval for patients with FGFR2 translocations was estimated at 123 months (95% CI, 51-123 months) and was significantly longer than for patients without FGFR2 translocations (P = .039).”
> “The disease-free intervals for the 3 cases were 26 months, 63 months, and 125 months. This was also significantly longer compared to the cases without FGFR translocations (P = .007).”
> “In retrospective studies of patients treated with various combinations of therapy and not matched for performance status and other characteristics, it is difficult to determine the generalizability of survival data.”
> “Therefore, a larger study of patients who are matched for age, performance status, underlying function and other factors is warranted to appropriately determine if there truly is a prognostic difference.”

Source: [Graham et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24837095/)

<a id="topic-2.2.1.3-8"></a>

###### Overall survival by FGFR2 fusion status in an RT-PCR series

> “No significant differences in age, gender, tumor differentiation, clinical stage, and prognosis were detected between fusion-positive and -negative cases.”
> “The outcome was not significantly different between FGFR2 fusion-positive and -negative cases (log-rank test).”

Source: [Arai et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24122810/)

<a id="topic-2.2.1.3-9"></a>

###### Survival after resection of intrahepatic cholangiocarcinoma by FGFR2 fusion status

> “Twelve (13%) of these were found to have FGFR2 fusion, none of which were treated with FGFR targeted therapy. Patients with FGFR2 fusions were found to have a longer 5-year (83 vs. 32%, p = 0.01) and 10-year (46 vs. 22%, p = 0.04) OS. Five and 10-year DFS was also increased (68 vs. 33% p = 0.04) and (68 vs. 25 %, p = 0.02,). FGFR2 fusion status was the strongest independent factor associated with improved OS (HR 0.23, 0.09-0.62, p=0.003) and DFS (HR 0.18, 0.05-0.67, p=0.01).”

Source: [Buckarma et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35718679/)

<a id="topic-2.2.1.3-10"></a>

###### Survival after resection by FGFR2 fusion status: pathological features, prognostic factors, and study limitations

> “When iCCA patients positive for FGFR2 fusions were compared to patients without, FGFR2 fusion patients were found to have improved 5-year (83 vs. 32%, p = 0.010) and 10-year (46 vs. 22%, p = 0.042) OS, respectively (Fig. 2), suggesting that CCA with FGFR2 fusions may have a more indolent course.”
> “Overall, there were no significant differences between iCCA patients with FGFR2 fusion and wildtype FGFR in terms of vascular invasion, perineural invasion, lymph node positivity, or presence of satellite lesions.”
> “Perineural invasion (HR:3.23, 95% CI: 1.39–7.55, p = 0.007), increasing tumor size (HR = 1.19, 95% CI: 1.08–1.31, p < 0.001), and lymph node invasion (HR = 2.85, 95% CI: 1.37–5.92, p = 0.005) correlated significantly with increased risk of death.”
> “Importantly, this cohort of patients were treated prior to widespread adoption of adjuvant therapy for resected CCA, and this is reflected in the fact that adjuvant therapy for patients with FGFR2 fusion was noted in a minority of patients (adjuvant radiotherapy, n = 1, 8.3% and adjuvant systemic chemotherapy, n = 2, 16.7%). Moreover, none of the patients in this cohort received FGFR-targeted therapy.”
> “Our work, predating the widespread use of adjuvant therapy in resected patients suggests that the biology of disease in patients with FGFR2 fusion is more indolent, which cannot be explained by common surrogates of biology alone, such as the incidence of satellite lesions or lymph node metastases.”
> “Our study has several limitations including sources of bias that are inherent in retrospective studies.”
> “Due to small numbers of FGFR2 fusion patients, our analyses should be considered exploratory and may be subject to both Type 1 and Type 2 errors.”

Source: [Buckarma et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35718679/)

<a id="topic-2.2.1.3-11"></a>

###### Prognostic association of FGFR2 fusions in a multicentre real-world cholangiocarcinoma cohort

> “Among ESCAT I-III-positive cases, 42 patients had FGFR2 fusions/rearrangements and 59 had IDH1 mutations. After excluding patients treated with targeted therapies, only FGFR2 fusions/rearrangements retained a prognostic association with OS.”

Source: [Genovesi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456632/)

<a id="topic-2.2.1.3-12"></a>

###### Overall and relapse-free survival by FGFR2 fusion status in a multicentre real-world cholangiocarcinoma cohort

> “Of all the individual gene alterations, only FGFR2 fusions/rearrangements showed a significant association with longer OS (26.5 months, 95% CI 17.4-48.2 vs. 17.0 months, 95% CI 15.4-19.5; p = 0.006) at univariate assessment.”
> “At univariate analysis, FGFR2 alterations demonstrated a positive correlation with OS (HR 0.49, 95% CI 0.33-0.74, p = 0.006), confirmed at multivariate analysis (HR 0.54, 95% CI 0.30-0.95, p = 0.035) after adjusting for confounders, such as carbohydrate antigen 19-9 levels (>500 UI/ml) before first-line chemotherapy, liver metastases, synchronous metastatic disease and multiple sites of metastases.”
> “Moreover, FGFR2 fusions/rearrangements and IDH1 R132x mutations were evaluated as potential determinants of benefit from first-line platinum-based chemotherapy. No role was found for either alteration”
> “Seventeen patients with FGFR2-fused/rearranged and 28 patients with IDH1-mutated BTCs were included in the analysis for RFS. Median RFS was 10.3 months (95% CI 2.0-18.9) in the former”
> “no significant difference was observed compared to wild-type counterparts (12.3 [95% CI 11.1-14.6] months and 12.5 [95% CI 11.0-15.0] months for FGFR2 and IDH1 wild-type, respectively, both p >0.05).”
> “our data support a positive prognostic role for FGFR2 fusion/rearrangements, but not IDH1 mutations. However, not all published data confirm the same prognostic value of these alterations.”

Source: [Genovesi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456632/)

<a id="topic-2.2.1.3-13"></a>

###### Survival with and without matched targeted therapy in a multicentre real-world cholangiocarcinoma cohort

> “Interestingly, median OS of patients with ESCAT I-III alterations who did not receive a matched targeted treatment was similar to that of non-profiled patients (19.1 months, 95% CI 16.6-23.0 vs. 17.7 months, 95% CI 13.0-19.4, respectively).”
> “Of note, considering the 84 patients with available EMP showing ESCAT I-III alterations who received second-line treatment, median OS from second-line systemic therapy was significantly longer in those treated with (43.6 months, 95% CI 10.2-43.6) than in those who did not receive (10.8 months, 95% CI 7.8-14.4) a targeted agent (HR 0.48, 95% CI 0.3-0.9; p = 0.040).”

Source: [Genovesi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456632/)

<a id="topic-2.2.1.3-14"></a>

###### Overall survival by FGFR2 fusion status in a European routine-testing cohort

> “Additionally, in our cohort, patients with FGFR2 fusions exhibited a numerically longer mOS compared to WT cases (32.2 (fus) vs. 13.6 (wt) months; HR = 0.81, CI: 0.42–1.55, p = 0.52).”
> “This non-significant trend mirrors the significant survival benefit firmly established in other cohorts”
> “The lack of significance may be due to limited sample size.”

Source: [Arnouts et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729926/)

<a id="topic-2.2.1.3-15"></a>

###### Prognosis and chemotherapy response with FGFR2 rearrangements

> “In smaller datasets, rearrangements and fusions involving the FGFR2 gene have been observed in 11%–17% of IHCC, and patients harboring these alterations have an improved prognosis but may be less likely to benefit from first‐line platinum chemotherapy [15, 16, 17, 18, 19, 20, 21].”

Source: [Israel et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8417854/)

> “No significant difference in time to progression was noted with other commonly altered genes including IDH1, FGFR2, BAP1, ATM, ARID1A and TP53 (Figure 3, Supplementary Table 1).”

Source: [Lowery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6642361/)

<a id="topic-2.2.1.3-16"></a>

###### Survival: first-line overall survival with durvalumab plus chemotherapy, TOPAZ-1 three-year update

> “After a median 41.3 (95% CI 39.3-44.1) months' follow-up in all participants, median OS (95% CI) for durvalumab+GemCis vs. placebo+GemCis was 12.9 (11.6-14.1) vs. 11.3 (10.1-12.5) months (hazard ratio, 0.74 [95% CI 0.63-0.87]); 36-month OS rate was 14.6% vs. 6.9%, respectively.”
> “The 36-month Kaplan-Meier OS rate for the durvalumab arm was more than double that of the placebo arm, and the OS rate ratio for durvalumab vs. placebo increased over time (12 months: 1.15; 24 months: 1.75; 36 months: 2.12).”
> “In total, 88/685 (12.8%) participants were eLTS, with more eLTS in the durvalumab arm (58/341 [17.0%]) vs. the placebo arm (30/344 [8.7%]).”

Source: [Oh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381735/)

<a id="topic-2.2.1.3-17"></a>

###### Survival: first-line overall survival with pembrolizumab plus chemotherapy, KEYNOTE-966

> “Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance threshold, p=0·0200]).”

Source: [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)

<a id="topic-2.2.1.3-18"></a>

###### Survival: second-line overall survival in ABC-06

> “Median overall survival was 6·2 months (95% CI 5·4–7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in the ASC alone group (adjusted HR 0·69 [95% CI 0·50–0·97], p=0·031; figure 2).”
> “The overall survival rate in the ASC alone group was 35·5% (95% CI 25·2–46·0) at 6 months and 11·4% (5·6–19·5) at 12 months, compared with 50·6% (39·3–60·9) at 6 months and 25·9% (17·0–35·8) at 12 months in the ASC plus FOLFOX group.”
> “Median progression-free survival was 4·0 months (95% CI 3·2–5·0; appendix p 4).”
> “The progression-free survival rate was 66·7% (95% CI 55·3–75·8) at 3 months, 32·1% (22·3–42·3) at 6 months, and 8·6% (3·8–16·0) at 12 months.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.1.3-19"></a>

###### Survival: prognostic value of baseline tumour markers in the second-line setting

> “Baseline CA19-9 data were available for 135 of 162 patients: 92 (68.1%) high, 43 (31.9%) low. High baseline CA19-9 was associated with shorter unadjusted OS [4.4 versus 6.4 months; hazard ratio (HR) 1.97, 95% confidence interval (CI) 1.33-2.93, P < 0.001] and unadjusted PFS (3.2 versus 5.0 months; HR 1.53, 95% CI 1.05-2.23, P = 0.027) in the FOLFOX arm.”
> “With each additional tumour marker that was elevated at baseline, median OS was numerically shorter: unadjusted median OS was 8.9 months if all tumour markers at baseline were not elevated and 7.0 months, 4.0 months, and 3.2 months in the event of having 1, 2, or 3 elevated baseline tumour markers, respectively (Figure 1).”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.3-20"></a>

###### Survival: real-world United States outcomes across lines of therapy

> “All-cause mortality was 53% with a median survival of 11.5 months.”
> “The median OS from the index date was 11.5 months (Figure 3A & B). In total, 70.1% (n = 289), 47.8% (n = 197), 34.9% (n = 144) and 29.6% (n = 122) of patients survived 6, 12, 18 and 24 months, respectively, from the index date.”
> “The median OS time from first presumed BTC diagnosis was 13.3 months.”
> “The median time on 2LOT was 3.6 months and was longer for patients with stage III disease (4.6 months) than for patients with stage IV and stage I/II disease (3.6 months).”

Source: [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.3-21"></a>

###### Mortality: United States and global mortality burden

> “Liver and intrahepatic bile duct cancer is the sixth leading cause of cancer death in the United States. The death rate was 6.6 per 100,000 men and women per year based on 2020–2024 deaths, age-adjusted.”

Source: [SEER Cancer Stat Facts Liver and Intrahepatic Bile Duct Cancer (2026)](https://seer.cancer.gov/statfacts/html/livibd.html)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Summary: cholangiocarcinogenesis and FGFR2 fusion signalling

Cholangiocarcinoma arises predominantly from cholangiocytes and can also develop from peribiliary glands and hepatocytes. Chronic inflammation, growth factors, and bile acids in the tumour microenvironment drive carcinogenesis, and the tumours are highly desmoplastic. Genomic alterations track with anatomic subtype: FGFR2 fusions, IDH1 and IDH2 mutations, and BAP1 mutations characterize intrahepatic disease, and in one sequenced cohort the most commonly altered genes in intrahepatic cholangiocarcinoma were IDH1 (30%), ARID1A (23%), BAP1 (20%), TP53 (20%), and FGFR2 fusions (14%).

FGFR2 fusions retain the extracellular and kinase domains of FGFR2 and lose the C-terminal negative regulatory region, and truncation of FGFR2 after exon 17 is oncogenic in itself. Fusion partners exhibit oligomerization capability, and fusion proteins interact in the absence of FGF ligand, so kinase activation is ligand-independent. Signalling proceeds through the MAPK (RAS, RAF, MEK, ERK) and PI3K, AKT, and mTOR pathways; expression of FGFR2 fusion kinases activated MAPK and conferred transforming ability in cell models, and patient-derived organoids were dependent on Ras-Erk signalling. Fusion partners are diverse: 56 different partners were identified among 107 participants in FIGHT-202, 42 (75%) unique to one participant, with BICC1 the most common (29%). FGFR2 fusions usually co-occur with inactivation of TP53, CDKN2A, or BAP1, and in a Japanese series of 102 cholangiocarcinomas they were mutually exclusive with KRAS and BRAF mutations. All tested FGFR2 rearrangement partners were oncogenic and sensitive to FGFR2 inhibition in vitro, which the authors interpret as indicating that the FGFR2 fusion, irrespective of partner gene, is the clinically important variable.

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/); [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/); [Lowery et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6642361/); [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10767308/); [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/); [Wu et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3694764/); [Xin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12897249/); [Arai et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24122810/); [Cristinziano et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33741397/); [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/); [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/)

<a id="topic-2.2.1.4-2"></a>

###### Pathophysiology: cell of origin and desmoplastic tumour immune microenvironment

> “CCA displays features of cholangiocyte differentiation and probably arises predominantly from the epithelial cells lining the bile ducts, which are termed cholangiocytes; however, the cancers may also develop from peribiliary glands and hepatocytes, depending on the underlying liver disease and location”
> “These cancers are highly desmoplastic and are enmeshed in dense networks of inflammatory cells and matrix termed the tumour immune microenvironment”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

> “CCA tumours, and particularly iCCAs and pCCAs, are characterized by a reactive desmoplastic stroma containing cancer-associated fibroblasts (CAFs) that crosstalk with CCA cells secreting paracrine factors such as heparin-binding EGF-like growth factor, stromal-cell derived factor 1 (SDF1), platelet-derived growth factor (PDGF)-B and extracellular matrix (ECM) proteins”
> “CAFs secrete a multitude of signalling molecules (such as IL-1β, PDGF-B, heparin-binding EGF-like growth factor and SDF1) that promote cancer progression by enhancing proliferation, survival, chemotaxis and angiogenesis”
> “Following stimulation by PDGF-D originated from the tumoural cholangiocytes in vitro, CAFs secrete VEGF-A and VEGF-C, which recruit and assemble lymphatic endothelial cells in vascular structures susceptible to tumour cell intravasation”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.4-3"></a>

###### Pathophysiology: cholangiocarcinogenesis driven by inflammatory and growth factor signalling

> “Cholangiocarcinogenesis is orchestrated by a complex interplay of extracellular ligands (such as pro-inflammatory cytokines, growth factors and bile acids, among others), which are present in the tumour microenvironment (TME), and increased expression and/or aberrant activation of cell surface receptors and the deregulation of intracellular signalling pathways, finally leading to cell proliferation, survival and genetic and/or epigenetic alterations”
> “The most common genes that might be mutated or amplified resulting in the overactivation of some of these pathways are KRAS, BRAF, ARID1, PBRM1, BAP1, IDH1 and IDH2.”
> “The main oncogenic networks comprised WNT-CTNNB1, MYC, ERBB, TNF and VEGF signalling, emphasizing cell survival signalling pathways in patients with poor OS”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.4-4"></a>

###### Pathophysiology: genomic alterations differ by anatomic subtype

> “Among CCAs, genetic aberrations differ depending on their anatomic locations; for example, FGFR2 fusions are almost exclusively found in iCCAs, whereas PRKCA–PRKCB fusions are observed in pCCAs and dCCAs”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

> “Small bile duct iCCA can be characterized by isocitrate dehydrogenase (IDH1, IDH2) mutations or fibroblast growth factor receptor 2 (FGFR2) fusions”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.4-5"></a>

###### Pathophysiology: frequency of recurrent alterations in a real-world profiling series

> “The most frequently altered genes were TP53 (51/91, 56.0%), KRAS (21/91, 23.1%), CDKN2A (18/91, 19.8%), SMAD4 (14/91, 15.4%), and ARID1A/PBRM1 (12/91, 13.2%).”

Source: [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/)

<a id="topic-2.2.1.4-6"></a>

###### FGFR2 fusion structure: retained kinase domain and loss of the C-terminal regulatory region

> “Approximately 10%–15% ICCs show genetic alterations of FGFR2, most commonly involving in-frame fusions of FGFR2 exons 1–17 with a diversity of partners”
> “These fusions, as well as other truncating events that are sometimes observed, contain the entire FGFR2 extracellular and kinase domains but lack a C-terminal negative regulatory domain encoded by the final exon 18, leading to constitutive kinase activity”

Source: [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10767308/)

> “FGFR2 fusions are the most common FGFR2 alteration in iCCA, occurring in 10% to 15% of cases”
> “It was recently demonstrated that the dimerization domain of a fusion partner is not a requirement for oncogenicity; rather the truncation of FGFR2 after exon 17”
> “is an oncogenic alteration itself, in which loss of the C-terminus is the key determinant of oncogenicity”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

<a id="topic-2.2.1.4-7"></a>

###### Ligand-independent oligomerization of FGFR fusion proteins

> “All FGFR fusion partners tested exhibit oligomerization capability, suggesting a shared mode of kinase activation.”
> “As examples, while FGFR3-BAIAP2L1, FGFR3-TACC3, FGFR2- BICC1, and FGFR2-CCDC6 interact in vitro, wild-type FGFR2 and FGFR3 do not in the absence of FGF ligands (Fig. 3A, Supplementary Fig. 2).”

Source: [Wu et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3694764/)

<a id="topic-2.2.1.4-8"></a>

###### Transforming activity of FGFR2 fusion kinases and MAPK activation

> “We performed massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations and identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1.”
> “Expression of the fusion kinases in NIH3T3 cells activated MAPK and conferred anchorage-independent growth and in vivo tumorigenesis of subcutaneous transplanted cells in immune-compromised mice. This transforming ability was attributable to its kinase activity.”

Source: [Arai et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24122810/)

> “Tumor organoids and 2D cell lines derived from CCA lesions were addicted to FF signaling via Ras-Erk, regardless of FF identity or V565F mutation.”

Source: [Cristinziano et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33741397/)

<a id="topic-2.2.1.4-9"></a>

###### FGFR2-AHCYL1 and FGFR2-BICC1 fusions: genomic origin, constitutive activation, and mutual exclusivity with KRAS and BRAF mutations

> “The FGFR2-AHCYL1 and FGFR2-BICC1 fusion proteins are likely to form homodimers through the coiled-coil motif of AHCYL1”
> “FGFR2 and BICC1 are located on the long arm of chromosome 10 in opposite directions, suggesting that the FGFR2-BICC1 fusion is generated by intrachromosomal inversion (Supporting Fig. 1B).”
> “The wild-type fusion expressing cells showed constitutive tyrosine phosphorylation in the activation loop of the FGFR kinase domain.”
> “Immunoblot analysis revealed that activation of MAPK, but not AKT or STAT3, was induced in clones expressing FGFR2-AHCYL1 and FGFR2-BHCC1.”
> “KRAS mutations were detected in 19 cases (19/102, 17.8%) and BRAF mutations in one (1/102, 1%); these mutations were mutually exclusive with the FGFR2 fusions (Fig. 3A; Supporting Table 4).”
> “The identification of two recurrent FGFR2 fusions (FGFR2-AHCYL1 and FGFR2-BICC1) that are mutually exclusive with KRAS/BRAF mutations warrants a new molecular classification of cholangiocarcinoma and suggests a novel therapeutic approach in cholangiocarcinomas driven by these fusions.”
> “Association between FGFR2 fusion positivity and hepatitis virus infection may suggest an involvement of the virus in the chromosomal rearrangements in CC.”

Source: [Arai et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24122810/)

<a id="topic-2.2.1.4-10"></a>

###### FGFR2 fusion-driven transformation of mouse liver organoids and ligand-independent signalling

> “Chromosomal rearrangements generate FGFR2 fusions (FFs) in 12–15% of intrahepatic CCAs.”
> “In FFs, FGFR2 residues 1-768 fuse to sequences encoded by a diverse array of partner genes (>60) causing oncogenic FF activation.”
> “It is thought that the fusion partner forces constitutive dimerization of adjacent FGFR2 sequences, triggering constitutive activation of the FGFR2 tyrosine kinase domain (TKD) and attendant oncogenic signaling.”
> “When expressed at levels comparable to those of F-TACC3, wild-type FGFR2IIIb required ligand stimulation in order to undergo catalytic activation (Fig. 1D). Thus, constitutive FF signaling in the above liver organoid models is caused by the ligand-independent mode of activation typical of FGFR2 fusions.”
> “In line with this observation, mutations affecting tumor suppressor genes (TSGs), most notably TP53, CDKN2A or BAP1, co-occur in the large majority of iCCA carrying FGFR2 fusions.”
> “Thus, FGFR2 fusions drive oncogenic conversion of liver bipotent precursors along the cholangiocellular lineage.”
> “All of the above phosphorylation events required FF catalytic activity, because they were suppressed by BGJ398 (Fig. 5A and S9A-C).”
> “The above data support a model whereby Erk1/2 activation plays a necessary role in shaping addiction of iCCA cells to FF oncogenic signaling.”

Source: [Cristinziano et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33741397/)

<a id="topic-2.2.1.4-11"></a>

###### Oncogenicity and pemigatinib sensitivity across FGFR2 fusion partners

> “In this study, in vitro analysis demonstrated the oncogenicity of all tested FGFR2 rearrangement partners by foci formation and sensitivity to FGFR2 inhibition. Combined, these data suggest the clinically important variable is the FGFR2 fusion irrespective of partner gene.”

Source: [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/)

<a id="topic-2.2.1.4-12"></a>

###### Downstream MAPK and PI3K/AKT signalling from FGFR2 fusion proteins

> “Constitutive activation of FGFR2 fusion proteins leads to persistent, ligand-independent stimulation of downstream oncogenic signaling, most prominently the MAPK (RAS/RAF/MEK/ERK) and PI3K/AKT/mTOR axes, thereby promoting sustained cellular proliferation, survival, and resistance to apoptosis (Figure 1)”

Source: [Xin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12897249/)

<a id="topic-2.2.1.4-13"></a>

###### Diversity of FGFR2 fusion partners and BICC1 as the most common partner

> “In these 107 patients, 56 different partners were identified, 42 (75%) of which were unique to individual patients. The most common FGFR2 partner was BICC1 (31 [29%] patients; appendix p 11).”

Source: [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/)

> “Consistent with previous reports, BICC1, which resides near FGFR2 on chromosome 10, was the most common fusion partner gene (26% of FGFR2 fusions), but was only one of 34 partner genes found (Fig. 4B).”

Source: [Kasi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10870120/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Summary: diagnostic pathway and detection of FGFR2 fusions or rearrangements

Diagnosis rests on cross-sectional imaging followed by histological or cytological confirmation, because no radiological pattern is specific for cholangiocarcinoma. Guidelines recommend a core biopsy for pathology and molecular profiling before non-surgical treatment, molecular analysis in advanced disease suitable for systemic treatment, and profiling when first-line systemic treatment is initiated; parallel testing by next-generation sequencing is preferred over single-gene testing, and ESMO recommends tumour next-generation sequencing in advanced cholangiocarcinoma. FGFR inhibitors are recommended for FGFR2 fusions after at least one prior line of systemic therapy.

FGFR2 fusion detection is technically demanding because partners are diverse. In 226 cases tested by three methods, detection rates were 9.7% with RNA-based sequencing, 7.1% with DNA-based sequencing, and 10.2% with FISH, and against RNA-confirmed fusions DNA-based sequencing had a sensitivity of 71.4% and FISH 95.2%. In an interlaboratory ring trial, 13 of 16 centres (81%) passed the sequencing round, and partner-agnostic methods were judged superior. FoundationOne CDx is FDA approved for detecting FGFR2 fusions or rearrangements for pemigatinib, with an adjusted positive percentage agreement of 87.1% against an externally validated assay and 100% agreement on all measures against the F1 CLIA/CAP assay, although 27 of 107 FGFR2 rearrangement-positive participants enrolled in FIGHT-202 could not be evaluated with it because of insufficient DNA; the futibatinib label states that no FDA-approved test is available, and the lirafugratinib approval letter requires validation studies to support labeling of a companion diagnostic using blood or tissue. Circulating tumour DNA detected FGFR2 rearrangements in 5.3% of cholangiocarcinoma liquid biopsies against 7.6% of tissue samples, rising to 8.4% when tumour fraction was 1% or higher, and detected 84% of tissue-confirmed FGFR2 fusions or rearrangements in one study, whose authors advise confirming fusions with unidentified partners by tissue profiling. ESMO ranks FGFR2 fusions at ESCAT level IB, with an estimated prevalence of 5%-15% of intrahepatic cholangiocarcinomas, and notes that a DNA-based test might miss a fusion whose break point region is not fully covered by the gene panel, whereas RNA-based panels identify the fusion transcript and the fusion partner. In a multicentre Italian cohort, extended molecular profiling was performed in 79.9% of participants with advanced cholangiocarcinoma, and 26 (18.7%) of the 139 participants with an ESCAT I-III alteration received a corresponding tailored treatment.

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/); [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/); [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/); [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/); [Mosele et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38834388/); [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12647265/); [Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9896158/); [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/); [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf); [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf); [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf); [Kasi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10870120/); [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/); [Genovesi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456632/)

<a id="topic-2.2.1.5-2"></a>

###### Diagnosis: guideline recommendations on pathology, molecular biology, and staging

> “Molecular analysis is recommended in advanced disease considered suitable for systemic treatment [I, A]”
> “Elevated CA 19-9 is associated with poorer prognosis and can be useful for assessing response to treatment [III, C]”
> “Thoraco-abdomino-pelvic CT remains the reference examination for lymph node and metastatic extension [III, A]”
> “FDG-PET is not recommended for imaging of the primary tumour. However, it may be considered where there is clinical suspicion of nodal metastases, distant metastases and disease recurrence [III, C; consensus = 100%].”
> “Radiological imaging should be carried out before ERCP or PTC in patients with jaundice [III, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.1.5-3"></a>

###### Diagnosis: guideline recommendations on tissue acquisition for molecular profiling

> “A core biopsy should be obtained for diagnostic pathology and molecular profiling before any nonsurgical treatment [III, A].”
> “In patients with d/pCCA without extraductal metastasis, PTC- or ERCP-guided biopsies should be carried out to obtain adequate tissue for diagnostic pathology and molecular profiling [III, A].”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="topic-2.2.1.5-4"></a>

###### Diagnosis: composition of the molecular testing panel

> “Parallel sequencing of several genes using focused next-generation sequencing (NGS) is preferred over single gene testing.”
> “Currently, the gene panel should include the respective coding DNA regions (target regions) of isocitrate dehydrogenase 1 (IDH1), human epidermal growth factor receptor 2 (HER2)/neu [v-erb-b2 avian erythroblastic leukaemia viral oncogene homologue 2 (ERBB2)] and BRAF to test for hotspot mutations, but the rapidly evolving landscape of drug targets and predictive biomarkers may soon necessitate larger panels.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="topic-2.2.1.5-5"></a>

###### Diagnosis: timing of molecular profiling in advanced disease

> “Molecular profiling is recommended when first-line systemic treatment is initiated in patients with locally advanced, advanced or metastatic disease, particularly in those at high risk of progression or recurrence [I, A].”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.2.1.5-6"></a>

###### FDA-approved test requirement for FGFR2 fusion or rearrangement detection: pemigatinib

> “Select patients for the treatment of locally advanced or metastatic cholangiocarcinoma with PEMAZYRE based on the presence of an FGFR2 fusion or rearrangement as detected by an FDA-approved test”

Source: [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf)

<a id="topic-2.2.1.5-7"></a>

###### FoundationOne CDx analytical validation for FGFR2 rearrangements

> “The next-generation sequencing (NGS)-based FoundationOneCDx (F1CDx) was US Food and Drug Administration approved for detecting FGFR2 fusions or rearrangements.”
> “Adjusted positive, negative, and overall percentage agreements were 87.1%, 99.6%, and 98.3%, respectively, between F1CDx and evNGS. Compared with evNGS, F1CDx had a positive predictive value of 96.2% and a negative predictive value of 98.5%.”

Source: [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/)

<a id="topic-2.2.1.5-8"></a>

###### FoundationOne CDx clinical validation, limit of detection, and discordant cases

> “The positive percentage agreement, negative percentage agreement, overall percentage agreement, positive predictive value, and negative predictive value all exhibited 100% agreement between the F1CDx assay and the F1 CLIA/CAP assay.”
> “The 80 enrolled patients who tested positive with both the F1 CLIA/CAP assay and F1CDx had a similar objective ORR of 37.5% (95% 2-sided exact CI, 26.9%–49.0%).”
> “Of the 107 FGFR2 rearrangement-positive patients enrolled in FIGHT-202, 27 could not be evaluated with F1CDx because of insufficient DNA.”
> “Using the empirical hit rate method, the analytical sensitivity was determined to be 10.75 chimeric reads or a tumor purity of 5.31%.”
> “F1CDx provided a reproducibility and repeatability of 100% for four of five samples, with one sample (sample number 4) demonstrating slightly lower reproducibility and repeatability of 95.5% and 90%, respectively (Supplemental Table S1).”
> “In our study comparison of F1CDx DNA versus RNA-based evNGS, only 2 of 130 patients who tested negative for FGFR2 rearrangement by F1CDx were found to be positive by RNA-based evNGS.”
> “Comparably, only 1 of 26 patients who tested positive by F1CDx was negative by RNA-based evNGS.”
> “Post hoc analysis of four select FGFR2-N/A rearrangements by RNA-based methods [RNA sequencing or evNGS (ArcherDX FusionPlex)] revealed the presence of in-frame fusions in each case, supporting this hypothesis.”

Source: [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/)

<a id="topic-2.2.1.5-9"></a>

###### Companion diagnostic status for futibatinib and lirafugratinib

> “An FDA-approved test for detection of FGFR2 gene fusions or other rearrangements in patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma for selecting patients for treatment with LYTGOBI is not available.”

Source: [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf)

> “Conduct adequate analytical and clinical validation studies to support revisions to the labeling of lirafugratinib to specify the use of an FDA- authorized in vitro companion diagnostic device to accurately and reliably identify patients using blood and/or tissue samples who have FGFR2 fusions and other rearrangements and for whom lirafugratinib therapy is indicated.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.1.5-10"></a>

###### Comparison of RNA-based NGS, DNA-based NGS, and FISH for FGFR2 fusion detection

> “The detection rates for FGFR2 fusion/rearrangement were 9.7% (22/226) for RNA-based NGS, 7.1% (16/226) for DNA-based NGS, and 10.2% (23/226) for FISH. Among the 26 FGFR2 fusion/rearrangement-positive cases identified by any method, only 15 (57.7%) were positive by all three techniques, yielding a concordance rate of 95.1% (215/226).”
> “FISH demonstrated a sensitivity of 95.2% and specificity of 98.5%, compared to oncogenic FGFR2 fusions confirmed by RNA-based NGS, while DNA-based NGS exhibited a sensitivity of 71.4% and specificity of 99.5%, identifying FGFR2 mutations in 4 cases.”

Source: [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12647265/)

<a id="topic-2.2.1.5-11"></a>

###### Limitations of break-apart FISH for FGFR2 rearrangement detection in routine practice

> “Furthermore, the detection of FGFR2 rearrangements relied on break-apart probe FISH rather than RNA-based NGS. Although reliable for detecting structural rearrangements, it does not provide information on fusion partners or confirm whether the resulting transcript is in-frame, and may yield false-negative results for rearrangements involving partners in close proximity to FGFR2”

Source: [Arnouts et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13729926/)

<a id="topic-2.2.1.5-12"></a>

###### Interlaboratory proficiency testing for FGFR2 fusion detection

> “Thirteen of 16 (81%) centres successfully passed the NGS only and 3 of 5 (60%) centres passed the combined NGS + FISH round robin test. Identified obstacles were bioinformatic pipelines not optimised for the detection of FGFR2 fusions and assays not capable of detecting unknown fusion partners.”
> “Due to the marked heterogeneity of the genomic architecture of these fusions, fusion partner agnostic (i.e. open) methodological approaches that are capable of identifying yet unknown fusion partners are superior.”

Source: [Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9896158/)

<a id="topic-2.2.1.5-13"></a>

###### Partner-agnostic sequencing to detect known and novel FGFR2 fusions

> “In view of the molecular diversity of cholangiocarcinoma, these results highlight the importance of incorporating DNA-based or RNA-basednext-generation sequencing assays into standard practice, to detect both known and novel FGFR2 fusions or rearrangements, and thus to identify all patients who might benefit from FGFR-targeted therapies.”

Source: [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/)

<a id="topic-2.2.1.5-14"></a>

###### Detection of FGFR2 rearrangements in circulating tumor DNA

> “The overall prevalence of FGFR2 rearrangements in CCA LBx was 5.3% (Fig. 2A), lower than the 7.6% observed in tissue (P = 0.004). However, among LBx samples with TF ≥1% (525/1,215; 43%), the prevalence of 8.4% was comparable to tissue (Fig. 4A).”

Source: [Kasi et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10870120/)

> “Among patients with known FGFR2 fusions/rearrangements, FGFR1 fusions, FGFR3 fusions, or FGFR2 amplifications per tissue analysis, detection rates in ctDNA for these aberrations were 84%, 0%, 11%, and 59%, respectively.”

Source: [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/)

> “Sixteen patients (88.9%) were positive for FGFR2 fusion events in plasma.”
> “Additionally, increased ctDNA or the emergence of resistance mutations allowed earlier detection of disease progression compared with standard radiologic imaging methods.”

Source: [González-Medina et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443220/)

<a id="topic-2.2.1.5-15"></a>

###### Confirmation of ctDNA-detected FGFR2 fusions by tissue profiling

> “The detection rate of FGFR2 fusions/rearrangements by ctDNA was 84% (98/117) among all tumor types and 85% (96/113) in cholangiocarcinoma (Figure 2A).”
> “Among 18 patients with FGFR2 fusions/rearrangements detected in tissue alone, 9 (50%) had a response to futibatinib”
> “Notably, FGFR2 fusions with unidentified partners and/or concurrent high-level FGFR2 amplifications in ctDNA may not be driver events; in these cases, FGFR2 fusions should be confirmed using tissue profiling.”

Source: [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/)

<a id="topic-2.2.1.5-16"></a>

###### Guideline recommendation for tumour next-generation sequencing in cholangiocarcinoma

> “As for 2020 recommendations, ESMO recommends running tumour NGS in advanced non-squamous non-small-cell lung cancer, prostate cancer, colorectal cancer, cholangiocarcinoma, and ovarian cancer.”

Source: [Mosele et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38834388/)

<a id="topic-2.2.1.5-17"></a>

###### ESMO actionability ranking of FGFR2 fusions in advanced cholangiocarcinoma

> “Based on the number of alterations classified as level I, it is recommended to carry out tumour NGS in patients with advanced CCA.”
> “Table 8 provides a list of genomic alterations level I/II according to ESCAT in advanced CCA.”

Source: [Mosele et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38834388/)

| Gene | Alteration | Estimated prevalence | ESCAT score | Drug class matched |
| --- | --- | --- | --- | --- |
| FGFR2 | “Fusions” | “5%-15% iCCA” | “IB” | “Pan-FGFR TKIs” |
| IDH1 | “Mutations” | “8%-18% iCCA” | “IA” | “IDH1 inhibitors” |

Source: [Mosele et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38834388/)

<a id="topic-2.2.1.5-18"></a>

###### ESMO guidance on DNA-based and RNA-based sequencing for fusion detection

> “ESMO recommends carrying out multigene NGS in patients with advanced cancers in countries where tumour-agnostic targeted therapies are accessible. Cost-effectiveness should be assessed at the local level and the decision to implement NGS should be taken accordingly. It is important for clinicians to ensure that fusions are integrated in the panel.”
> “The main point is also to stress the fact that clinicians must assess whether the NGS panel includes the detection of the fusions recommended in a specific disease.”
> “DNA sequencing has the advantage that DNA is more stable than RNA. However, DNA sequencing can only identify break points of translocations leading to gene fusions.”
> “For example, a test that does not detect a fusion might be false negative if the break point region is not fully covered by the gene panel employed for the diagnostic test.”
> “Several limitations of DNA-based fusion gene sequencing are overcome by RNA-based sequencing methods.”
> “RNA-based gene panels identify the transcript of the fusion gene resulting from a translocation, and provide data on the ‘expression’ of the fusion transcript, the fusion partner as well as the potential functionality (e.g. out-of-frame versus in-frame fusions).”
> “In contrast to DNA-based assays, it does not provide information on break points.”

Source: [Mosele et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38834388/)

<a id="topic-2.2.1.5-19"></a>

###### Diagnosis: guideline recommendations on second-line molecularly directed therapy

> “Ivosidenib is recommended for the treatment of patients with CCA and IDH1 mutations who have progressed after ≥1 prior line of systemic therapy”
> “FGFR inhibitors are recommended for the treatment of patients with FGFR2 fusions who have progressed after ≥1 prior line of systemic therapy”
> “Pembrolizumab is recommended in patients with MSI-H/dMMR who have progressed on or are intolerant to prior non-immune checkpoint inhibitor-containing treatment”
> “Dabrafenib-trametinib is recommended for the treatment of patients with BRAFV600E mutations who have progressed after ≥1 prior line of systemic therapy”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.1.5-20"></a>

###### Diagnosis: imaging and tissue acquisition in intrahepatic cholangiocarcinoma

> “iCCA is often seen at presentation as an intrahepatic mass and is incidentally found in 25–30% of patients”
> “Carbohydrate antigen 19-9 (CA19-9) is the primary serum biomarker used in CCA diagnosis, although it has subpar specificity and can be elevated in various conditions, such as biliary obstruction or pancreatic cancer.”
> “MRI may provide enhanced assessment of the primary mass, whereas CT imaging has superior detection of vascular enhancement and is, therefore, important in determining resectability”
> “Histopathological analysis of a biopsy specimen remains the mainstay for confirmation of an iCCA diagnosis.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.5-21"></a>

###### Diagnosis: perihilar and distal cholangiocarcinoma

> “Patients with pCCA and dCCA typically present with painless jaundice owing to underlying biliary obstruction.”
> “The sensitivity and specificity of MRCP to distinguish benign and malignant causes of hilar obstruction are 87% and 85%, respectively”
> “ERC has a diagnostic and therapeutic role in pCCA and dCCA as it enables detection of malignant strictures and acquisition of biliary brushings for cytology and fluorescence in situ hybridization (FISH) analysis.”
> “However, the sensitivity of biliary cytology for pCCA detection is low (43% according to one meta-analysis127). FISH analysis has a higher sensitivity than cytology (65% versus 19% in one series) and similar specificity for detection of CCA”
> “EUS–FNA has a higher sensitivity for detection of dCCA than detection of pCCA (81% versus 59%)”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.5-22"></a>

###### Diagnosis: histological confirmation and the limits of imaging

> “As no specific CCA radiology pattern exists, histopathological or cytological analysis is mandatory to confirm the diagnosis1,28. This diagnosis is based on the WHO classification of biliary tract cancer showing an adenocarcinoma or mucinous carcinoma101, with tubular and/or papillary structures and a variable fibrous stroma102.”
> “CT is considered the standard imaging method for the preoperative assessment of both iCCA and pCCA; it provides a comprehensive evaluation of the primary tumour, the relationship with adjacent structures, and potential thoracic and abdominal spread”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="topic-2.2.1.5-23"></a>

###### Diagnosis: staging and its limitations

> “There is no widely used staging system for CCA, although it can be staged according to the American Joint Committee on Cancer (AJCC) TNM system103,104.”
> “Finally, the TNM classification misses relevant prognostic factors such as the presence of cancer-related symptoms (such as abdominal pain or malaise) or the degree of liver function impairment.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “Disease stage was defined as locally advanced versus metastatic as per the American Joint Committee on Cancer staging (version 7),21 according to which intrahepatic cholangiocarcinoma with multifocal or satellite liver lesions or metastases were classified as locally advanced in the absence of extrahepatic metastatic disease.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.1.5-24"></a>

###### Diagnosis: yield of comprehensive genomic profiling in biliary tract tumours

> “Reportable genomic alterations were detected in 88 patients (96.7%), whereas no reportable alteration was detected in three patients (3.3%).”
> “Potentially actionable genomic alterations were identified in 21 patients (23.1%). Expert panel-based therapeutic options were identified in 15 patients (16.5%), and genomically matched therapy was introduced in 7 patients (7.7%).”
> “Site-specific frequencies of potentially actionable alterations were highest in iCCA (17/46, 37.0%), followed by GBC (4/24, 16.7%), whereas no potentially actionable genomic alteration was identified in eCCA or ampullary tumors using this definition.”

Source: [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/)

<a id="topic-2.2.1.5-25"></a>

###### Diagnosis: uptake of and barriers to extended molecular profiling in routine practice

> “EMP was performed in 79.9% of patients with advanced CCA. The rate of EMP increased significantly over time (2017–2023: +25.8%).”
> “Our results show that a larger proportion of patients with BTCs have had access to EMP in recent years, with a clear increase of 25.8%, from 43.2% in 2017 to 69.0% in 2023.”
> “EMP should at least include the identification of FGFR2 and NTRK rearrangements, IDH1 R132x and BRAF V600E mutations, microsatellite instability (MSI)/mismatch repair (MMR) status and HER2 amplification”
> “On the other hand, several limitations to the widespread application of EMP have been identified in daily clinical practice throughout Europe: complex pre-analytical steps, high rates of test failure in samples with low tumor cell content, prolonged turnaround time, increased costs and the need for a dedicated molecular tumor board to correctly interpret the biological data all make the implementation of EMP in BTCs challenging.”
> “All the analyses were performed on tissue samples, and no plasma samples were collected to perform molecular profiling.”
> “Of the 139 patients harboring a druggable alteration according to ESCAT I-III tiers, only 26 (18.7%) received one or more corresponding tailored treatments.”

Source: [Genovesi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41456632/)

<a id="topic-2.2.1.5-26"></a>

###### Diagnosis: misclassification as cancer of unknown primary

> “Therefore, patients with CUP often face protracted diagnostic journeys, rapidly spreading metastases, and median OS ranging from two to eight months.”

Source: [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Obstructive and biliary symptoms: jaundice from biliary tract obstruction

> “CCAs are usually asymptomatic during early stages. The most frequent symptom of pCCA and dCCA is jaundice due to biliary tract obstruction88. In iCCA, jaundice is less frequent and mostly associated with advanced disease.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “Patients with pCCA and dCCA typically present with painless jaundice owing to underlying biliary obstruction.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

> “Intrahepatic disease may manifest as a liver mass or cholangitis with possible intrahepatic abscess formation as well as right upper quadrant pain related to capsular distension, whereas extrahepatic neoplasms lead to painless obstructive jaundice and cholangitis.”

Source: [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)

<a id="topic-2.2.1.6-2"></a>

###### Pruritus and its consequences in malignant biliary obstruction

> “In fact, the presence of pruritus can cause severe sleep deprivation resulting in lassitude, fatigue, depression, and suicidal ideation [3]. On the other hand, in patients with better prognosis, biliary obstruction and jaundice also lead to hepatic failure and compromise the administration of chemotherapy, when clinically indicated.”

Source: [Ferraz Gonçalves et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33123850/)

<a id="topic-2.2.1.6-3"></a>

###### Pain: abdominal and right upper quadrant pain

> “Other symptoms of advanced disease include asthenia, abdominal pain, malaise, nausea, anorexia and weight loss.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “Gallbladder cancer may be found incidentally at cholecystectomy; however, it may present with pain due to mass effects and may also trigger obstructive jaundice.”

Source: [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)

<a id="topic-2.2.1.6-4"></a>

###### Constitutional symptoms: asthenia, anorexia, nausea, and weight loss

> “Patients with iCCA are often asymptomatic during early disease stages and develop symptoms or signs, such as abdominal pain or less commonly jaundice, during disease progression to an advanced stage.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

> “There was also a trend towards worsening of nausea and pain in the ASC arm, which remained stable in the ASC + FOLFOX arm.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.6-5"></a>

###### Asymptomatic and incidental presentation

> “iCCA is an incidental finding in around 20–25% of cases88. In patients with cirrhosis, ultrasonography surveillance for HCC enables iCCA diagnosis at an asymptomatic, early stage89.”
> “However, most patients (∼70%) are diagnosed at late stages due to lack of specific symptoms104.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

> “iCCA is often seen at presentation as an intrahepatic mass and is incidentally found in 25–30% of patients”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.6-6"></a>

###### Symptom domains captured by the disease-specific quality-of-life module

> “The QLQ-BIL21 consists of 21 questions: 3 single-item assessments relating to treatment side effects, difficulties with drainage bags/tubes and concerns regarding weight loss, in addition to 18 items grouped into 5 proposed scales: eating symptoms (4 items), jaundice symptoms (3 items), tiredness (3 items), pain symptoms (4 items) and anxiety symptoms (4 items).”

Source: [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Summary: cumulative morbidity in advanced and second-line disease

Long-term morbidity in advanced biliary tract cancer arises mainly from recurrent biliary obstruction and its management, by infection, and by functional decline after progression on first-line therapy. Active symptom control in the second-line setting is defined to include biliary drainage, antibiotics, analgesia, steroids, anti-emetics, palliative radiotherapy, and transfusion of blood products. In a single-centre series of 171 participants who received a palliative biliary stent, complications occurred in 91 (53%) and cholangitis was the most frequent, in 48 (53%) of those with complications; median survival was 75.5 days. In a United States claims cohort, 69.5% of participants had an all-cause inpatient hospitalization and 65.6% a biliary-tract-cancer-related hospitalization, with a mean stay of 7 days per visit and the largest share of inpatient visits occurring during third-line therapy. Rapid decline in performance status after first-line progression limits how many participants can be treated at all.

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Ferraz Gonçalves et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33123850/); [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.7-2"></a>

###### Long-term morbidity: recurrent biliary obstruction and the content of active symptom control

> “ASC consisted of early identification and treatment of biliary-related complications and cancer-related symptom management; it could include (and was not limited to) the following as per requirements of individual patients: biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy (eg, for painful bone metastases), and transfusion of blood products.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “In patients with biliary obstruction, biliary drainage and subsequent treatment should be carried out; when endoscopic access is not possible, percutaneous transhepatic drainage is recommended [IV, A].”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.1.7-3"></a>

###### Long-term morbidity: complications of palliative biliary drainage

> “Insertion of a biliary stent was performed in 171 patients. The most common diagnoses were gastric and colorectal cancers, each with 42 (24%), followed by pancreatic (34 (20%)) and biliary tract cancer (25 (14%)). Most stents (155 (91%)) were placed percutaneously. Complications were seen in 91 (53%) patients and the most common was cholangitis in 48 (53%) patients, and the median survival was 75.5 days (3-1246).”
> “The 30-day mortality was 27%. Some patients had relatively long survivals: 12 (7%) lived more than 1 year, 2 (1%) more than 2 years, and one more than 3 years.”
> “The type of complications described in this study need admission to a health service for treatment of infections, insertion of another stent or other procedure, and all this have a negative impact in the quality of life of patients with a very limited life expectancy.”

Source: [Ferraz Gonçalves et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33123850/)

<a id="topic-2.2.1.7-4"></a>

###### Long-term morbidity: hospitalization burden rises with each line of therapy

> “Overall, 69.5% of patients had all-cause inpatient hospitalizations and 65.6% patients had BTC-related inpatient hospitalizations during the follow-up period. Patients stayed in hospital for a mean period of 7 days per visit. Both all-cause and BTC-related inpatient hospitalizations increased in number as the LOT advanced, with most inpatient visits (55.1%) reported during 3LOT among all LOTs (Table 3).”

Source: [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.7-5"></a>

###### Long-term morbidity: functional decline after progression on first-line therapy

> “Patients with advanced biliary tract cancer often experience a rapid decline in performance status following progression on first-line chemotherapy, and only 15–25% receive second-line therapy.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “In the current study, 46.0% of patients received 2LOT, which could be due to a number of reasons such as potentially high morbidity in patients who progress after 1LOT, poor performance status, or lack of effective treatment options in 2LOT.”

Source: [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.7-6"></a>

###### Long-term morbidity: recurrence after curative-intent resection

> “Tumour resection is still the only potentially curative option for these patients, although only a small percentage of patients are eligible and the percentage recurrence is high.”

Source: [Banales et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7447603/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Summary: health-related quality of life in advanced and second-line disease

Robust health-related quality-of-life data in cholangiocarcinoma are sparse, which the authors of a disease primer attribute to low incidence, high lethality, limited trial enrollment until recently, and a historical lack of dedicated measurement tools. The EORTC QLQ-BIL21 was validated in 172 participants with cholangiocarcinoma and 91 with gallbladder cancer and measures eating, jaundice, tiredness, pain, and anxiety symptoms alongside the generic QLQ-C30.

In the second-line setting, the ABC-06 quality-of-life analysis found no difference between arms in time to deterioration of the global health scale (adjusted hazard ratio 0.97, 95% CI 0.48 to 1.97, P = 0.937) and found that adding FOLFOX did not worsen global, physical, social, or symptom scores, whereas the active-symptom-control arm declined across several domains including the EQ-5D utility value, which fell from 0.75 at baseline to 0.62 at month 4. In the first-line setting, neither durvalumab nor pembrolizumab added to gemcitabine and cisplatin worsened patient-reported outcomes: median time to deterioration of global health status or quality of life was 7.4 months versus 6.7 months in TOPAZ-1, and estimates were similar between arms in KEYNOTE-966.

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/); [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/); [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/); [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/); [Yoo et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40154623/)

<a id="topic-2.2.1.8.1-2"></a>

###### Humanistic burden: sparse quality-of-life evidence in cholangiocarcinoma

> “Robust studies and data on the quality of life of patients with CCA are sparse. This paucity of information is due to the low incidence of the disease, its high lethality, the limited number of patients enrolling in clinical trials until very recently, and the lack of dedicated quality-of-life measurement tools.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.8.1-3"></a>

###### Humanistic burden: validated disease-specific instrument

> “There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice.”
> “This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder.”
> “The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.”

Source: [Kaupp-Roberts et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5117782/)

<a id="topic-2.2.1.8.1-4"></a>

###### Humanistic burden: quality-of-life dynamics from baseline to month 4 in the second-line setting

| Measure | Active symptom control, baseline | Active symptom control, month 4 | Active symptom control, P value | Active symptom control plus FOLFOX, baseline | Active symptom control plus FOLFOX, month 4 | Active symptom control plus FOLFOX, P value |
| --- | --- | --- | --- | --- | --- | --- |
| EQ-5D utility value | “0.75” | “0.62” | “0.0309” | “0.77” | “0.70” | “0.6183” |
| QLQ-C30 Summary score | “77” | “64” | “0.0446” | “79” | “71” | “0.1846” |
| QLQ-C30 Physical health scale | “74” | “59” | “0.0221” | “78” | “66” | “0.1238” |
| QLQ-C30 Social function scale | “77” | “61” | “0.0272” | “76” | “65” | “0.1307” |
| QLQ-C30 Role scale | “71” | “49” | “0.0283” | “76” | “57” | “0.2713” |
| QLQ-C30 Nausea | “10” | “25” | “0.0009” | “10” | “16” | “0.4495” |
| QLQ-C30 Pain | “29” | “44” | “0.0323” | “28” | “21” | “0.2089” |

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.8.1-5"></a>

###### Humanistic burden: time to deterioration of global health in the second-line setting

> “Exposure to FOLFOX did not have a significant impact on the time to Global Health Scale deterioration (n = 76 participants; 36 patients ASC-alone arm; 40 patients in the FOLFOX arm), with similar TTD in both arms”
> “aHR 0.97, 95% CI 0.48-1.97, P = 0.937”
> “Addition of FOLFOX to ASC did not appear to induce worsening of the QoL parameters assessed (Table 3) at 4 months of study entry. In contrast, patients in the ASC-alone arm appeared to experience worsening of the EQ-5D utility values and most of the QLQ-C30 scales (including global, physical, social, and role scales), whereas these were stable in the FOLFOX arm.”
> “The absence of QoL deterioration with chemotherapy in this frail population highlights the importance of disease control, even in the absence of symptomatic improvement.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.1.8.1-6"></a>

###### Humanistic burden: baseline symptom burden in the first-line setting

> “Mean global health status or QOL scores for participants at baseline were 63·0 (95% CI 60·7–65·3) in the durvalumab group and 65·7 (63·3–68·1) in the placebo group.”
> “Symptoms with mean scores greater than 20 in either treatment group were anxiety, fatigue, tiredness, insomnia, pain, appetite loss, weight loss, and abdominal pain (table).”

Source: [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/)

<a id="topic-2.2.1.8.1-7"></a>

###### Humanistic burden: patient-reported outcomes in the first-line setting

> “Median time to deterioration of global health status or quality of life was 7·4 months (95% CI 5·6 to 8·9) in the durvalumab group and 6·7 months (5·6 to 7·9) in the placebo group (hazard ratio 0·87 [95% CI 0·69 to 1·12]).”
> “The adjusted mean change from baseline scores for all patient-reported outcomes did not meet the predefined threshold of an absolute change of 10 points or greater.”
> “In a post-hoc analysis, the HR for time to deterioration of global health status or QOL in the durvalumab group compared with the placebo group was 0·95 (0·74–1·24) up to 7 months, and 0·45 (0·22–0·91) after 7 months (figure 2A).”

Source: [Burris et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38697156/)

> “Time to confirmed deterioration estimates were also similar between arms, including for global health status/quality of life (median not reached [NR] in the pembrolizumab arm vs. 21.2 months in the placebo arm; hazard ratio [HR] 0.86, 95% CI 0.70-1.07); jaundice (NR vs. NR; HR 1.20, 95% CI 0.94-1.54), and pain (NR vs. NR; HR 0.79, 95% CI 0.59-1.05).”
> “For the six prespecified domains, similar results between treatment arms were observed in the LSM change from baseline to week 18 (Table 1), including GHS/QoL (difference = 0.04, 95% CI -2.52 to 2.60; nominal p = 0.98), physical functioning (difference = 1.24; 95% CI -1.42 to 3.90; nominal p = 0.36) and role functioning (difference = 2.68, 95% CI -0.76 to 6.11; nominal p = 0.13).”
> “Comparable changes from baseline to week 18 between the two treatment arms were also seen for jaundice (difference = 0.26; 95% CI -1.35 to 1.87; nominal p = 0.75) and pain (difference = -1.87, 95% CI -4.26 to 0.53; nominal p = 0.13) symptom scale scores, as well as EQ-5D-5L VAS (difference = 0.14; 95% CI -2.18 to 2.46; nominal p = 0.91).”
> “The PRO endpoints were exploratory and were not powered to provide statistical significance nor adjusted for multiple comparisons, and therefore the results should be interpreted with caution.”

Source: [Yoo et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40154623/)

<a id="topic-2.2.1.8.1-8"></a>

###### Humanistic burden: quality of life during FGFR inhibitor therapy in FGFR2 fusion-positive disease

> “A total of 92 patients (89%) completed at least one EORTC QLQ-C30 or EQ-5D at baseline and at one or more follow-up assessments.”
> “During these 9.0 months of treatment, EORTC QLQ-C30 scores were stable and global health status was well maintained, except for constipation, which worsened by the minimal threshold of 10.0 points only at cycle 4 (Fig. S6 and Table S11).”
> “Mean (±SD) EQ VAS scores were sustained from baseline (71.7±20.3) to cycle 13 (75.6±21.6) (Fig. S8).”

Source: [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)

<a id="topic-2.2.1.8.1-9"></a>

###### Humanistic burden: perspective of a patient and advocate

> “All patients, including myself, desire to increase our survival time. However, I came to a point in my journey in which quality of life became more important than the quantity of life, and my fellow patients agree with this sentiment. I came to this decision because my quality of life declined after 2 years of undergoing chemotherapy, and I had no desire to continue.”
> “Because there is no proven treatment and minimal options for CCA, patients are willing to try treatments that have no guarantee of working.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Summary: costs and resource use in advanced biliary tract cancer

In a United States commercially insured cohort of participants with advanced biliary tract cancer treated before immuno-oncology regimens were approved, mean per-patient-per-month all-cause costs were $18,274 overall, of which approximately 84% ($15,296) were biliary-tract-cancer-related. Costs rose with each line of therapy, from $19,589 in first line to $22,617 in second line and $33,534 in third line. Outpatient and inpatient utilization were the main cost drivers, and approximately 70% of participants had at least one inpatient visit. Earlier estimates cited in the same study were $7,743 per-patient-per-month for advanced cholangiocarcinoma-associated costs after first-line failure and $20,696 per-patient-per-month for all-cause biliary tract cancer management. In a separate claims analysis of participants receiving pemigatinib, mean per-patient-per-month medical costs were $13,444 for those with a prior cancer-of-unknown-primary diagnosis and $9,881 for those without. In a second United States claims analysis of 221 participants initiating pemigatinib, mean all-cause health care costs were $11,139 per patient per month, of which $8,889 was attributable to cholangiocarcinoma-related care, driven mainly by ambulatory visits and inpatient stays.

Source: [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/); [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/); [Verma et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13129466/)

<a id="topic-2.2.1.8.2-2"></a>

###### Economic burden: per-patient-per-month costs by line of therapy

> “The mean PPPM costs for the overall population were $18,274 for all-cause costs, of which approximately 84% ($15,296) comprised BTC-related costs.”
> “The total mean (SD) PPPM all-cause costs by LOT were $19,589 ($22,603) for 1LOT, $22,617 ($19,302) for 2LOT and $33,534 ($40,588) for 3LOT.”
> “We found that total all-cause PPPM cost was $19,589 during 1LOT, increasing to $22,617 and $33,534 as the treatment advanced to 2LOT and 3LOT, respectively, with >80% of PPPM costs only related to BTC.”
> “The primary driver of costs across all three LOTs was outpatient (including antineoplastic therapy visits) and inpatient utilization followed by outpatient pharmaceutical costs.”

Source: [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.8.2-3"></a>

###### Economic burden: previously published cost estimates

> “One study focused on costs of second-line therapies in selected patients with advanced cholangiocarcinoma who experienced failure of a first-line therapy containing either gemcitabine or fluorouracil; the total mean per-patient-per-month (PPPM) advanced cholangiocarcinoma-associated healthcare costs were $7,743 [20]. Another study noted high total all-cause healthcare costs of $20,696 PPPM for the management of BTC; however, this study did not account for disease stage or 1LOT using a validated clinical data source [21].”

Source: [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.8.2-4"></a>

###### Economic burden: complications as cost drivers

> “Healthcare professionals could implement strategies to identify and prevent some of these complications at an early stage and initiate pre-emptive discussions regarding advanced treatment options and patient preferences for further management to limit excess costs.”
> “In addition to the unmet treatment needs of patients with advanced BTC, the care costs pose a significant burden on patients and payers that has increased over time [20].”

Source: [Wang et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534106/)

<a id="topic-2.2.1.8.2-5"></a>

###### Economic burden: resource use and cost among participants treated with pemigatinib

> “CUP was associated with significantly higher prevalence of metastatic disease (100.0% vs 63.6%), per patient per month (PPPM) ambulatory HCRU (8.2 vs 5.5), and ambulatory costs ($8584 vs $5308). Medical costs averaged $13 444 vs $9881 PPPM for CUP and non-CUP, respectively (P = .066). Median OS was significantly shorter with CUP (10.2 vs 30.7 months).”

Source: [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)

<a id="topic-2.2.1.8.2-6"></a>

###### Economic burden: health care costs among participants treated with pemigatinib, United States claims data

> “During the follow-up period, mean all-cause health care costs (PPPM) were $11 139, based on 2022 US dollars, with $8889 attributable to CCA-related care.”
> “The majority of all-cause health care costs were driven by ambulatory visits ($6464 PPPM) and inpatient stays ($3888 PPPM).”

Source: [Verma et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13129466/)

<a id="topic-2.2.1.8.2-7"></a>

###### Economic burden: direct medical costs in an employed population

> “Patients with iCCA vs. eCCA had higher inpatient, outpatient medical, outpatient pharmacy, and all-cause healthcare costs PPPM.”
> “Patients with CCA had high productivity losses, indirect costs, and medical costs. Outpatient services costs contributed greatly to the higher healthcare expenditure observed in patients with iCCA vs. eCCA.”
> “Whereas reported costs from the previous analysis were higher than the mean all-cause healthcare costs (range: $10,321–$11,175) and inpatient costs (range: $3,798–$4,883) PPPM across CCA cohorts in our analysis, these disparities may be owing to differences in the patient inclusion criteria of each analysis; selecting for patients with previously treated CCA may have resulted in an older patient population with more advanced disease.”

Source: [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/)

<a id="topic-2.2.1.8.2-8"></a>

###### Economic burden: inpatient admission rates in an employed cholangiocarcinoma cohort

> “The percentage of patients with CCA, iCCA, or eCCA being admitted to the hospital were similar across each cohort of absenteeism (75.7, 72.1, and 78.0%, respectively), short-term disability (75.9, 73.9, and 75.3%, respectively), and long-term disability (73.8, 71.2, and 74.5%, respectively).”

Source: [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Summary: work loss, indirect costs, and family financial exposure

Cholangiocarcinoma imposes measurable work loss and indirect costs on working-age households. In a United States retrospective claims analysis of 1,065 participants with cholangiocarcinoma who had work absence and disability benefits eligibility, mean all-cause days absent per patient per month for illness were 6.0 for intrahepatic and 4.3 for extrahepatic disease, and 12.9% and 6.6% respectively had at least one cholangiocarcinoma-related short-term disability claim. Median indirect costs per patient per month from absenteeism, short-term disability, and long-term disability were $622, $635, and $690 for intrahepatic disease and $304, $589, and $465 for extrahepatic disease. A patient and advocate writing in a disease primer describes declining a first-line clinical trial because insurance would not cover the associated standard-of-care costs and she did not want to put her family in financial distress, and describes travel for trial participation as a source of financial burden.

Source: [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/); [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.8.3-2"></a>

###### Economic impact on families: productivity loss and indirect costs

> “One thousand and sixty-five patients with CCA were included (iCCA: n = 624 [58.6%]; eCCA: n = 380 [35.7%]). The mean age was 51.9-53.9 years across cohorts. In patients with iCCA and eCCA, respectively, the number of mean all-cause days absent PPPM for illness was 6.0 and 4.3, and 12.9 and 6.6% had ≥1 CCA-related short-term disability claim. Median indirect costs PPPM owing to absenteeism, short-term disability, and long-term disability, respectively, in patients with iCCA were $622, $635, and $690, and $304, $589, and $465 in patients with eCCA.”
> “Cholangiocarcinoma (CCA) is associated with poor prognosis. Healthcare-related management likely presents a substantial economic burden associated with time away from work in patients with CCA.”
> “In the absenteeism, short-term disability, and long-term disability cohorts, respectively, mean indirect costs associated with productivity loss contributed to 8.6, 7.2, and 6.7% of the total costs ($11,287, $11,887, and $11,977).”
> “This suggests that patients in our analysis are more economically advantaged than the overall population of the United States, many of whom do not have access to paid sick leave or are not provided with insurance by their employers. Thus, our analysis may underestimate the productivity losses within the overall population of the United States.”

Source: [Parasuraman et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36883994/)

<a id="topic-2.2.1.8.3-3"></a>

###### Economic impact on families: out-of-pocket exposure and travel for clinical trials

> “Unfortunately, my insurance at that time would not cover the standard-of-care costs that go along with being in a clinical trial. I chose not to join the trial because I did not want to put my family in financial distress.”
> “Patients most likely will have to travel to be able to participate in a trial and that, in turn, causes other issues, such as financial burden.”

Source: [Brindley et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9246479/)

<a id="topic-2.2.1.8.3-4"></a>

###### Economic impact on families: household income relative to the cost of oral targeted therapy

> “According to the U.S. Census Bureau, the average U.S. household income in 2022 was $105,555, while the median U.S. household income was $74,580. Without private or public health insurance, the kinase inhibitor costs are prohibitive.”

Source: [Roskoski (2024)](https://pubmed.ncbi.nlm.nih.gov/38096958/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Summary: cost consequences of FGFR2 testing and of diagnostic delay

Eligibility for lirafugratinib requires identification of an FGFR2 fusion or rearrangement, and the guideline recommendation for molecular analysis in advanced disease applies to all participants suitable for systemic treatment. The yield of testing is low relative to the number tested: in 91 biliary tract tumours profiled at one centre, potentially actionable alterations were found in 23.1% and genomically matched therapy was introduced in 7.7%, and FGFR2 fusions or rearrangements occur in approximately 9% of profiled cholangiocarcinomas. The Canadian drug agency estimated that testing costs approximately $38,000 to identify a single patient eligible for pemigatinib. NICE estimated that adding FGFR2 as a target to the NHS panel test would incur an additional cost of £34, or £340 for each additional person identified who is FGFR2-positive, and a Taiwanese cost-effectiveness model applied a genetic testing fee of NT$30,000. Tissue sufficiency also limits yield: 27 of 107 FGFR2 rearrangement-positive participants in FIGHT-202 could not be evaluated with FoundationOne CDx because of insufficient DNA, and ESMO advises that the cost-effectiveness of next-generation sequencing be assessed at the local level. Tissue-based profiling fails in up to 26.8% of metastatic biliary tract cancers, which is one reason for plasma-based testing. Among 221 participants initiating pemigatinib, those with a prior cancer-of-unknown-primary diagnosis had higher ambulatory costs ($8,584 versus $5,308 per patient per month) and shorter median overall survival (10.2 versus 30.7 months), and the authors recommend reflexive genomic testing for cancer of unknown primary. At approval, the FDA required further validation studies before a companion diagnostic for lirafugratinib is specified in labeling.

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/); [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/); [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/); [CDA-AMC pemigatinib reimbursement recommendation (2025)](https://www.ncbi.nlm.nih.gov/books/NBK616196/); [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/); [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/); [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf); [NICE TA722 committee discussion (2021)](https://www.nice.org.uk/guidance/ta722/chapter/3-Committee-discussion); [Chueh et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36575331/); [Mosele et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38834388/)

<a id="topic-2.2.1.8.4-2"></a>

###### Economic impact of diagnostic testing: cost consequences of an unresolved primary site

> “CUP was associated with significantly higher prevalence of metastatic disease (100.0% vs 63.6%), per patient per month (PPPM) ambulatory HCRU (8.2 vs 5.5), and ambulatory costs ($8584 vs $5308). Medical costs averaged $13 444 vs $9881 PPPM for CUP and non-CUP, respectively (P = .066). Median OS was significantly shorter with CUP (10.2 vs 30.7 months).”
> “With the advent of targeted treatments for gene-altered CCA, reflexive genomic testing should be encouraged for all patients with CUP.”
> “Reflexive genomic testing upon CUP diagnosis may help reduce delays in identifying actionable targets and initiating appropriate targeted therapy.”

Source: [Verma et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12611303/)

<a id="topic-2.2.1.8.4-3"></a>

###### Economic impact of diagnostic testing: yield of comprehensive genomic profiling

> “This retrospective single-center observational study included 91 patients with BTTs who underwent CGP.”
> “Potentially actionable genomic alterations were identified in 21 patients (23.1%). Expert panel-based therapeutic options were identified in 15 patients (16.5%), and genomically matched therapy was introduced in 7 patients (7.7%).”
> “CGP revealed a heterogeneous genomic landscape across BTT subtypes and provided clinically actionable information in a limited but meaningful subset of patients. The practical utility of CGP was the greatest in selected molecular subsets, particularly iCCA.”

Source: [Nakaoka et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13406710/)

<a id="topic-2.2.1.8.4-4"></a>

###### Economic impact of diagnostic testing: guideline requirement for molecular analysis

> “Molecular analysis is recommended in advanced disease considered suitable for systemic treatment [I, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.1.8.4-5"></a>

###### Economic impact of diagnostic testing: cost of FGFR2 testing per eligible patient identified in Canada

> “The price reduction is influenced by the cost of testing, which is estimated to be $38,000 to identify a single patient eligible for treatment with pemigatinib.”

Source: [CDA-AMC pemigatinib reimbursement recommendation (2025)](https://www.ncbi.nlm.nih.gov/books/NBK616196/)

<a id="topic-2.2.1.8.4-6"></a>

###### Economic impact of diagnostic testing: failure rate of tissue-based profiling

> “The failure rate of tissue-biopsy profiling in metastatic biliary tract cancer is as high as 26.8%”

Source: [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)

<a id="topic-2.2.1.8.4-7"></a>

###### Economic impact of diagnostic testing: companion diagnostic for lirafugratinib

> “Conduct adequate analytical and clinical validation studies to support revisions to the labeling of lirafugratinib to specify the use of an FDA- authorized in vitro companion diagnostic device to accurately and reliably identify patients using blood and/or tissue samples who have FGFR2 fusions and other rearrangements and for whom lirafugratinib therapy is indicated.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.1.8.4-8"></a>

###### Economic impact of diagnostic testing: tissue sufficiency and parallel profiling with a comprehensive panel

> “Of the 107 FGFR2 rearrangement-positive patients enrolled in FIGHT-202, 27 could not be evaluated with F1CDx because of insufficient DNA.”
> “F1CDx offers the additional benefit of profiling multiple actionable alterations (eg, IDH1) in parallel, especially in diseases like CCA, where tumor tissue is scarce.”
> “F1CDx provides important options for patients with CCA; it is the first companion diagnostic approved in the United States for CCA, a devastating disease with limited treatment options but rich with actionable targets.”
> “Widespread adoption of testing for FGFR2 rearrangements by comprehensive genomic profiling in patients with CCA will enable more patients to be matched with targeted therapies with the goal of improving outcomes for this disease.”

Source: [Silverman et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35176488/)

<a id="topic-2.2.1.8.4-9"></a>

###### Economic impact of diagnostic testing: local assessment of the cost-effectiveness of next-generation sequencing

> “ESMO recommends carrying out multigene NGS in patients with advanced cancers in countries where tumour-agnostic targeted therapies are accessible. Cost-effectiveness should be assessed at the local level and the decision to implement NGS should be taken accordingly.”

Source: [Mosele et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38834388/)

<a id="topic-2.2.1.8.4-10"></a>

###### Economic impact of diagnostic testing: cost of adding FGFR2 to the NHS England panel test

> “At the first appraisal committee meeting, the clinical experts advised that FGFR2 testing is not done as part of routine clinical practice in the UK. The committee noted that the 2020/21 National Genomic Test Directory does not include FGFR2 mutation testing for people with cholangiocarcinoma.”
> “The prevalence of FGFR2 fusion or rearrangement is about 10% across all types of cholangiocarcinoma. So, adding FGFR2 as a target would incur an additional cost of £34, which would be applicable if pemigatinib is recommended for routine use in NHS practice. This gives a preferred cost of £340 for each additional person identified who is FGFR2-positive.”

Source: [NICE TA722 committee discussion (2021)](https://www.nice.org.uk/guidance/ta722/chapter/3-Committee-discussion)

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Gemcitabine and Cisplatin Plus an Immune Checkpoint Inhibitor

<a id="topic-2.2.2.1.1-1"></a>

###### ESMO recommendation: first-line chemoimmunotherapy

> “Cisplatin–gemcitabine–durvalumab and cisplatin–gemcitabine–pembrolizumab are recommended as first-line therapy [I, A].”
> “Cisplatin–gemcitabine combined with either pembrolizumab or durvalumab is a viable option for first-line treatment.”
> “At present, there are no discernible clinical, biochemical or molecular biomarkers, nor any notable differences in efficacy or toxicity, favouring one immune checkpoint inhibitor over the other.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

<a id="topic-2.2.2.1.1-2"></a>

###### Durvalumab plus gemcitabine and cisplatin: TOPAZ-1 phase 3 results

> “Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years.”
> “The hazard ratio for overall survival was 0.80 (95% confidence interval [CI], 0.66 to 0.97; P=0.021).”
> “The estimated 24-month overall survival rate was 24.9% (95% CI, 17.9 to 32.5) for durvalumab and 10.4% (95% CI, 4.7 to 18.8) for placebo.”
> “Objective response rates were 26.7% with durvalumab and 18.7% with placebo.”

Source: [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/)

<a id="topic-2.2.2.1.1-3"></a>

###### Durvalumab plus gemcitabine and cisplatin: TOPAZ-1 median survival, response, and safety

> “Median overall survival was 12.8 months (95% CI, 11.1 to 14.0) in the durvalumab group and 11.5 months (95% CI, 10.1 to 12.5) in the placebo treatment group (Fig. 1A).”
> “Median progression-free survival was 7.2 months (95% CI, 6.7 to 7.4) with durvalumab and 5.7 months (95% CI, 5.6 to 6.7) with placebo (Fig. 1B).”
> “The rate of immune-mediated adverse events was 12.7% with durvalumab and 4.7% with placebo.”
> “Of the full analysis set, the number of patients who received one or more regimens of subsequent anticancer therapy post-discontinuation was 145 (42.5%) in the durvalumab group and 170 (49.4%) in the placebo group (Table S4).”

Source: [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/)

| Outcome | Durvalumab plus gemcitabine and cisplatin | Placebo plus gemcitabine and cisplatin |
| --- | --- | --- |
| Objective response rate, no. (%) | “91 (26.7)” | “64 (18.7)” |
| Disease control rate, no. (%) | “291 (85.3)” | “284 (82.6)” |
| Median duration of response (IQR), mo | “6.4 (4.6–17.2)” | “6.2 (3.8–9.0)” |
| Median time to response (IQR), mo | “1.6 (1.3–3.0)” | “2.7 (1.4–4.1)” |

Source: [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/)

| Adverse events, no. (%) | Durvalumab plus gemcitabine and cisplatin (n=338) | Placebo plus gemcitabine and cisplatin (n=342) |
| --- | --- | --- |
| Grade 3 or 4, any cause | “256 (75.7)” | “266 (77.8)” |
| Serious, any cause | “160 (47.3)” | “149 (43.6)” |
| Leading to discontinuation of any study treatment | “44 (13.0)” | “52 (15.2)” |
| Leading to death | “12 (3.6)” | “14 (4.1)” |
| Treatment-related, grade 3 or 4 | “212 (62.7)” | “222 (64.9)” |

Source: [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/)

<a id="topic-2.2.2.1.1-4"></a>

###### Pembrolizumab plus gemcitabine and cisplatin: KEYNOTE-966 phase 3 results

> “Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance threshold, p=0·0200]).”
> “At the first interim analysis, 153 (29% [95% CI 25 to 33]) of 533 participants in the pembrolizumab group and 153 (29% [25 to 33]) of 536 participants in the placebo group had a complete or partial response (table 2).”
> “Median duration of response was 9·7 months (95% CI 6·9 to 12·2) in the pembrolizumab group and 6·9 months (5·7 to 8·2) in the placebo group.”

Source: [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)

<a id="topic-2.2.2.1.1-5"></a>

###### Subsequent anticancer therapy after first-line gemcitabine and cisplatin plus an immune checkpoint inhibitor

> “Median (95% CI) time to first SAT was longer for participants in the durvalumab arm (18.7 [13.2–42.2] months) vs. the placebo arm (12.3 [11.3–24.1] months) (HR 0.92; 95% CI 0.75–1.13; Fig. S2).”
> “In the small number of participants who received targeted therapies, the mean time to death or censoring from starting targeted therapy for durvalumab vs. placebo was 21.4 vs. 7.5 months (n = 4 vs. n = 2) with FGFR inhibitors and 11.3 vs. 8.4 months (n = 5 vs. n = 5) with IDH1 inhibitors, when given as subsequent therapy (Fig. S4).”

Source: [Oh et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40381735/)

> “253 (47%) of 533 participants in the pembrolizumab group and 261 (49%) of 536 participants in the placebo group had received one or more subsequent anticancer therapies”

Source: [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)

<a id="topic-2.2.2.1.1-6"></a>

###### Alternative first-line regimens for reduced fitness or organ dysfunction

> “Oxaliplatin or carboplatin may be substituted for cisplatin when renal or auditory function is of concern, while gemcitabine plus S-1 can be an option for patients who present with or are susceptible to peripheral sensory neuropathy [II, B]”
> “Gemcitabine monotherapy may be used in patients with a PS of 2 [IV, B]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.1-7"></a>

###### Grade 3 or 4 adverse events and treatment discontinuations in KEYNOTE-966

> “In the as-treated population, the maximum adverse event grade was 3 to 4 in 420 (79%) of 529 participants in the pembrolizumab group and 400 (75%) of 534 in the placebo group; 369 (70%) participants in the pembrolizumab group and 367 (69%) in the placebo group had treatment-related adverse events with a maximum grade of 3 to 4.”
> “31 (6%) participants in the pembrolizumab group and 49 (9%) in the placebo group died due to adverse events, including eight (2%) in the pembrolizumab group and three (1%) in the placebo group who died due to treatment-related adverse events.”
> “Adverse events led to discontinuation of one or more study drugs in 138 (26%) participants in the pembrolizumab group and in 122 (23%) participants in the placebo group; discontinuation of all study drugs occurred in 35 (7%) participants in the pembrolizumab group and 39 (7%) in the placebo group.”

Source: [Kelley et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37075781/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Fluoropyrimidine-Based Second-line Chemotherapy

<a id="topic-2.2.2.1.2-1"></a>

###### Guideline recommendation: FOLFOX as the second-line standard of care

> “FOLFOX is the standard of care in the second-line setting after cisplatin-gemcitabine-based treatment”
> “Irinotecan monotherapy or irinotecan- or liposomal irinotecan-based combination therapy may be considered [III, B]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

> “For patients who progressed after frontline therapy and lack actionable alterations, fluoropyrimidine plus oxaliplatin and fluoropyrimidine plus liposomal irinotecan are recommended second-line options, supported by ABC-06 and NIFTY, respectively.”
> “The primary endpoint, median OS, was significantly improved with ASC plus FOLFOX over ASC alone (Table 1B). The median PFS was 4.0 months, and the ORR was 4.9% in the FOLFOX arm.”

Source: [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/)

> “FOLFOX is the SoC in the second-line setting after cisplatin–gemcitabine [I, A; ESMO-MCBS v1.1 score: 1; no specific licensed indication in BTC].”
> “Second-line ChT has previously been used ad hoc by clinicians with limited knowledge of the magnitude of benefit.”
> “Evidence for irinotecan-based therapies is currently limited.”

Source: [Vogel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36372281/)

<a id="topic-2.2.2.1.2-2"></a>

###### FOLFOX versus active symptom control: ABC-06 phase 3 results

> “Overall survival was significantly longer in the ASC plus FOLFOX group than in the ASC alone group, with a median overall survival of 6·2 months (95% CI 5·4–7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in the ASC alone group (adjusted hazard ratio 0·69 [95% CI 0·50–0·97]; p=0·031).”
> “Objective response was observed in four (5%) of 81 patients in the ASC plus FOLFOX group: one (1%) patient had a complete response and three (4%) patients had a partial response.”
> “Grade 3–5 adverse events were reported in 42 (52%) of 81 patients in the ASC alone group and 56 (69%) of 81 patients in the ASC plus FOLFOX group, including three chemotherapy-related deaths (one each due to infection, acute kidney injury, and febrile neutropenia).”
> “Based on these findings, FOLFOX should become standard-of-care chemotherapy in second-line treatment for advanced biliary tract cancer and the reference regimen for further clinical trials.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.2.1.2-3"></a>

###### Liposomal irinotecan plus fluorouracil and leucovorin: NIFTY randomized phase 2b trial

> “At a median follow-up of 11·8 months (IQR 7·7-18·7), the median BICR-assessed progression-free survival was significantly longer in the liposomal irinotecan plus fluorouracil and leucovorin group (7·1 months, 95% CI 3·6-8·8) than in the fluorouracil and leucovorin group (1·4 months, 1·2-1·5; hazard ratio 0·56, 95% CI 0·39-0·81; p=0·0019).”
> “Liposomal irinotecan plus fluorouracil and leucovorin could be considered a standard-of-care second-line therapy for advanced biliary tract cancer.”
> “The discordance rate for the date of tumour progression between the investigator and the BICR assessments was 30% (52 of 174; appendix 2 pp 5–8).”
> “the possibility of overestimation in the median progression-free survival by BICR assessment cannot be excluded.”

Source: [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)

<a id="topic-2.2.2.1.2-4"></a>

###### Liposomal irinotecan plus fluorouracil and leucovorin: NALIRICC randomized phase 2 trial

> “Median progression-free survival was 2·6 months (95% CI 1·7-3·6) in the nanoliposomal irinotecan group and 2·3 months (1·6-3·4) in the control group (hazard ratio [HR] 0·87 [0·56-1·35]).”
> “The addition of nanoliposomal irinotecan to fluorouracil plus leucovorin did not improve progression-free survival or overall survival and was associated with higher toxicity compared with fluorouracil plus leucovorin.”

Source: [Vogel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38870977/)

<a id="topic-2.2.2.1.2-5"></a>

###### Liposomal irinotecan plus fluorouracil and leucovorin: NALIRICC overall survival, response, toxicity, and subsequent therapy

> “Median overall survival was 6·9 months (95% CI 5·3–10·6) in the nanoliposomal irinotecan group and 8·2 months (5·4–11·9) in the control group (HR 1·08 [0·68–1·72]).”
> “The objective response rate was 14% (95% CI 6–27; seven patients) in the nanoliposomal irinotecan group and 4% (1–14; two patients) in the control group.”
> “There was a marked difference between groups in the number of severe (grade 3 or worse) adverse events, of which 95, affecting 34 (71%) of 48 patients, were reported for the nanoliposomal irinotecan group, and 57, affecting 24 (50%) of 48 patients, were reported for the control group.”
> “Discontinuation of study treatment due to toxicity was reported in five (10%) patients in the nanoliposomal irinotecan group and in one (1%) patient in the control group.”
> “After end of study participation, 18 (37%) of 49 patients in the nanoliposomal irinotecan group and 30 (59%) of 51 patients in the control group received subsequent anticancer treatment (appendix p 3). Of note, 21 (70%) of 30 patients from the control group who received subsequent therapies were treated with irinotecan-based regimens.”

Source: [Vogel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38870977/)

<a id="topic-2.2.2.1.2-6"></a>

###### Sources of discordance between the NIFTY and NALIRICC results

> “Differences in sample size (174 vs. 100), iCCA proportion (64% vs. 43%), ethnicity (Asian vs. White), and more frequent early treatment discontinuations due to toxicity in NALIRICC may have contributed to the discordant results [28].”

Source: [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/)

<a id="topic-2.2.2.1.2-7"></a>

###### Pooled individual patient data from NIFTY and NALIRICC

> “Current standard of care for second-line therapy in patients with advanced biliary tract cancer (BTC) is FOLFOX.”
> “The nal-IRI plus 5-FU/LV group showed significantly longer median PFS (3.6 months [95% CI 2.7-4.4] vs. 1.8 months [95% CI 1.5-2.6]; hazard ratio 0.65, p <0.001).”
> “There was no statistically significant difference in OS (median 8.1 vs. 6.1 months, HR 0.77, p = 0.051).”
> “However, nal-IRI plus 5-FU/LV may be considered a viable alternative to second-line FOLFOX for patients of East Asian ethnicity or those deemed unfit for FOLFOX (e.g. due to severe peripheral neuropathy caused by prior platinum-based therapy).”

Source: [Yoo et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40147791/)

Additional sources: [Benson et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40930144/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Reversible FGFR Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

###### Guideline recommendations for FGFR inhibition after progression

> “Futibatinib [ESMO-Magnitude of Clinical Benefit (MCBS) v1.1 score: 3] and pemigatinib (ESMO-MCBS v1.1 score: 2) are recommended in patients with FGFR2 fusions or rearrangements who have progressed after one or more prior lines of systemic therapy [III, A; ESCAT score: I-B].”
> “These findings led to both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approval of pemigatinib and futibatinib.”

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/)

> “FGFR inhibitors are recommended for the treatment of patients with FGFR2 fusions who have progressed after ≥1 prior line of systemic therapy [III, A; ESMO-MCBS v1.1 score: 3; ESCAT score: I-B]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.3-2"></a>

###### Pemigatinib: FIGHT-202 final analysis

> “The ORR in cohort A was 37.0% (95% confidence interval 27.9% to 46.9%); complete and partial responses were observed in 3 and 37 patients, respectively.”
> “Median DOR was 9.1 (6.0-14.5) months; median PFS and OS were 7.0 (6.1-10.5) months and 17.5 (14.4-22.9) months, respectively.”
> “The most common TEAEs of any grade were hyperphosphatemia (58.5%), alopecia (49.7%), and diarrhea (47.6%).”

Source: [Vogel et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190465/)

<a id="topic-2.2.2.1.3-3"></a>

###### Pemigatinib: FIGHT-202 primary analysis

> “38 (35·5% [95% CI 26·5–45·4]) of 107 patients with FGFR2 fusions or rearrangements achieved a centrally confirmed objective response (table 2).”

Source: [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/)

<a id="topic-2.2.2.1.3-4"></a>

###### Infigratinib: phase 2 trial in previously treated FGFR2 fusion-positive cholangiocarcinoma

> “After a median follow-up of 10·6 months (IQR 6·2-15·6), the BICR-assessed objective response rate was 23·1% (95% CI 15·6-32·2; 25 of 108 patients), with one confirmed complete response in a patient who only had non-target lesions identified at baseline and 24 partial responses.”
> “The most common treatment-emergent adverse events of any grade were hyperphosphataemia (n=83), stomatitis (n=59), fatigue (n=43), and alopecia (n=41). The most common ocular toxicity was dry eyes (n=37). Central serous retinopathy-like and retinal pigment epithelial detachment-like events occurred in 18 (17%) patients, of which ten (9%) were grade 1, seven (6%) were grade 2, and one (1%) was grade 3.”

Source: [Javle et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34358484/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Irreversible FGFR Inhibitors

<a id="topic-2.2.2.1.4-1"></a>

###### Futibatinib: FOENIX-CCA2 phase 2 trial

> “A total of 43 of 103 patients (42%; 95% confidence interval, 32 to 52) had a response, and the median duration of response was 9.7 months.”
> “At a median follow-up of 17.1 months, the median progression-free survival was 9.0 months and overall survival was 21.7 months.”
> “Common treatment-related grade 3 adverse events were hyperphosphatemia (in 30% of the patients), an increased aspartate aminotransferase level (in 7%), stomatitis (in 6%), and fatigue (in 6%).”
> “Overall, treatment-related adverse events led to dose interruptions in 52 patients (50%) and dose reductions in 56 patients (54%).”

Source: [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)

<a id="topic-2.2.2.1.4-2"></a>

###### Futibatinib after progression on reversible FGFR inhibitors

> “Here, we report that the irreversible pan-FGFR inhibitor, TAS-120, demonstrated efficacy in four patients with FGFR2-fusion-positive ICC who developed resistance to BGJ398 or Debio1347. Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to BGJ398 or Debio1347.”
> “Our findings suggest that strategic sequencing of FGFR inhibitors, guided by serial biopsies and ctDNA, may prolong the duration of benefit from FGFR inhibition in patients with FGFR2 fusion-positive ICC.”

Source: [Goyal et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6677584/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Locoregional Therapy

<a id="topic-2.2.2.1.5-1"></a>

###### Guideline recommendations for ablation, stereotactic radiotherapy, and intra-arterial therapy

> “Local ablation could be considered as an option for patients with iCCA ≤3 cm who have contraindications or are otherwise unfit for surgery [III, B]”
> “SBRT can be considered for patients with iCCA in case of contraindication to surgery for liver-limited disease in the palliative setting [III, C]”
> “Intraarterial therapies, in combination with systemic ChT, can be an option for patients with liver-limited iCCA and discussed by the MDTB according to local availability [III, C]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.5-2"></a>

###### Hepatic artery infusion pump chemotherapy: pooled analysis of four phase 2 trials

> “Systemic therapy is the standard of care for unresectable intrahepatic cholangiocarcinoma (iCCA), but overall survival (OS) remains poor.”
> “The pooled median OS was 26 months (95% CI 22-30), with 3-year and 5-year OS rates of 28% (95% CI 22-37) and 15% (95% CI 10-23), respectively.”
> “Hepatic artery infusion pump (HAIP) chemotherapy with floxuridine (FUDR) has been shown to prolong survival but is limited to expert centers.”
> “Liver-confined disease was defined as absence of extrahepatic metastatic disease, although locoregional lymph node metastases were allowed in the two most recent trials.”

Source: [Rousian et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42331230/)

<a id="topic-2.2.2.1.5-3"></a>

###### Hepatic artery infusion pump chemotherapy: pump implantation complications and biliary sclerosis

> “Twenty patients (14%) had major postoperative complications following pump implantation requiring reintervention. Three patients (2%) developed ascites, which was treated with percutaneous drainage.”
> “Biliary sclerosis, a long-term complication associated with HAIP chemotherapy with FUDR, necessitated biliary stenting in two patients (1.4%).”

Source: [Rousian et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42331230/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Best Supportive Care

<a id="topic-2.2.2.1.6-1"></a>

###### Composition of active symptom control in the ABC-06 trial

> “ASC consisted of early identification and treatment of biliary-related complications and cancer-related symptom management; it could include (and was not limited to) the following as per requirements of individual patients: biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy (eg, for painful bone metastases), and transfusion of blood products.”
> “The overall survival rate in the ASC alone group was 35·5% (95% CI 25·2–46·0) at 6 months and 11·4% (5·6–19·5) at 12 months, compared with 50·6% (39·3–60·9) at 6 months and 25·9% (17·0–35·8) at 12 months in the ASC plus FOLFOX group.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.2.1.6-2"></a>

###### Quality of life with active symptom control alone versus active symptom control plus FOLFOX

> “FOLFOX did not worsen global, physical, social, or symptom QoL scores, whereas patients receiving ASC recorded declines across several domains.”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="topic-2.2.2.1.6-3"></a>

###### Guideline recommendations for biliary drainage and infection

> “In patients with biliary obstruction, biliary drainage and subsequent treatment should be carried out; when endoscopic access is not possible, percutaneous transhepatic drainage is recommended [IV, A]”
> “Sepsis secondary to biliary obstruction is common and should be treated promptly [IV, A]”
> “Patients should be advised of the likely duration of stent patency and of symptoms and signs which are indicative of biliary obstruction or infection [V, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Summary: limitations of current treatment for previously treated FGFR2 fusion-positive cholangiocarcinoma

Non-targeted second-line chemotherapy provides limited benefit. In ABC-06, the only positive phase 3 second-line trial, median overall survival was 6.2 months with FOLFOX plus active symptom control versus 5.3 months with active symptom control alone, and an objective response occurred in 4 of 81 participants (5%); the Pan-Asian adaptation of the ESMO guideline downgraded the level of evidence for this recommendation. Randomized results for liposomal irinotecan are inconsistent between NIFTY and NALIRICC; in NALIRICC median overall survival was 6·9 months with liposomal irinotecan plus fluorouracil and leucovorin and 8·2 months in the control group (HR 1·08), and grade 3 or worse adverse events affected 34 (71%) of 48 and 24 (50%) of 48 participants.

Reversible FGFR inhibitors produce responses in a minority and benefit that is time-limited. Pemigatinib produced an objective response rate of 37.0% with median progression-free survival of 7.0 months and median overall survival of 17.5 months in the FIGHT-202 final analysis, and infigratinib an objective response rate of 23.1%; the United States approval of infigratinib was withdrawn in May 2024 after the confirmatory PROOF 301 trial randomized 48 of approximately 300 planned participants and closed for poor accrual. The irreversible inhibitor futibatinib produced an objective response rate of 42% with median progression-free survival of 9.0 months. The accelerated approvals of futibatinib and infigratinib rested on single-group trials, and randomized first-line trials of FGFR inhibitors have enrolled slowly.

Toxicity arises from inhibition of FGFR isoforms other than FGFR2. Hyperphosphatemia, attributed to FGFR1 inhibition, was reported from laboratory values in 93% of participants receiving pemigatinib and 88% receiving futibatinib, and 77% of futibatinib recipients received phosphate binders; diarrhea attributed to FGFR4 inhibition occurs in 15% to 36%. Retinal pigment epithelial detachment occurred in 11% with pemigatinib and 9% with futibatinib, nail toxicity in 42% of FIGHT-202 participants, and dose reductions for adverse reactions in 58% of futibatinib recipients.

Acquired resistance is common. Progression on reversible FGFR inhibitors is typically observed within 1 year, 49 of 82 participants (60%) had one or more secondary FGFR2 kinase domain mutations at acquired resistance, most often at the N550 molecular brake (63% of mutations) and the V565 gatekeeper (47%), and resistance is frequently polyclonal; new MAPK pathway alterations appeared in 9 of 17 participants with repeat sequencing. Every participant analysed at progression on pemigatinib had at least 1 acquired FGFR2 mutation, and after futibatinib FGFR2 kinase domain mutations were identified in 62% (23/37) of FGFR inhibitor-naive participants with cholangiocarcinoma, RAS mutations in 33% (14/43), and BRAF mutations in 21% (9/43). A second FGFR inhibitor produced an objective response rate of 13.6% and median progression-free survival of 3.8 months, against 47.6% and 8.5 months with the first. Median overall survival in advanced biliary tract cancer as a whole remains around 1 year.

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/); [Yoo et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40147791/); [Vogel et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190465/); [Javle et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34358484/); [FDA Federal Register notice (2024)](https://www.federalregister.gov/documents/2024/05/16/2024-10714/helsinn-healthcare-sa-withdrawal-of-approval-of-new-drug-application-for-truseltiq-infigratinib); [Abou-Alfa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13015651/); [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/); [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/); [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf); [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf); [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/); [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10767308/); [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/); [DiPeri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11900356/); [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/); [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/); [Vogel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38870977/); [Silverman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33218975/)

<a id="topic-2.2.2.1.7-2"></a>

###### Acquired resistance to FGFR inhibition and next-generation agents

> “Cholangiocarcinoma is a rare, aggressive cancer often driven by FGFR2 fusions, which are targetable with inhibitors such as pemigatinib and futibatinib. However, resistance frequently develops due to acquired FGFR2 mutations.”
> “Among 51 patients included in the efficacy evaluable set, the objective response rate was 6·3% (95% CI 0·2-30·2; one confirmed partial response) in cohort A1, 30·0% (6·7-65·3; three confirmed partial responses) in cohort A2, 23·1% (5·0-53·8; three confirmed partial responses) in cohort B, and 0% in cohort C.”

Source: [Javle et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41349554/)

<a id="topic-2.2.2.1.7-3"></a>

###### Landscape of clinical resistance mechanisms to FGFR inhibitors

> “Overall, 49 of 82 patients (60%) had one or more detectable secondary FGFR2 kinase domain mutations upon acquired resistance. N550 molecular brake and V565 gatekeeper mutations were most common, representing 63% and 47% of all FGFR2 kinase domain mutations, respectively.”
> “Interestingly, disruption of the cysteine residue covalently bound by futibatinib (FGFR2 C492) was rare, observed in 1 of 42 patients treated with this drug.”
> “While reversible ATP-competitive FGFR inhibitors provide benefit to most patients with FGFR2 fusion–positive ICC, with approximately 80% showing stable disease or partial response, progression is typically observed within less than 1 year.”

Source: [Wu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10767308/)

<a id="topic-2.2.2.1.7-4"></a>

###### Acquired resistance to reversible FGFR inhibitors: polyclonal FGFR2 kinase domain mutations

> “Serial analysis of cfDNA demonstrated multiple recurrent point mutations in the FGFR2 kinase domain at progression.”
> “Accordingly, biopsy of post-progression lesions and rapid autopsy revealed marked inter- and intra-lesional heterogeneity, with different FGFR2 mutations in individual resistant clones.”
> “The p.V564F gatekeeper mutation, which was common to all three patients, confers resistance by inducing a steric clash with BGJ398 in its FGFR2 binding pocket (Figure 2A).”

Source: [Goyal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5433349/)

<a id="topic-2.2.2.1.7-5"></a>

###### Acquired resistance to pemigatinib: FGFR2 kinase domain mutations at progression

> “Strikingly, every patient analyzed had at least 1 acquired mutation in FGFR2.”
> “Polyclonal resistance, involving multiple acquired FGFR2 mutations, was observed in 3 patients.”
> “Interestingly, no gatekeeper (FGFR2 p.V564) mutations were identified in this study as has been reported with other FGFR inhibitors (28,29).”
> “There is a need for FGFR inhibitors whose potency is not affected by these kinase domain mutations, including the gatekeeper mutations.”

Source: [Silverman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33218975/)

<a id="topic-2.2.2.1.7-6"></a>

###### Acquired resistance to futibatinib

> “Acquired resistance to futibatinib was frequently polyclonal and driven by an array of mutations within the relevant FGFR kinase domain, predominantly V565L, V565F, and N550K variants.”

Source: [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/)

> “In cholangiocarcinoma, at resistance to both reversible inhibitors (e.g., pemigatinib and erdafitinib) and the irreversible inhibitor futibatinib, polyclonal FGFR2 kinase domain mutations were frequent (14/27 patients).”

Source: [Facchinetti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7616615/)

<a id="topic-2.2.2.1.7-7"></a>

###### Acquired resistance to futibatinib: frequency of kinase domain, RAS, and BRAF mutations at progression

> “Among FGFR inhibitor-naive patients with cholangiocarcinoma, FGFR2 kinase domain mutations were identified in 62% (23/37) of patients, and among those who harbored at least one FGFR2 variant, the frequency of polyclonal resistance was 87%, and the mean number of variants was 3.6 (Table 3).”
> “Patients with a partial response exhibited the highest rate (100%, 11/11) and number of kinase domain mutations (mean 3.6), while those with progressive disease as their best overall response harbored the lowest rate (14%, 1/7) and number (mean 2.0).”
> “Substitutions affecting V565 were seen in 74% (20/27) of all patients with clinical benefit, including 86% (18/21) and 50% (2/4) of FGFR inhibitor-naive and -exposed patients, respectively, with cholangiocarcinoma.”
> “In the 43 patients with cholangiocarcinoma with post-progression ctDNA samples, RAS mutations were detected at progression in 33% (14/43) and BRAF mutations in 21% (9/43)”
> “Compared with mechanisms of acquired resistance to reversible FGFR inhibitors reported in previously published case series and case reports, RAS mutations, gatekeeper mutations, and polyclonality appear to emerge more frequently with futibatinib.”
> “Consequently, treatment selection following progression on FGFR inhibitors may require a tailored approach accounting for FGFR2 kinase domain mutations and alternative signaling pathways.”

Source: [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/)

<a id="topic-2.2.2.1.7-8"></a>

###### Off-target MAPK pathway resistance to FGFR inhibitors

> “On retrospective analysis of 17 patients with repeat sequencing following FGFRi treatment, 11 (64.7%) had new FGFR2 mutations detected, 9 (52.9%) had new alterations in MAPK pathway genes, 7 of these patients developing new alterations in both FGFR2 and MAPK pathway.”
> “These findings suggest convergent genomic evolution in the MAPK pathway may be a potential mechanism of acquired resistance to FGFRi.”

Source: [DiPeri et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11900356/)

<a id="topic-2.2.2.1.7-9"></a>

###### Limited evidence for a second FGFR inhibitor after progression

> “A major challenge to the efficacy of FGFRi is the development of acquired resistance, frequently mediated by secondary on-target mutations within the FGFR kinase domain, such as gatekeeper mutations, that interfere with drug binding [11].”
> “Evidence supporting FGFRi second use after disease progression on first FGFRi remains limited to some case report or case series [13,14].”

Source: [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/)

<a id="topic-2.2.2.1.7-10"></a>

###### Hyperphosphatemia as an FGFR1-mediated class toxicity of pan-FGFR inhibitors

> “Hyperphosphatemia is attributed to the inhibition of FGFR1, which then increases phosphate reabsorption in the kidney”
> “In addition, diarrhea is reported in 15% to 36% of patients (all CTCAE grades), owing to inhibition of FGFR4”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

> “The most common adverse effects are hyperphosphatemia caused by FGFR1 inhibition and diarrhea due to FGFR4 inhibition, as current therapies are not selective among the FGFRs.”

Source: [Schönherr et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10861881/)

<a id="topic-2.2.2.1.7-11"></a>

###### Pemigatinib label: retinal pigment epithelial detachment and hyperphosphatemia

> “Among 635 patients who received a starting dose of PEMAZYRE 13.5 mg across clinical trials, RPED occurred in 11% of patients, including Grade 3-4 RPED in 1.3%.”
> “PEMAZYRE can cause hyperphosphatemia leading to soft tissue mineralization, cutaneous calcification, calcinosis, and non-uremic calciphylaxis.”
> “hyperphosphatemia was reported in 93% of patients based on laboratory values above the upper limit of normal. The median time to onset of hyperphosphatemia was 8 days (range 1-169). Phosphate lowering therapy was required in 33% of patients receiving PEMAZYRE.”

Source: [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf)

<a id="topic-2.2.2.1.7-12"></a>

###### Pemigatinib: nail toxicity, stomatitis, and serous retinal detachment in FIGHT-202

> “Among other clinically notable adverse events, nail toxicities (all related Medical Dictionary for Regulatory Activities [MedDRA] preferred terms combined; appendix p 17) were experienced by 62 (42%) of 146 patients (three [2%] grade ≥3) and occurred with a median time to onset of 6・0 months (95% CI 4・8–8・8). Five (3%) of 146 patients had dose reductions and six (4%) had dose interruptions because of nail toxicities.”
> “Adverse events related to serous retinal detachment due to subretinal fluid accumulation (all related MedDRA preferred terms combined; appendix p 17) occurred in six (4%) of 146 patients; all events were grade 1 or 2, except for one grade 3 event that was classified as of rhegmatogenous origin and unrelated to treatment.”
> “62 (42%) patients had dose interruptions due to adverse events, most frequently (at least four patients) stomatitis (n=11), palmar-plantar erythrodysaesthesia syndrome (n=8), arthralgia (n=7), fatigue (n=6), and abdominal pain (n=4).”

Source: [Abou-Alfa et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8461541/)

<a id="topic-2.2.2.1.7-13"></a>

###### Futibatinib label: retinal pigment epithelial detachment, hyperphosphatemia, and dose reductions

> “Among 318 patients who received LYTGOBI across clinical trials [see Adverse Reactions (6.1)] where ophthalmologic monitoring did not routinely include optical coherence tomography (OCT), RPED occurred in 9% of patients.”
> “hyperphosphatemia was reported in 88% of patients based on laboratory values above the upper limit of normal.”
> “Phosphate binders were received by 77% of patients who received LYTGOBI.”
> “Dose reductions due to an adverse reaction occurred in 58% of patients who received LYTGOBI.”

Source: [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf)

<a id="topic-2.2.2.1.7-14"></a>

###### Infigratinib: withdrawal of US approval

> “On May 28, 2021, FDA approved NDA 214622 for TRUSELTIQ (infigratinib phosphate) Capsules, 25 mg and 100 mg, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (advanced bile duct cancer or advanced cholangiocarcinoma) with a fibroblast growth factor receptor 2 fusion or other rearrangement as detected by an FDA-approved test, under the Agency's accelerated approval regulations, 21 CFR part 314, subpart H”
> “In its letter requesting withdrawal of approval, Helsinn stated that it is voluntarily requesting withdrawal due to difficulties in recruiting and enrolling study subjects for the required confirmatory clinical trial in first line cholangiocarcinoma (a new indication under investigation for TRUSELTIQ), and the determination that, as a result, continued distribution of TRUSELTIQ in second line cholangiocarcinoma (the accelerated approval indication) is not commercially reasonable.”
> “Approval is withdrawn as of May 16, 2024.”

Source: [FDA Federal Register notice (2024)](https://www.federalregister.gov/documents/2024/05/16/2024-10714/helsinn-healthcare-sa-withdrawal-of-approval-of-new-drug-application-for-truseltiq-infigratinib)

<a id="topic-2.2.2.1.7-15"></a>

###### Infigratinib: early termination of the confirmatory PROOF 301 trial

> “Over 40 months, 1127 patients were pre-screened at 120 sites, and 48 patients were randomly allocated to the study in a 2 : 1 ratio (29 to infigratinib, 19 to chemotherapy). With a target accrual of ∼300 patients, this study was terminated early due to poor accrual.”
> “This study illustrates the challenges of powering confirmatory studies in biomarker-selected subpopulations of rare tumors and highlights the need for regulatory collaboration to develop pragmatic frameworks for assessing novel therapies in ultra-rare malignancies.”

Source: [Abou-Alfa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13015651/)

<a id="topic-2.2.2.1.7-16"></a>

###### Single-group design and slow enrollment of confirmatory randomized trials of FGFR inhibitors

> “The limitations of the current study include the single-group design and the relatively small sample size.”
> “However, enrollment in these trials is occurring slowly, and other research strategies may be considered for assessing benefit in the interim.”

Source: [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)

<a id="topic-2.2.2.1.7-17"></a>

###### Downgraded strength of the second-line chemotherapy recommendation

> “Furthermore, FOLFOX treatment showed a limited survival benefit compared with active symptom control (6.2 months for FOLFOX versus 5.3 months for active symptom control).”
> “Moreover, because the ABC-06 trial is the only positive phase III trial for the second-line treatment of BTC, the LoE was also downgraded from ‘I’ to ‘II’.”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.1.7-18"></a>

###### Proposed explanations for the divergent NIFTY and NALIRICC results

> “Treatment discontinuation due to toxicity, without disease progression, was more common in the NALIRICC trial compared to the NIFTY trial.”
> “As the efficacy of cytotoxic chemotherapy is often limited by early discontinuation, this might be one of the potential reasons why the ORR improvement did not translate into better survival outcomes.”
> “This study is limited by its unplanned nature, which may introduce biases, resulting in a lower level of evidence compared to a single randomized trial.”

Source: [Yoo et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/40147791/)

<a id="topic-2.2.2.1.7-19"></a>

###### NALIRICC: tolerability, crossover to irinotecan, and single-country design

> “This trial does not support the use of nanoliposomal irinotecan plus fluorouracil and leucovorin as a second-line treatment in patients with biliary tract cancer after progression on gemcitabine-based therapy.”
> “High use of subsequent therapy and crossover to irinotecan-based therapy in the control group pose a challenge to the interpretation of the overall survival data.”
> “NALIRICC was exclusively conducted in a single country, involving a homogeneous patient population, which might pose a limitation to the generalisability of the study’s findings to more diverse populations.”
> “Because molecular biomarker analysis was not mandatory for this study, we are not in a position to delineate the correlation between genetic variants and efficacy outcomes.”

Source: [Vogel et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/38870977/)

<a id="topic-2.2.2.1.7-20"></a>

###### Internal validity and generalizability limitations of the NIFTY trial

> “As this result implies that the HRs for progression-free survival might not be representative for the entire study period, further validation should be done in a large, phase 3 trial.”
> “Because this trial was done in a single country and all patients were of east Asian ethnicity, its findings might have limited generalisability.”

Source: [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)

<a id="topic-2.2.2.1.7-21"></a>

###### Survival remains approximately one year despite recent advances

> “Although recent advances have improved clinical outcomes in patients with advanced BTC, median overall survival remains around 1 year, underscoring the need for further therapeutic innovation.”
> “Several targeted agents have demonstrated clinically meaningful efficacy in phase 2-3 trials and are recommended as subsequent-line therapy for biomarker-selected disease, including FGFR2 gene rearrangements, IDH1 mutations, and HER2 amplification.”

Source: [Yoon and Yoo (2026)](https://pubmed.ncbi.nlm.nih.gov/41429598/)

> “Despite incremental advancements, a breakthrough in advanced BTC treatment remains elusive.”

Source: [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11840543/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated position of lirafugratinib

The FDA approved lirafugratinib on 23 September 2026 for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement. Efficacy was established in 116 participants who had received prior chemotherapy or chemoimmunotherapy and no FGFR inhibitor. Its place is therefore the one guidelines assign to FGFR inhibitors: after progression on at least one prior systemic line, which in current practice is gemcitabine and cisplatin with durvalumab or pembrolizumab, as an alternative to pemigatinib and futibatinib, with FOLFOX as the non-targeted second-line standard of care. Use depends on molecular testing that identifies the fusion or rearrangement.

Lirafugratinib differs from the approved FGFR inhibitors in selectivity. In vitro it shows more than 250-fold selectivity over FGFR1 and more than 5,000-fold over FGFR4, and it retained activity against FGFR2 resistance mutations, including V565 gatekeeper variants, in preclinical models. Hyperphosphatemia was reported as an adverse reaction in 21% of lirafugratinib recipients, whereas the pemigatinib and futibatinib labels report hyperphosphatemia from laboratory values in 93% and 88%; the definitions differ and no head-to-head comparison exists. Activity after a prior FGFR inhibitor was lower (see 2.2.2.3), and FGFR inhibitor-pretreated participants are outside the population in which approval efficacy was established. In an institutional cohort, median progression-free survival was 3.8 months with a second FGFR inhibitor and 8.5 months with the first, stable disease was achieved in 13 (59.1%) participants given a second FGFR inhibitor, and all 3 partial responses with a second FGFR inhibitor occurred with lirafugratinib; the authors conclude that the utility of a second FGFR inhibitor may depend on the nature of the resistance mechanism. Resistance profiles to lirafugratinib and futibatinib differ, and three participants who progressed on lirafugratinib responded to futibatinib, which supports sequencing guided by the resistance mutation detected.

Lirafugratinib is taken orally at 70 mg once daily until progression or unacceptable toxicity, which places care in the outpatient and specialty pharmacy setting with scheduled ophthalmologic examinations. The manufacturer expects United States availability by the fourth quarter of 2026.

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic); [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/); [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/); [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/); [Facchinetti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7616615/); [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/); [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf); [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf); [Facchinetti et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13080319/); [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/)

<a id="topic-2.2.2.2-2"></a>

###### Approved indication and the population in which efficacy was established

> “On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.”
> “Efficacy was evaluated in REFOCUS (NCT04526106), a multicenter, open-label, single-arm trial in 116 patients with unresectable or metastatic cholangiocarcinoma who were naïve to FGFR inhibitor treatment and had received prior chemotherapy or chemoimmunotherapy.”

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

<a id="topic-2.2.2.2-3"></a>

###### Care setting: oral once-daily outpatient therapy

> “The recommended lirafugratinib dose is 70 mg orally once daily until disease progression or unacceptable toxicity.”

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

<a id="topic-2.2.2.2-4"></a>

###### Manufacturer and clinician statements on the position of lirafugratinib

> “The FDA approval of Lyrfigtu introduces a vital second-line treatment option for patients living with CCA and their families”
> “Lyrfigtu is expected to be available to patients in the U.S. by Q4 2026.”
> “And unlike earlier pan-FGFR inhibitors, it selectively targets FGFR2 while minimizing off-isoform toxicities.”
> “The results also reinforce the importance of molecular testing at diagnosis so that patients can be matched to therapies most likely to benefit them.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.2.2.2-5"></a>

###### Lirafugratinib: FGFR2 selectivity designed to spare FGFR1 and FGFR4

> “Although the clinical efficacy of pan-FGFR inhibitors (pan-FGFRi) validates FGFR2 driver status in FGFR2 fusion–positive intrahepatic cholangiocarcinoma, their benefit is limited by incomplete target coverage due to FGFR1- and FGFR4-mediated toxicities (hyperphosphatemia and diarrhea, respectively) and the emergence of FGFR2 resistance mutations.”
> “In vitro, RLY-4008 demonstrates >250- and >5,000-fold selectivity over FGFR1 and FGFR4, respectively, and targets primary alterations and resistance mutations.”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

> “Our drug discovery efforts culminated in the development of lirafugratinib (RLY-4008), a covalent inhibitor of FGFR2 that shows substantial selectivity over FGFR1 (~250-fold) and FGFR4 (~5,000-fold) in vitro,”

Source: [Schönherr et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10861881/)

<a id="topic-2.2.2.2-6"></a>

###### Lirafugratinib: activity against FGFR2 resistance mutations in preclinical models

> “In addition, RLY-4008 has potent in vitro and in vivo activity against FGFR2 mutations that drive clinical resistance to available pan-FGFRi.”
> “Finally, RLY-4008 spares FGFR1 in vivo, indicating the potential to avoid FGFR1-mediated toxicities in the clinic.”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

> “In cell viability assays on Ba/F3 and in pharmacologic studies on patient-derived xenografts, irreversible inhibitors retained better activity against FGFR2 kinase domain mutations, with lirafugratinib active against the recalcitrant V565L/F/Y.”

Source: [Facchinetti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7616615/)

<a id="topic-2.2.2.2-7"></a>

###### Sequencing of irreversible FGFR inhibitors guided by resistance mutations

> “After lirafugratinib progression, three patients received futibatinib and experienced prolonged disease response.”
> “The complementary activity of lirafugratinib and futibatinib against FGFR2 kinase domain mutations supports their sequential use when precise resistance mutations are detected in patients.”

Source: [Facchinetti et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13080319/)

> “Resistance to FGFR inhibitors can be overcome by sequential, molecularly oriented treatment strategies across FGFR2-driven tumors.”

Source: [Facchinetti et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7616615/)

<a id="topic-2.2.2.2-8"></a>

###### Outcomes with a second FGFR inhibitor in routine care and trials

> “Among the 22 patients who received a second FGFRi, outcomes were inferior to firsts exposure (ORR of 13.6% vs 47.6% and median PFS of 3.8 vs 8.5 months).”

Source: [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/)

<a id="topic-2.2.2.2-9"></a>

###### Second FGFR inhibitor after progression: survival, disease control, and dependence on the resistance mechanism

> “However, the median PFS during second use was 3.8 months [95%CI, 2.9–7.0] versus 8.5 months [95%CI, 5.9–12.6] during first-line therapy. Median OS dropped from 22.4 months [95%CI, 15.7–50.6] to 10.9 months [95%CI, 4.5–22.6].”
> “While second FGFRi was associated with lower ORR and shorter PFS, but disease control was achieved in almost 60% of patients, and a subset derived durable benefit.”
> “The clinical utility of using a second FGFRi may therefore depend on the nature of the resistance mechanism and the ability of subsequent inhibitors to overcome it.”
> “Also, the small numbers in certain tumor subgroups, particularly for rarer histology and FGFRi second use cases, limit the statistical power for subgroup comparisons.”

Source: [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Summary: modifiers of FGFR inhibitor treatment effect

Prior FGFR inhibitor exposure is the largest reported modifier of lirafugratinib activity. In the ReFocus dose-escalation analysis, the objective response rate among participants with FGFR2 fusion or rearrangement-positive cholangiocarcinoma was 52% (13 of 25) without and 14% (7 of 50) with prior FGFR inhibitor therapy, with median duration of response of 8.2 and 5.6 months. Resistance mutations explain part of the difference: 28 of 46 pretreated participants evaluable by circulating tumour DNA had at least one baseline FGFR2 resistance mutation, and the proportion with such mutations rose from 1 of 6 without prior FGFR inhibitor to 5 of 12 after one and 6 of 7 after two or more. Acquired resistance to lirafugratinib differs from that to pan-FGFR inhibitors, with FGFR2 M538 or L618 mutations in 11 of 16 cases and receptor tyrosine kinase or MAPK bypass alterations in 9 of 16.

Co-occurring alterations modify outcome with approved FGFR inhibitors. In a real-world pemigatinib cohort, median progression-free survival was 4.79 versus 8.66 months with and without CDKN2A mutations and 5.97 versus 8.52 months with and without BAP1 mutations, without a difference in overall survival. With futibatinib, progression-free survival was shorter with CDKN2B alterations (4.8 versus 11.0 months), responses did not correlate with fusion partner, and response rates did not differ by TP53 status. With pemigatinib in FIGHT-202, participants with TP53 alterations (n = 9) had no objective responses and a median progression-free survival of 2.8 months vs 9.0 months, CDKN2A/B alterations were associated with shorter median progression-free survival (6.4 months vs 9.0 months), and response did not differ between rearrangements and predicted fusions (40.0% vs 34.8%) or between BICC1 and other partners. In an institutional series, TP53 and CDKN2A/B alterations were associated with shorter overall survival and BAP1 had no prognostic effect. By alteration type, FGFR fusions were associated with the most favourable FGFR inhibitor outcomes (objective response rate 45.9%), with median progression-free survival of 7.3 months, against 4.1 months for mutations and 2.1 months for amplifications. Within second-line chemotherapy, FOLFOX benefit in ABC-06 was independent of platinum sensitivity and the number of elevated tumour markers stratified survival. In first-line chemoimmunotherapy, the survival benefits of durvalumab in TOPAZ-1 were generally consistent across the subgroups analysed, including PD-L1 tumour area positivity of 1% or greater and of less than 1%.

Source: [Borad et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.4009); [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/); [Facchinetti et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13080319/); [Ellis et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41571046/); [Liguori et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396969/); [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/); [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/); [Jain et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/35135097/); [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/); [Silverman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33218975/); [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/)

<a id="topic-2.2.2.3-2"></a>

###### Molecular covariates of response to futibatinib in FGFR2-altered disease

> “Analysis of the molecular profile of the tumors in the 103 patients in the efficacy population indicated that responses did not correlate with FGFR2 fusion-partner status or co-occurring alterations in tumor-suppressor genes or oncogenes (Fig. 2).”
> “Numerical differences were noted with respect to median progression-free survival between patients with and those without CDKN2A (4.9 months and 9.7 months, respectively) and those with and those without CDKN2B alterations (4.8 months and 11.0 months).”

Source: [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/)

<a id="topic-2.2.2.3-3"></a>

###### Lirafugratinib: ReFocus dose escalation in FGFR inhibitor-naive and FGFR inhibitor-pretreated cholangiocarcinoma

> “As of 30 Jan 23, 116 pts (82 f/r, 27 mutation, 6 amplification) received RLY-4008 at doses of 20-200 mg/day, including 91 with CCA. 50% had prior FGFRi, and median lines of prior therapies was 3 (1-15).”
> “28/46 ct-DNA-evaluable pts with CCA with prior FGFRi had ≥1 baseline resistance mutation, most commonly at FGFR2 N549X (23/46) or V564X (17/46).”

Source: [Borad et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.4009)

<a id="topic-2.2.2.3-4"></a>

###### Lirafugratinib: ReFocus dose escalation outcomes by prior FGFR inhibitor exposure

| Outcome | FGFR inhibitor-naive cholangiocarcinoma with FGFR2 fusion or rearrangement (N = 25) | Prior FGFR inhibitor cholangiocarcinoma with FGFR2 fusion or rearrangement (N = 50) |
| --- | --- | --- |
| Objective response rate, n (%) [95% CI] | “13 (52% [31.3%-72.2%])” | “7 (14% [5.8%-26.7%])” |
| Median duration of response, months (range) | “8.2 (1.9-18.6)” | “5.6 (1.9-7.4)” |
| Duration of response longer than 24 weeks | “10/13 (77%)” | “4/7 (57%)” |
| Response ongoing | “6/13 (46%)” | “2/7 (29%)” |
| Disease control rate, n (%) | “22 (88%)” | “40 (80%)” |

Source: [Borad et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.4009)

<a id="topic-2.2.2.3-5"></a>

###### Lirafugratinib: clinical activity after prior FGFR inhibitor therapy

> “Importantly, lirafugratinib demonstrated clinical efficacy in the FGFR inhibitor-refractory setting, with ctDNA dynamics showing resolution of multiple FGFR2 mutations and persistence or emergence of others.”

Source: [Ellis et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41571046/)

> “In the pan-FGFRi–resistant setting, patient B had a confirmed PR to RLY-4008 following progression on infigratinib.”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

<a id="topic-2.2.2.3-6"></a>

###### FGFR inhibitor-pretreated participants with baseline FGFR2 resistance mutations

> “Of 25 FGFR2 fusion/rearrangement–positive cholangiocarcinoma patients evaluable by circulating tumor DNA (ctDNA), one of six (17%) FGFRi-naive patients, five of 12 (42%) patients with one previous line of pan-FGFRi therapy, and six of seven (86%) patients with two or more previous lines of pan-FGFRi therapy at their approved doses had FGFR2 kinase domain resistance mutations at baseline”

Source: [Subbiah et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10481131/)

<a id="topic-2.2.2.3-7"></a>

###### Resistance mechanisms to lirafugratinib

> “Polyclonal FGFR2 kinase domain mutations and receptor tyrosine kinase-mitogen activated protein kinase (RTK-MAPK) bypass alterations emerged as common lirafugratinib resistance mechanisms in the FGFR inhibitor-naive context (8/16 and 9/16 patients, respectively). Resistance profiles differed markedly from pan-FGFR inhibitors, with decreased FGFR2 V565F/L and N550H/K mutations, increased M538I and L618F mutations, and more frequent RTK-MAPK bypass alterations.”

Source: [Ellis et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41571046/)

> “Patients with acquired lirafugratinib resistance manifested an unprecedented emergence of FGFR2 mutations in the M538 and/or L618 residues of the kinase domain, documented in 11 of 16 cases (69%). Compared with futibatinib resistance, FGFR2 molecular brake (N550) and gatekeeper (V565) mutations were rare.”

Source: [Facchinetti et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13080319/)

<a id="topic-2.2.2.3-8"></a>

###### Co-occurring BAP1 and CDKN2A alterations and progression-free survival with pemigatinib

> “Of 72 patients of PEMIREAL‐PEMIBIL, 63 patients had evaluable NGS data, with concomitant GAs identified in 28 patients (44.4%). The most frequently observed concomitant GAs involved BAP1 (7/63, 11.1%), CDKN2A (7/63, 11.1%), TP53 (6/63, 9.5%), CDKN2B (5/63, 7.9%), PTEN (3/63, 4.7%) and IDH1 (1/63, 1.5%). A significantly shorter PFS was observed in patients with CDKN2A mutations compared to CDKN2A wild‐type tumours (4.79 vs. 8.66 months, p = 0.0011, HR: 3.48 95% CI: 0.91–13.24), and similarly in patients with BAP1 mutations compared to BAP1 wild‐type tumours (5.97 vs. 8.52 months, p = 0.025, HR:2.55 95% CI: 0.72–9.00). No significant differences in OS were observed.”

Source: [Liguori et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13396969/)

<a id="topic-2.2.2.3-9"></a>

###### Co-occurring CDKN2B and TP53 alterations and outcomes with futibatinib

> “Objective response rates on futibatinib were not significantly different between patients with TP53-altered versus -unaltered solid tumors; progression-free survival was reduced in patients with CDKN2B-altered versus -unaltered cholangiocarcinoma (median 4.8 versus 11.0 months; P = 0.03).”

Source: [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/)

<a id="topic-2.2.2.3-10"></a>

###### Futibatinib outcomes by baseline ctDNA co-alteration in FOENIX-CCA2

> “In total, 93 patients from FOENIX-CCA2 with baseline ctDNA samples were included in this analysis. No individual gene alterations or lack of alterations correlated significantly with ORR (Table 2).”

Source: [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/)

| Molecular subgroup (n) | Objective response, n (%, 95% CI) | P value for objective response | Median PFS, months (95% CI) | P value for PFS |
| --- | --- | --- | --- | --- |
| FGFR2 fusion/rearrangement (93) | “40 (43%, 33-53)” | | “8.9 (6.6-13.1)” | |
| BAP1 unaltered (53) | “26 (49%, 35-63)” | “0.2” | “8.0 (4.9-13.8)” | “0.7” |
| BAP1 altered (40) | “14 (35%, 21-52)” | | “9.0 (5.1-13.3)” | |
| CDKN2A unaltered (73) | “32 (44%, 32-56)” | “0.8” | “9.7 (6.9-13.8)” | “0.2” |
| CDKN2A altered (20) | “8 (40%, 19-64)” | | “4.9 (3.4-13.3)” | |
| CDKN2B unaltered (77) | “33 (43%, 32-55)” | “1.0” | “11.0 (7.2-15.1)” | “0.03” |
| CDKN2B altered (16) | “7 (44%, 20-70)” | | “4.8 (3.4-4.9)” | |
| TP53 unaltered (80) | “35 (44%, 33-55)” | “0.8” | “9.0 (6.6-13.3)” | “0.2” |
| TP53 altered (13) | “5 (39%, 14-68)” | | “7.0 (1.4-13.8)” | |
| PBRM1 unaltered (84) | “38 (45%, 34-56)” | “0.3” | “9.0 (6.7-13.1)” | “0.2” |
| PBRM1 altered (9) | “2 (22%, 2.8-60)” | | “4.8 (1.2-NC)” | |

Source: [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/)

> “Limitations of this exploratory analysis included differences between the phase Ib and II patient populations and the sample size of tumor type subgroups.”
> “Data from various tumor types were included from the phase Ib portion of the study, and individual subgroups were too small to make clinically meaningful inferences, thereby making any statistically significant findings hypothesis-generating only.”

Source: [Goyal et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39672383/)

<a id="topic-2.2.2.3-11"></a>

###### Prognostic co-alterations in FGFR-altered cholangiocarcinoma

> “BAP1 mutation was the most common coexisting mutation without prognostic impact, whereas TP53 (P = .04) and CDKN2A/B (P = .04) were correlated with a shorter OS.”

Source: [Jain et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/35135097/)

> “About 15% of intrahepatic cholangiocarcinomas (iCCAs) express fibroblast growth factor receptor 2 (FGFR2) fusion proteins (FFs), usually alongside mutational inactivation of TP53, CDKN2A or BAP1.”

Source: [Cristinziano et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33741397/)

<a id="topic-2.2.2.3-12"></a>

###### Preclinical determinants of FGFR2 fusion dependence: fusion identity, tumour suppressor background, and gatekeeper-resistant mutants

> “Clinical responses to FGFR kinase inhibitors in CCA are often of modest durability.”
> “a number of mutations causing single amino acid substitutions in the FF TKD were found to be a genetic determinant of secondary resistance, due to their ability to impair drug-target interactions.”
> “The penetrance of this tumorigenic phenotype was influenced by FF identity.”
> “We observed that structurally different FFs diverged in terms of oncogenic potential.”
> “A recent study reported that FGFR2-AHCYL1 was tumorigenic when expressed in Cdkn2a-null mouse liver organoids”
> “Therefore, it is possible that FF-driven iCCA pathogenesis might be influenced by the genetic background generated by loss of a specific tumor suppressor gene on one side and still unclear biological properties intrinsic to individual FFs on the other.”
> “We also generated an iCCA model driven by the BGJ398-resistant FGFR2-TACC3 V565F mutant (Fig. 2C and S11A-D) and determined that the resulting F-TKI-resistant tumoroids (Fig. S11E, F) were also dependent on Erk1/2 signaling (Fig. S11G).”
> “The advantage offered by the B+T combo in our experiments must also be considered in light of the finding that TP53 mutations are associated with an aggressive disease course and less favorable responses to single agent FGFR TKIs in iCCA with FGFR2 rearrangements.”

Source: [Cristinziano et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33741397/)

<a id="topic-2.2.2.3-13"></a>

###### FGFR inhibitor outcomes by FGFR alteration type

> “FGFR fusions, most common in cholangiocarcinoma, were associated with the most favorable outcomes with an overall response rate (ORR) of 45.9%, median progression free survival (PFS) and overall survival (OS) of 7.3 and 19.7 months, respectively.”

Source: [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/)

<a id="topic-2.2.2.3-14"></a>

###### FGFR inhibitor survival by alteration type, FGFR gene, and tumor type in an institutional cohort

> “By FGFR alteration type, PFS was longer in the fusion group with 7.3 months 95%CI[5.6–8.5]), compared to 4.1 months 95%CI [2.7–5.6] for mutations, and 2.1 months 95%CI[1.6–3.0] for amplifications (p < 0.001).”
> “Compared to other patients, FGFR fusion was associated with a significantly reduced risk of death (HR=0.633, 95%CI[0.449–0.894], p = 0.009), while amplifications and mutations did not reach statistical significance (Fig. 3, supplementary data Table 2).”
> “FGFR3 was associated with a shorter PFS at 3.4 months 95%CI[1.5–7.4] vs 7.9 months 95%CI[6.1–9.3] for FGFR2 (HR=1.940, 95%CI[1.120–3.360], p = 0.020).”
> “Regarding survival for most frequent tumor types, cholangiocarcinoma had a median PFS/OS of 8.4/49.6 months, breast cancer 2.4/20.2, urothelial carcinoma 4.6/18.4 and CNS tumor 3.0/14.3.”
> “As a retrospective analysis, it is susceptible to selection and reporting biases.”
> “However, no multivariate analysis was performed to explore the impact of these variables due to the insufficient number of patients for each subgroup.”

Source: [Pobel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42330567/)

<a id="topic-2.2.2.3-15"></a>

###### Primary and acquired resistance identified by clinicogenomic analysis of pemigatinib-treated participants

> “Clinicogenomic analysis of pemigatinib-treated patients identified mechanisms of primary and acquired resistance.”

Source: [Silverman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33218975/)

> “Among those experiencing primary resistance to lirafugratinib, we identified potential resistance mechanisms in five of six pretreatment samples.”

Source: [Facchinetti et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13080319/)

<a id="topic-2.2.2.3-16"></a>

###### Co-occurring tumor suppressor alterations and fusion partner and outcomes with pemigatinib in FIGHT-202

> “Among FGFR2-rearranged versus non-FGFR2-rearranged patients, the most frequent co-alterations were BAP1 (38.4% vs 8.2%), CDKN2A (21.7% vs 30.0%), CDKN2B (15.2% vs 20.2%), and PBRM1 (9.4% vs 10.7%) (Fig. 2D).”
> “ORR was higher in BAP1 altered versus unaltered patients but did not reach statistical significance (43.6% vs 30.9%, P = 0.19).”
> “Patients with GAs in CDKN2A/B or PBRM1 alterations trended toward a lower ORR (CDKN2A/B, 23.8% vs 38.4%, P = 0.22; PBRM1, 30.0% vs 36.1%; P = 0.70), although not statistically significant, and significantly shorter median PFS (CDKN2A/B, 6.4 months vs 9.0 months, P = 0.03; PBRM1, 4.7 months vs 7.0 months, P = 0.05).”
> “Of note, patients with TP53 alterations (n = 9) had no objective responses and significantly shorter median PFS (2.8 months vs 9.0 months, P = 0.0003) (Table 1 and Fig. 4B).”
> “This group of patients, accounting for 63% of all patients, had significantly shorter median PFS although ORR was similar between the two groups.”
> “No significant difference in ORR was observed for patients with FGFR2 alterations classified as rearrangements versus for patients with predicted fusions (40.0% vs 34.8%, P = 0.70).”
> “Importantly, we saw no differences in clinical response to pemigatinib in patients with BICC1 versus other partners.”
> “However, the small number of patients, particularly with TP53 or PBRM1 alterations, must be acknowledged as a limitation.”

Source: [Silverman et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33218975/)

<a id="topic-2.2.2.3-17"></a>

###### Subgroup findings in the second-line chemotherapy comparator

> “The ABC-06 study showed how the overall survival and progression-free survival benefit was independent of whether patients were classed as being platinum sensitive or platinum refractory or resistant. In fact, subgroups with suspected poorer prognosis seemed to benefit most from FOLFOX.”
> “Our subgroup analysis also showed a weaker overall survival benefit from treatment with FOLFOX in the extrahepatic cholangiocarcinoma subgroup; however, this observation should be viewed with caution owing to insufficient statistical power.”
> “The insufficient power for subgroup analyses, which challenges some interpretations, is an acknowledged limitation, especially in such a heterogeneous disease.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

<a id="topic-2.2.2.3-18"></a>

###### Subgroup findings in the first-line chemoimmunotherapy comparator

> “The overall and progression-free survival benefits observed with durvalumab in combination with gemcitabine and cisplatin were generally consistent across the clinically relevant subgroups analyzed (Fig. 2A and 2B).”
> “Although the Asia subgroup appeared to have a relatively larger improvement in survival compared with the rest-of-the-world subgroup, the study was not sized for any individual subgroup evaluations, and no adjustments were made for multiplicity.”
> “The addition of durvalumab to chemotherapy benefited patients with tumors characterized by a PD-L1 TAP of 1% or greater and a TAP of less than 1%, indicating that PD-L1 status may have limited value in predicting clinical benefit with durvalumab plus chemotherapy in this patient population.”
> “Exploratory analyses using tumor tissue samples are needed to assess potential survival and response correlations to biomarkers, including driver mutations and tumor mutational burden.”

Source: [Oh et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/38319896/)

<a id="topic-2.2.2.3-19"></a>

###### Tumor markers as prognostic stratifiers in second-line treatment

> “In addition, median OS decreased from 8.9 months (no markers elevated) to 3.2 months (all three elevated).”

Source: [Lamarca et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13325283/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Summary: testing, monitoring, and supportive care relevant to lirafugratinib

Care management starts with molecular profiling at initiation of first-line systemic therapy, using a method able to detect FGFR2 fusions with unknown partners, so that an FGFR2 fusion or rearrangement is known before progression. During lirafugratinib therapy, a comprehensive ophthalmological examination including optical coherence tomography of the macula is required before initiation, every 2 months for the first 13 months, and every 4 months thereafter, with urgent evaluation for visual symptoms; retinal pigment epithelial detachment occurred in 31% of recipients (grade 3 in 1.8%) at a median of 57 days, and dry eye in 38%, treated with ocular demulcents. The corresponding schedule for pemigatinib and futibatinib is every 2 months for the first 6 months and every 3 months thereafter. Serum phosphate is monitored throughout treatment; hyperphosphatemia occurred in 21% of lirafugratinib recipients at a median of 15 days, and phosphate binders were required in 7 (1.8%), whereas the pemigatinib and futibatinib labels specify a low-phosphate diet and phosphate-lowering therapy at defined serum thresholds. Effective contraception is required during treatment and for 6 months (females) or 3 months (males with female partners) after the last dose.

Disease-directed care continues alongside targeted therapy: follow-up every 8 to 12 weeks with CT or MRI and CA 19-9 or CEA where secreted, biliary drainage for obstruction, prompt treatment of biliary sepsis, and education on stent patency. Serial circulating tumour DNA can detect emerging resistance mutations before radiologic progression.

Source: [Vogel and Ducreux (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11846563/); [Neumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9896158/); [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/); [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf); [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf); [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/); [González-Medina et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443220/); [Elevar Therapeutics LYRFIGTU prescribing information (2026)](https://lyrfigtu.com/LYRFIGTU-Prescribing-Information.pdf)

<a id="topic-2.2.2.4-2"></a>

###### Ophthalmologic monitoring for retinal pigment epithelial detachment with lirafugratinib

> “Among 385 patients who received LYRFIGTU, RPED occurred in 31% of patients, including Grade 3 events in 1.8%. The median time to first onset was 57 days. RPED led to dose interruption in 15% of patients and dose reduction in 10%.”
> “Perform a comprehensive ophthalmological examination, including OCT of the macula, prior to initiation of therapy, every 2 months for the first 13 months, and every 4 months thereafter. For onset of visual symptoms, obtain ophthalmologic evaluation urgently, with follow-up every 3 weeks until resolution or discontinuation of LYRFIGTU. Withhold, reduce the dose, or discontinue LYRFIGTU based on severity.”
> “Dry eye occurred in 38% of patients. Treat patients with ocular demulcents as needed.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.2.2.4-3"></a>

###### Serum phosphate monitoring with lirafugratinib

> “Hyperphosphatemia occurred in 21% of patients. The median time to onset was 15 days. Hyperphosphatemia led to dose interruption in one (0.3%) patient and no permanent discontinuation. Monitor serum phosphate throughout treatment and manage as clinically appropriate.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.2.2.4-4"></a>

###### Contraception counselling for embryo-fetal toxicity

> “Advise females of reproductive potential to use effective contraception during treatment and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 months after the last dose.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.2.2.4-5"></a>

###### Ophthalmologic monitoring and phosphate management with pemigatinib

> “Perform a comprehensive ophthalmological examination including OCT prior to initiation of PEMAZYRE and every 2 months for the first 6 months and every 3 months thereafter during treatment.”
> “Monitor for hyperphosphatemia and initiate a low phosphate diet when serum phosphate level is > 5.5 mg/dL. For serum phosphate levels > 7 mg/dL, initiate phosphate lowering therapy and withhold, reduce the dose, or permanently discontinue PEMAZYRE based on duration and severity of hyperphosphatemia”

Source: [FDA PEMAZYRE prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf)

<a id="topic-2.2.2.4-6"></a>

###### Ophthalmologic monitoring and phosphate management with futibatinib

> “Perform a comprehensive ophthalmological examination, including OCT of the macula, prior to initiation of therapy, every 2 months for the first 6 months, and every 3 months thereafter.”
> “Monitor for hyperphosphatemia throughout treatment. Initiate a low phosphate diet and phosphate lowering therapy when serum phosphate level is ≥5.5 mg/dL. For serum phosphate levels >7 mg/dL, initiate or intensify phosphate lowering therapy and dose reduce, withhold, or permanently discontinue LYTGOBI based on duration and severity of hyperphosphatemia”

Source: [FDA LYTGOBI prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/214801s005lbl.pdf)

<a id="topic-2.2.2.4-7"></a>

###### Longitudinal ctDNA monitoring during FGFR inhibitor therapy

> “Examination of serial biopsies, circulating tumor DNA (ctDNA), and patient-derived ICC cells revealed that TAS-120 was active against multiple FGFR2 mutations conferring resistance to BGJ398 or Debio1347.”

Source: [Goyal et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6677584/)

> “The integration of information from various plasma biomarkers holds the potential to predict clinical outcomes and identify treatment failure prior to radiologic progression, offering valuable guidance for the clinical management of patients with iCCA.”

Source: [González-Medina et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443220/)

<a id="topic-2.2.2.4-8"></a>

###### Follow-up interval and tumor marker monitoring during systemic therapy

> “During systemic and locoregional therapy for advanced disease, follow-up should be conducted at a frequency of 8-12 weeks. In addition to imaging with CT or MRI, CA 19-9 or CEA levels may be used to monitor the course of the disease if one or both are known to be secreted [IV, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="topic-2.2.2.4-9"></a>

###### Biliary drainage, infection management, and patient education

> “In patients with biliary obstruction, biliary drainage and subsequent treatment should be carried out; when endoscopic access is not possible, percutaneous transhepatic drainage is recommended [IV, A]”
> “Sepsis secondary to biliary obstruction is common and should be treated promptly [IV, A]”
> “Patients should be advised of the likely duration of stent patency and of symptoms and signs which are indicative of biliary obstruction or infection [V, A]”

Source: [Chen et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410730/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

<a id="topic-2.2.2.5-1"></a>

###### Postmarketing requirement 5057-1: randomized trial of 70 mg once daily compared with a lower dosage

> “Conduct a randomized clinical trial to further characterize known serious risks with lirafugratinib including severe stomatitis, palmar-plantar erythrodysesthesia syndrome, retinal pigment epithelial detachment, and nail toxicities, and to compare the safety and activity of lirafugratinib 70 mg once daily versus a lower dosage in patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or other rearrangements, who have not received prior FGFR inhibitors.”
> “Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess these serious risks.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-2"></a>

###### Postmarketing requirement 5057-1: timetable

| Milestone | Date |
| --- | --- |
| Draft protocol submission | “01/2027” |
| Final protocol submission | “05/2027” |
| Trial completion | “11/2031” |
| Final report submission | “05/2032” |

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-3"></a>

###### Postmarketing requirement 5057-2: drug interaction trial with a sensitive P-gp and BCRP substrate

> “Conduct a clinical pharmacokinetic trial to assess a serious potential risk of increased drug toxicity by evaluating the effect of repeat doses of lirafugratinib on the single dose pharmacokinetics of a sensitive P-gp and BCRP substrate and inform appropriate management strategies for clinically relevant drug interactions.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-4"></a>

###### Postmarketing requirement 5057-2: timetable

| Milestone | Date |
| --- | --- |
| Draft protocol submission | “01/2027” |
| Final protocol submission | “05/2027” |
| Trial completion | “05/2032” |
| Final report submission | “09/2032” |

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-5"></a>

###### Postmarketing commitment 5057-3: companion diagnostic validation

> “Conduct adequate analytical and clinical validation studies to support revisions to the labeling of lirafugratinib to specify the use of an FDA-authorized in vitro companion diagnostic device to accurately and reliably identify patients using blood and/or tissue samples who have FGFR2 fusions and other rearrangements and for whom lirafugratinib therapy is indicated.”
> “The final study report should be accompanied by a labeling supplement to incorporate information about the use of an FDA-authorized companion diagnostic device.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-6"></a>

###### Postmarketing commitment 5057-3: timetable

| Milestone | Date |
| --- | --- |
| Study completion | “01/2029” |
| Final report submission | “09/2029” |

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-7"></a>

###### Pediatric Research Equity Act requirement

> “We are waiving the pediatric studies requirement for this application, in pediatric patients less than 17 years of age because necessary studies are impossible or highly impracticable, due to the exceedingly low incidence of FGFR2 altered tumors.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-8"></a>

###### Supplemental application planned for other FGFR2-altered solid tumors

> “The FDA recommended that the company first file an NDA for FGFR2-driven CCA, followed by a supplemental NDA for FGFR2-altered other solid tumors with data from an expanded cohort of patients.”

Source: [Elevar Therapeutics and Relay Therapeutics licensing announcement (2024)](https://elevartx.com/2024/12/03/elevar-therapeutics-relay-therapeutics-licensing-agreement/)

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

###### Basis for requiring a clinical trial to assess serious risks

> “known serious risks of severe stomatitis, palmar-plantar erythrodysesthesia syndrome, retinal pigment epithelial detachment, and nail toxicities; and to assess a signal of a serious risk of increased drug toxicity when lirafugratinib is used concomitantly with sensitive P-gp and BCRP substrates.”
> “Finally, we have determined that only a clinical trial (rather than a nonclinical or observational study) will be sufficient to assess these serious risks.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-2"></a>

###### Periodic status reporting and investigational new drug application

> “requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.”
> “Submit clinical protocol(s) to your IND 147405 with a cross-reference letter to this NDA.”

Source: [FDA NDA 220425 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220425Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-3"></a>

###### Ongoing clinical study of lirafugratinib after approval

> “Elevar is also conducting ReFocus202, a global Phase 2 study evaluating lirafugratinib in patients with various solid tumors harboring FGFR2 fusions or rearrangements. Patient enrollment and dosing are currently underway at clinical sites globally, including in the EU, U.K., Korea and U.S.”

Source: [Elevar Therapeutics EMA submission announcement (2026)](https://elevartx.com/2026/09/15/elevar-ema-authorization-application-1/)

<a id="topic-2.2.2.6-4"></a>

###### Adverse event reporting

> “To report SUSPECTED ADVERSE REACTIONS, contact Elevar Therapeutics at 1-866-4ELEVAR or contact the FDA at 1-800-FDA-1088, or visit www.fda.gov/medwatch.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.2.2.6-5"></a>

###### Confirmatory trial registration

No evidence found.

Additional sources: [ClinicalTrials.gov NCT07359820](https://clinicaltrials.gov/study/NCT07359820); [ClinicalTrials.gov NCT04526106](https://clinicaltrials.gov/study/NCT04526106)

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary: expected outcomes and the benchmarks they are measured against

In the 116 FGFR inhibitor-naive participants of the REFOCUS pivotal cohort, the FDA reports an objective response rate of 46% (95% CI 36 to 55) by independent review and a median duration of response of 11.8 months (95% CI 7.5 to 13.0). The manufacturer reports median progression-free survival of 11.3 months (95% CI 9.2 to 14.8) with a 12-month rate of 49.2%, and the congress report of the same cohort gives median overall survival of 22.8 months (95% CI 17.3 to 27.2) with a 12-month rate of 74.6%, responses lasting more than 6 months in 76.2% of responders, treatment-related dose reductions in 75.9%, and discontinuation for treatment-related adverse events in 4.3%.

These values come from a single-arm trial and are read against cross-trial benchmarks: pemigatinib, objective response rate 37.0%, median progression-free survival 7.0 months, and median overall survival 17.5 months (FIGHT-202 final analysis); futibatinib, 42%, 9.0 months, and 21.7 months (FOENIX-CCA2); and FOLFOX in unselected second-line biliary tract cancer, 5%, 4.0 months, and 6.2 months (ABC-06). In routine care, median overall survival among 221 United States participants who initiated pemigatinib was 15.9 months, and in a Canadian patient support program median real-world progression-free survival with pemigatinib was 12.1 months. Quality of life was stable over 9.0 months of futibatinib in FOENIX-CCA2; no quality-of-life result for lirafugratinib was identified in the cited sources.

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic); [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/); [Hollebecque et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.476); [Vogel et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11190465/); [Goyal et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36652354/); [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/); [Verma et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13129466/); [Ding et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12293483/)

<a id="topic-2.2.2.7-2"></a>

###### Response, duration of response, and progression-free survival supporting approval

> “The major efficacy outcome measures were objective response rate (ORR) and duration of response (DOR) as determined by an independent review committee according to RECIST v1.1. ORR was 46% (95% CI: 36, 55) and median DOR was 11.8 months (95% CI: 7.5, 13.0).”

Source: [FDA lirafugratinib approval notice (2026)](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic)

> “Median progression-free survival was 11.3 months (95% CI, 9.2, 14.8), with a 12-month rate of 49.2%.”
> “Its safety profile in the clinical data was shown to be predictable and manageable through dose adjustments.”

Source: [Elevar Therapeutics approval announcement (2026)](https://elevartx.com/2026/09/23/elevar-fda-approval-lyrfigtu-2/)

<a id="topic-2.2.2.7-3"></a>

###### Lirafugratinib: ReFocus pivotal cohort in FGFR inhibitor-naive cholangiocarcinoma

> “Pivotal cohort of patients (n=116) with advanced/metastatic CCA harboring FGFR2 f/r previously treated with ≥1 systemic therapy and FGFRi-naive were treated with oral lirafugratinib 70 mg once daily until disease progression or unacceptable toxicity.”
> “Median age 57 years with 61.4% female.”
> “IRC-assessed ORR was 47%, and median DOR was 11.8 months (mos) (95% CI, 7.5-13.0), where 76.2% of responses lasted >6 mos. Median PFS was 11.3 mos (95% CI, 9.2, 14.8), with 12-month rate of 49.2%. Median OS was 22.8 mos (95% CI, 17.3-27.2), with 12-month rate of 74.6%.”
> “Common grade ≥3 on-target, off-tumor treatment-related adverse events (TRAEs) included palmar-plantar erythrodysesthesia (32.8%) and stomatitis (12.1%). TRAEs led to dose reductions of 75.9%, dose interruption of 82.8%, and treatment discontinuation of 4.3%.”

Source: [Hollebecque et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.476)

<a id="topic-2.2.2.7-4"></a>

###### Real-world pemigatinib outcomes: US claims analysis

> “Overall, 221 patients with CCA were included (median age 57 years); 90.5% had iCCA, and the population was racially diverse. The most common baseline regimen was gemcitabine + cisplatin (34.4%). Most patients (86.9%) initiated pemigatinib at the recommended dose (13.5 mg). During observation, 47.1% of patients discontinued pemigatinib; median [95% confidence interval (CI)] time to discontinuation was 7.0 (6.1-9.7) months. During 6-month follow-up, 68.4% of patients had a medication possession ratio ≥0.8. Median (95% CI) OS was 15.9 (13.4-23.2) months.”

Source: [Verma et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13129466/)

<a id="topic-2.2.2.7-5"></a>

###### Real-world pemigatinib outcomes: Canadian patient support program

> “The median follow-up time on pemigatinib was 12.6 (range: 2.3–28.4) months, and their median real-world progression-free survival (rwPFS) was 12.1 months (95% CI 7.2-NR). The physician-assessed objective response and disease control rates were 56% and 89%, respectively. For the nine patients who discontinued pemigatinib, the median treatment duration was 10.6 months (range: 0.8–21.7). Disease progression was the most common reason for discontinuation (89%). None discontinued due to adverse events.”

Source: [Ding et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12293483/)

<a id="topic-2.2.2.7-6"></a>

###### Benchmarks for response and survival with second-line chemotherapy

> “The combinations of therapeutics used in this setting, which are not labeled for this indication, generally have an ORR of ~5% or less and patients face a median overall survival of approximately six months.”

Source: [Compass Therapeutics COMPANION-002 primary endpoint announcement (2025)](https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/exh_991.htm)

> “Overall survival was significantly longer in the ASC plus FOLFOX group than in the ASC alone group, with a median overall survival of 6·2 months (95% CI 5·4–7·6) in the ASC plus FOLFOX group versus 5·3 months (4·1–5·8) in the ASC alone group (adjusted hazard ratio 0·69 [95% CI 0·50–0·97]; p=0·031).”
> “Objective response was observed in four (5%) of 81 patients in the ASC plus FOLFOX group: one (1%) patient had a complete response and three (4%) patients had a partial response.”

Source: [Lamarca et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8082275/)

> “second-line FOLFOX resulted in a median progression-free survival of 4·0 months (95% CI 3·2–5·0), a median overall survival of 6·2 months (95% CI 5·4–7·6), and an objective response rate of 5%.”

Source: [Yoo et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34656226/)

## Related pages
- [Lirafugratinib (Lyrfigtu): Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Terms and abbreviations](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/terms-and-abbreviations.md)
- [Lirafugratinib (Lyrfigtu): Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/executive-summary.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Clinical evidence](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/clinical-evidence.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: Economic information and modeling report](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/economics) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/economics.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: References](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/references) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/references.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: new drug review](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/monograph/review) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/monograph/review.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: prevalence by geography](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/prevalence) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/prevalence.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/cost-effectiveness-analyses.md)
- [Lirafugratinib (Lyrfigtu) in Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma: interactive budget impact model](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/budget-impact-model) · [Markdown](https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/budget-impact-model.md)
